

Rituximab chimeric anti-CD20 monoclonal antibody therapy in low-grade non-Hodgkin's lymphoma: half of patients respond to a four-dose treatment

Journal of Clinical Oncology

16, 2825-2833

DOI: 10.1200/jco.1998.16.8.2825

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 441.	1.1	30
2	Sun Tzu and the Art of BusinessSun Tzu and the Art of Business By McNeillyMark R., Oxford: Oxford University Press, 1996, 225 pages, hard, cover, \$25.00. Academy of Management Perspectives, 1997, 11, 129-130.	6.8	5
3	Rituxan in the Treatment of Cold Agglutinin Disease. Blood, 1998, 92, 3490-3491.	1.4	123
4	Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Annals of Oncology, 1999, 10, 1525-1527.	1.2	93
5	Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance. Journal of Clinical Oncology, 1999, 17, 791-791.	1.6	250
6	Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20 ⁺ B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 1999, 17, 3793-3803.	1.6	525
7	Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab. Journal of Clinical Oncology, 1999, 17, 1851-1851.	1.6	274
8	Clinical Investigation of the Monoclonal Anti-CD20 Antibody Rituximab (IDEC-C2B8) in Patients with B Cell Lymphoma. Contributions To Oncology / Beitrage Zur Onkologie, 1999, 54, 343-360.	0.1	0
9	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. Blood, 1999, 94, 3340-3348.	1.4	161
10	Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8). Blood, 1999, 94, 2217-2224.	1.4	608
11	Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.. International Journal of Oncology, 1999, 15, 1017-25.	3.3	39
12	An array of immunotherapeutic strategies for B-cell lymphomas. Expert Opinion on Investigational Drugs, 1999, 8, 2059-2071.	4.1	0
13	Cancer dormancy and cell signaling: Induction of p21waf1 initiated by membrane IgM engagement increases survival of B lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8711-8715.	7.1	42
14	Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2. Leukemia and Lymphoma, 1999, 35, 641-642.	1.3	31
15	Perceptions of Herceptin®: A Monoclonal Antibody for the Treatment of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 5-10.	1.0	50
16	Rituximab Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 237-240.	1.0	4
17	Rituximab Immunotherapy for Non-Hodgkin's Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 1999, 14, 241-250.	1.0	13
18	Immunotoxins in cancer therapy. Current Opinion in Immunology, 1999, 11, 570-578.	5.5	200

#	ARTICLE	IF	CITATIONS
19	Signaling antibodies in cancer therapy. <i>Current Opinion in Immunology</i> , 1999, 11, 541-547.	5.5	125
20	The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. <i>Pediatric Transplantation</i> , 1999, 3, 271-281.	1.0	122
21	The problem of anti-pig antibodies in pig-to-primate xenografting: current and novel methods of depletion and/or suppression of production of anti-pig antibodies. <i>Xenotransplantation</i> , 1999, 6, 157-168.	2.8	80
22	Costâ€minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent Bâ€cell nonâ€Hodgkin's lymphoma in the U.K.. <i>British Journal of Haematology</i> , 1999, 106, 47-54.	2.5	49
23	Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 1999, 106, 545-552.	2.5	28
24	Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma. <i>Immunology and Cell Biology</i> , 1999, 77, 451-459.	2.3	27
25	Do selfâ€perpetuating B lymphocytes drive human autoimmune disease?. <i>Immunology</i> , 1999, 97, 188-196.	4.4	163
26	A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. <i>Nature Biotechnology</i> , 1999, 17, 276-281.	17.5	87
27	Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkinâ€™s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 521-526.	2.4	34
28	Use of rituximab and irradiated donor-derived lymphocytes to control Epsteinâ€Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 1253-1258.	2.4	43
30	Detection and relevance of minimal disease in lymphomas. , 1999, 18, 127-142.		15
31	Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. , 1999, 18, 465-471.		135
32	The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 517-524.	4.2	30
33	Chimeric monoclonal anti-CD20 antibody (rituximab)â€™an effective treatment for a patient with relapsing hairy cell leukaemia. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999, 16, 221-222.	1.1	23
34	Behandlung von malignen Lymphomen mit dem mono-klonalen anti-CD20 AntikÃ¶rper Rituximab (IDEC-C2B8). <i>Onkologie</i> , 1999, 5, 532-540.	0.7	1
35	Einsatz mono- und bispezifischer AntikÃ¶rper in der Tumorthherapie. <i>Onkologie</i> , 1999, 5, 679.	0.7	1
36	Clinical applications of anti-CD20 antibodies. <i>Translational Research</i> , 1999, 134, 445-450.	2.3	95
37	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 889-918.	2.2	11

#	ARTICLE	IF	CITATIONS
38	Rituximab is a new option for patients with relapsed indolent non-Hodgkin's lymphoma. <i>Drugs and Therapy Perspectives</i> , 1999, 14, 1-5.	0.6	0
39	Monoclonal Antibodies in Cancer Treatment. <i>BioDrugs</i> , 1999, 12, 209-236.	4.6	6
41	New drug classes. <i>Lancet</i> , The, 1999, 353, 8.	13.7	3
42	Rituximab. <i>Drugs</i> , 1999, 58, 79-88.	10.9	121
43	Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. <i>Hematology</i> , 1999, 4, 283-303.	1.5	1
44	Limited Stage I and II Follicular Non-Hodgkin's Lymphoma: The Nebraska Lymphoma Study Group Experience. <i>Leukemia and Lymphoma</i> , 1999, 34, 273-285.	1.3	19
45	Antibody therapy has arrived. Now where does it fit?. <i>Annals of Oncology</i> , 1999, 10, 619-621.	1.2	7
46	Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. <i>Annals of Oncology</i> , 1999, 10, 1249-1250.	1.2	16
47	A New Approach to Non-Hodgkin's Lymphoma.. <i>Internal Medicine</i> , 2000, 39, 197-208.	0.7	11
48	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 1622-1636.	1.6	416
49	Lymphoma: a clinical view. <i>Cancer Imaging</i> , 2000, 1, 64-76.	2.8	0
50	Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. <i>Annals of Oncology</i> , 2000, 11, 857-860.	1.2	8
51	Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2000, 11, 363-366.	1.2	32
52	Improving results of intestinal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 295-299.	1.6	1
53	Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches. <i>Current Opinion in Hematology</i> , 2000, 7, 247-254.	2.5	6
54	Chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2000, 7, 223-234.	2.5	86
55	Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1675-1688.	2.2	96
56	Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 104-112.	5.1	32

#	ARTICLE	IF	CITATIONS
57	Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha?. Microscopy Research and Technique, 2000, 50, 251-257.	2.2	20
58	Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity. Cancer, 2000, 89, 1134-1144.	4.1	50
59	Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer, 2000, 89, 1835-1844.	4.1	126
60	Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. European Journal of Immunology, 2000, 30, 3165-3170.	2.9	26
61	Rituximab in cutaneous B-cell lymphoma: a report of two cases. British Journal of Dermatology, 2000, 143, 157-161.	1.5	50
62	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 2000, 109, 81-88.	2.5	101
63	In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. British Journal of Haematology, 2000, 109, 729-735.	2.5	80
64	Rituximab (Anti-CD20) Therapy of B-Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms. Scandinavian Journal of Immunology, 2000, 51, 634-641.	2.7	234
65	Advances in the systemic treatment of cancers in the elderly. Critical Reviews in Oncology/Hematology, 2000, 35, 201-218.	4.4	15
66	Follicular lymphomas â€” a review of treatment modalities. Critical Reviews in Oncology/Hematology, 2000, 35, 13-32.	4.4	15
67	Immunology and immunotherapy of human cancer: present concepts and clinical developments. Critical Reviews in Oncology/Hematology, 2000, 34, 1-25.	4.4	64
68	Aggressive lymphoma in the elderly. Critical Reviews in Oncology/Hematology, 2000, 33, 119-128.	4.4	8
69	Clinical trials of antibody therapy. Trends in Immunology, 2000, 21, 403-410.	7.5	277
70	Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplantation, 2000, 26, 1051-1056.	2.4	13
71	Monoclonal Antibodies in Chronic Lymphocytic Leukemia. Reviews in Clinical and Experimental Hematology, 2000, 4, 134-144.	0.1	0
72	Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leukemia Research, 2000, 24, 411-415.	0.8	76
73	Promising approaches in acute leukemia. , 2000, 18, 57-82.		7
74	Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. Transgenic Research, 2000, 9, 155-159.	2.4	8

#	ARTICLE	IF	CITATIONS
75	Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines. <i>Cellular Immunology</i> , 2000, 204, 55-63.	3.0	137
76	Antibody immunotherapy for leukemia. <i>Current Oncology Reports</i> , 2000, 2, 114-122.	4.0	9
77	Biotherapy for lymphoma. <i>Current Oncology Reports</i> , 2000, 2, 157-162.	4.0	4
78	Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 173-180.	4.2	23
79	IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. <i>Annals of Hematology</i> , 2000, 79, 493-500.	1.8	96
80	Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2000, 79, 167-174.	1.8	13
81	Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. <i>Annals of Hematology</i> , 2000, 79, 175-182.	1.8	60
82	Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab. <i>Annals of Hematology</i> , 2000, 79, 332-335.	1.8	16
83	Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. <i>Medical Oncology</i> , 2000, 17, 203-210.	2.5	27
84	Risk factors for side effects during first infusion of rituximab—definition of a low risk group. <i>Medical Oncology</i> , 2000, 17, 218-221.	2.5	13
85	Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. <i>Medical Oncology</i> , 2000, 17, 225-228.	2.5	17
86	Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. <i>Blood</i> , 2000, 95, 3052-3056.	1.4	271
87	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	1.4	523
88	Characterization of Epstein-Barr virus—infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. <i>Blood</i> , 2000, 96, 4055-4063.	1.4	167
89	Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. <i>Blood</i> , 2000, 96, 1259-1266.	1.4	465
90	Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line. <i>Annals of Internal Medicine</i> , 2000, 132, 916.	3.9	5
91	Phase I/II Trial of Multiple Dose ¹³¹ Iodine-MAb LL2 (CD22) in Patients with Recurrent Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 38, 91-101.	1.3	62
92	T-Cell Infiltrate After Monoclonal Anti-CD20 Antibody Therapy for B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 37, 387-391.	1.3	2

#	ARTICLE	IF	CITATIONS
93	Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment. Journal of Clinical Oncology, 2000, 18, 3135-3143.	1.6	653
94	Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients. Journal of Clinical Oncology, 2000, 18, 2603-2606.	1.6	220
95	High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. Journal of Clinical Oncology, 2000, 18, 527-527.	1.6	168
96	The Curious Case of the Baffling Biological. Journal of Clinical Oncology, 2000, 18, 2007-2009.	1.6	14
97	European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma. Journal of Clinical Oncology, 2000, 18, 317-317.	1.6	448
98	Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2000, 18, 1316-1323.	1.6	337
99	Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease. Annals of Internal Medicine, 2000, 133, 275.	3.9	132
100	Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?. Annals of Oncology, 2000, 11, 374-375.	1.2	78
101	Response criteria for NHL: Importance of "normal" lymph node size and correlations with response rates. Annals of Oncology, 2000, 11, 399-408.	1.2	62
102	Demonstration of highly specific toxicity of the ^{211}At -emitting radioimmunoconjugate ^{211}At -rituximab against non-Hodgkin's lymphoma cells. British Journal of Cancer, 2000, 83, 1375-1379.	6.4	40
103	Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma: Best of Both Worlds?. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 1-5.	1.0	2
104	Treatment advances in non-Hodgkin's lymphoma. Expert Opinion on Pharmacotherapy, 2000, 1, 451-465.	1.8	4
105	Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. Annals of Oncology, 2000, 11, S117-S121.	1.2	59
106	The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Annals of Oncology, 2000, 11, S123-S126.	1.2	62
107	Acute Toxicity of Mitoxantrone, Chlorambucil and Prednisolone (MCP) versus MCP plus Rituximab in Low-Grade Non-Hodgkin's Lymphoma " Interim Results of a Phase III Trial. Oncology Research and Treatment, 2000, 23, 164-166.	1.2	1
108	Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Annals of Oncology, 2000, 11, S107-S111.	1.2	28
109	Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma. Current Pharmaceutical Biotechnology, 2000, 1, 1-9.	1.6	122
110	Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Annals of Oncology, 2000, 11, S113-S116.	1.2	223

#	ARTICLE	IF	CITATIONS
111	Immunotoxins. Expert Opinion on Pharmacotherapy, 2000, 1, 1117-1129.	1.8	27
112	Follicular lymphoma: Have we made any progress?. Annals of Oncology, 2000, 11, S23-S27.	1.2	56
113	Diffuse large-cell lymphoma. Annals of Oncology, 2000, 11, S29-S33.	1.2	9
114	Non-Hodgkin's lymphoma: Follicle centre cell lymphoma: optimal use of therapeutic options. Annals of Oncology, 2000, 11, 111-116.	1.2	3
115	Monoclonal Antibody Therapy in Lymphoid Malignancies. Oncologist, 2000, 5, 376-384.	3.7	56
117	Effect of interferon- γ on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines, Cellular & Molecular Therapy, 2000, 6, 81-87.	0.3	36
118	Triggering Fc γ -Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. Journal of Immunology, 2000, 165, 5954-5961.	0.8	125
119	Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis. Blood Cells, Molecules, and Diseases, 2000, 26, 133-143.	1.4	200
120	Monoclonal antibody therapy for solid tumors. Cancer Treatment Reviews, 2000, 26, 269-286.	7.7	142
121	Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Seminars in Oncology Nursing, 2000, 16, 2-12.	1.5	21
123	Physics for practitioners: The use of radiolabeled monoclonal antibodies in B-Cell non-Hodgkin's lymphoma. Seminars in Hematology, 2000, 37, 2-8.	3.4	9
124	Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy. Seminars in Hematology, 2000, 37, 17-26.	3.4	13
125	Investigation of monoclonal antibody therapy with conventional and high-dose treatment: Current clinical trials. Seminars in Hematology, 2000, 37, 27-33.	3.4	4
126	Monoclonal antibody-based therapy of lymphoid neoplasms: What's on the horizon?. Seminars in Hematology, 2000, 37, 34-42.	3.4	2
127	A perspective on monoclonal antibody therapy: Where we have been and where we are going. Seminars in Hematology, 2000, 37, 43-46.	3.4	15
128	In vitro and in vivo purging of B lymphoma cells from stem-cell products using anti-CD20 Abs. Cytotherapy, 2000, 2, 445-453.	0.7	2
129	Prolonged Disease-Free Survival after Autografting for Chemosensitive Non-Bulky Low Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2000, 39, 283-290.	1.3	4
130	Therapeutic uses of MAbs directed against CD20. Cytotherapy, 2000, 2, 455-461.	0.7	1

#	ARTICLE	IF	CITATIONS
131	Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma1. Clinical Lymphoma and Myeloma, 2000, 1, 27-28.	2.1	18
133	The Expanding Frontier of Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 158-159.	2.1	0
134	Commentary on "Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma" Clinical Lymphoma and Myeloma, 2000, 1, 152-153.	2.1	3
136	Commentary on "Rituximab Therapy of B-Cell Neoplasms" Clinical Lymphoma and Myeloma, 2000, 1, 195-196.	2.1	3
137	Progressive Intermediate-Grade Non-Hodgkin's Lymphoma After High-Dose Therapy and Autologous Peripheral Stem-Cell Transplantation: Changing the Natural History with Monoclonal Antibody Therapy. Clinical Lymphoma and Myeloma, 2000, 1, 62-66.	2.1	6
139	The History of the Development of Vaccines for the Treatment of Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 129-139.	2.1	30
140	Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2000, 1, 146-151.	2.1	11
141	Rituximab Therapy of B-Cell Neoplasms. Clinical Lymphoma and Myeloma, 2000, 1, 186-194.	2.1	25
142	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. Human Gene Therapy, 2000, 11, 611-620.	2.7	126
146	Current Understanding of Possible Mechanisms of Action and Resistance of Rituximab. Clinical Lymphoma and Myeloma, 2001, 2, 145-147.	2.1	0
147	Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Review of Anticancer Therapy, 2001, 1, 177-186.	2.4	25
148	Antibody-Targeted Immunotherapy for Treatment of Malignancy. Annual Review of Medicine, 2001, 52, 125-145.	12.2	121
149	Management of AIDS-Related Non-Hodgkin's Lymphomas. Drugs, 2001, 61, 1301-1315.	10.9	12
150	Advances in the Therapy of Primary Central Nervous System Lymphoma. Clinical Lymphoma and Myeloma, 2001, 1, 263-275.	2.1	12
151	Weekly x 4 Induction Therapy with the Anti-CD20 Antibody Rituximab: Effect on Circulating t(14;18)+ Follicular Lymphoma Cells. Clinical Lymphoma and Myeloma, 2001, 1, 293-297.	2.1	7
152	Feasibility and Safety of Outpatient Bexxar® Therapy (Tositumomab and Iodine I 131 Tositumomab) for Non-Hodgkin's Lymphoma Based on Radiation Doses to Family Members. Clinical Lymphoma and Myeloma, 2001, 2, 164-172.	2.1	22
153	Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. Journal of Clinical Pharmacology, 2001, 41, 1206-1214.	2.0	124
154	Rituximab-Induced Vasculitis. Dermatology, 2001, 203, 83-84.	2.1	61

#	ARTICLE	IF	CITATIONS
155	Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2001, 15, 163-205.	2.2	65
157	High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. Biology of Blood and Marrow Transplantation, 2001, 7, 294-301.	2.0	75
158	Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 2001, 98, 1326-1331.	1.4	334
159	Progress in CLL, chemotherapy, antibodies and transplantation. Biomedicine and Pharmacotherapy, 2001, 55, 524-528.	5.6	10
160	Human therapeutic antibodies. Current Opinion in Pharmacology, 2001, 1, 404-408.	3.5	28
161	The therapeutic use of antibodies for malignancy. Transfusion Clinique Et Biologique, 2001, 8, 255-259.	0.4	5
162	A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 41, 77-87.	1.3	48
163	Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood, 2001, 97, 3995-3997.	1.4	147
164	Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. Expert Review of Anticancer Therapy, 2001, 1, 501-505.	2.4	1
165	Radioimmunotherapy. BioDrugs, 2001, 15, 151-162.	4.6	11
166	Prolonged Molecular and Clinical Remission after Treatment of a Patient with Follicular Lymphoma with Rituximab. Leukemia and Lymphoma, 2001, 41, 451-455.	1.3	5
167	Chemotherapy Plus Interferon- γ 2b Versus Chemotherapy in the Treatment of Follicular Lymphoma. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 669-674.	1.8	7
168	Behandlung indolenter Non-Hodgkin-Lymphome: Neue Akzente für die Praxis. Oncology Research and Treatment, 2001, 24, I-I.	1.2	0
169	Some Like It Hot!. Journal of Clinical Oncology, 2001, 19, 3908-3911.	1.6	23
170	Rituximab: An innovative therapy for non-Hodgkin's lymphoma. American Journal of Health-System Pharmacy, 2001, 58, 215-229.	1.0	19
171	Therapeutic immunology. , 2001, , 68-86.		0
172	Follicular lymphoma. , 2001, , 111-125.		0
173	Palliative systemic antineoplastic therapy. , 2001, , 399-420.		0

#	ARTICLE	IF	CITATIONS
174	Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity. Journal of Clinical Oncology, 2001, 19, 2153-2164.	1.6	487
175	Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2001, 19, 3918-3928.	1.6	555
176	Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2001, 19, 2165-2170.	1.6	572
177	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of Immunotherapy, 2001, 24, 272-279.	2.4	144
178	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy, 2001, 24, 263-271.	2.4	188
179	Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments. Cancer Investigation, 2001, 19, 833-841.	1.3	61
180	Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. Annals of Oncology, 2001, 12, 1493-1494.	1.2	15
181	Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Annals of Oncology, 2001, 12, 457-462.	1.2	17
182	Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Annals of Oncology, 2001, 12, 109-114.	1.2	58
183	Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 2001, 97, 1392-1398.	1.4	175
184	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 2001, 98, 952-957.	1.4	531
185	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, 2001, 98, 1352-1357.	1.4	207
186	A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood, 2001, 98, 2535-2543.	1.4	130
187	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 2001, 98, 2771-2777.	1.4	184
188	Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2001, 19, 389-397.	1.6	415
189	Immunotherapy of Non-Hodgkin's Lymphomas. Hematology American Society of Hematology Education Program, 2001, 2001, 221-240.	2.5	72
190	Non-Hodgkin's lymphoma. Clinical Medicine, 2001, 1, 362-364.	1.9	0
192	Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy. Cancer Immunology, Immunotherapy, 2001, 50, 157-162.	4.2	4

#	ARTICLE	IF	CITATIONS
193	Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. <i>Annals of Hematology</i> , 2001, 80, 170-173.	1.8	36
194	Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab. <i>Annals of Hematology</i> , 2001, 80, 479-481.	1.8	10
197	Antibody-based diagnostic and therapeutic innovations for human cancer. <i>Comprehensive Therapy</i> , 2001, 27, 183-194.	0.2	1
198	Antik�rper, Immuntoxine, Radioimmunkonjugate. <i>Onkologe</i> , 2001, 7, 1206-1219.	0.7	1
199	Autologous peripheral blood stem cell transplantation and anti-B-cell directed immunotherapy for refractory auto-immune haemolytic anaemia. <i>European Journal of Pediatrics</i> , 2001, 160, 492-496.	2.7	21
200	Efficacy of anti-CD20 chimeric Fab�™ fragment on proliferation of B lymphoma cells. <i>Science Bulletin</i> , 2001, 46, 1182-1186.	1.7	2
201	Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab. <i>International Journal of Hematology</i> , 2001, 73, 213-221.	1.6	43
202	Assessment of Prognostic Factors in Follicular Lymphoma Patients. <i>International Journal of Hematology</i> , 2001, 73, 363-368.	1.6	19
203	Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody. <i>International Journal of Hematology</i> , 2001, 74, 70-75.	1.6	39
204	Intralesional rituximab for cutaneous B-cell lymphoma. <i>British Journal of Dermatology</i> , 2001, 144, 1239-1243.	1.5	71
205	Spontaneous remission of juvenile idiopathic myelofibrosis. <i>British Journal of Haematology</i> , 2001, 112, 1083-1083.	2.5	10
206	Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. <i>British Journal of Haematology</i> , 2001, 114, 800-809.	2.5	175
207	Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. <i>British Journal of Haematology</i> , 2001, 115, 79-83.	2.5	100
208	Rituximab, a chimaeric anti�CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. <i>British Journal of Haematology</i> , 2001, 115, 609-611.	2.5	102
209	Complement activation plays a key role in the side�effects of rituximab treatment. <i>British Journal of Haematology</i> , 2001, 115, 807-811.	2.5	273
210	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 13-25.	4.4	37
211	Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 47-61.	4.4	27
212	Susceptibility of B-cell lymphoma to human antibodies encoded by the V4-34 gene. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 39, 59-68.	4.4	5

#	ARTICLE	IF	CITATIONS
213	Rituximab: perspective on single agent experience, and future directions in combination trials. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 40, 3-16.	4.4	72
214	Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. <i>American Journal of Hematology</i> , 2001, 66, 142-144.	4.1	171
215	Humanization and characterization of the anti-HLA-DR antibody 1D10. <i>International Journal of Cancer</i> , 2001, 93, 556-565.	5.1	57
216	A novel β -thalassemia intermedia phenotype containing Nt494+129T>C and NT494+132C>A mutations in cis and a Nt168C>T (β o 39 point) mutation in trans. <i>American Journal of Hematology</i> , 2001, 67, 57-58.	4.1	2
217	Normal β globin gene sequence in carrier of the silent β 101 (C-T) β -thalassemia mutation with normal HbA2 level. <i>American Journal of Hematology</i> , 2001, 67, 58-58.	4.1	4
218	Multiple complications of IVIG therapy in a patient with Guillain-Barré syndrome. <i>American Journal of Hematology</i> , 2001, 67, 59-59.	4.1	15
219	Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. <i>American Journal of Hematology</i> , 2001, 67, 59-60.	4.1	30
220	Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. <i>Arthritis and Rheumatism</i> , 2001, 44, 2836-2840.	6.7	362
221	Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors. <i>European Journal of Immunology</i> , 2001, 31, 259-264.	2.9	7
222	Metastatic gastric maltoma: a rare cause of obscure gastrointestinal bleeding. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1167-1170.	2.3	0
223	Rituximab (Mabthera TM , Rituxan TM) in Patients with Recurrent Indolent Lymphoma. <i>Medical Oncology</i> , 2001, 18, 141-148.	2.5	24
224	Trastuzumab: Designer Drug or Fashionable Fad?. <i>Clinical Oncology</i> , 2001, 13, 427-433.	1.4	1
225	Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. <i>British Journal of Cancer</i> , 2001, 85, 129-136.	6.4	59
226	Rituximab: mechanisms and applications. <i>British Journal of Cancer</i> , 2001, 85, 1619-1623.	6.4	86
227	New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2001, 73, 32-38.	1.6	14
228	Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. <i>Leukemia</i> , 2001, 15, 186-187.	7.2	21
229	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. <i>Leukemia</i> , 2001, 15, 1619-1626.	7.2	124
230	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	7.2	49

#	ARTICLE	IF	CITATIONS
231	Improving the efficacy of antibody-based cancer therapies. <i>Nature Reviews Cancer</i> , 2001, 1, 118-129.	28.4	767
238	Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. <i>Journal of Immunological Methods</i> , 2001, 248, 103-111.	1.4	71
239	Monoclonal Antibody Therapy for Lymphoma. An Update. <i>Cancer Practice</i> , 2001, 9, 71-80.	0.7	37
240	Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. <i>Experimental Hematology</i> , 2001, 29, 1410-1416.	0.4	33
241	Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. <i>European Journal of Haematology</i> , 2001, 66, 408-411.	2.2	41
242	Anti-CD20 Monoclonal Antibody Treatment of Human Herpesvirus 8-Associated, Body Cavity-Based Lymphoma with an Unusual Phenotype in a Human Immunodeficiency Virus-Negative Patient. <i>Vaccine Journal</i> , 2001, 8, 993-996.	2.6	31
243	Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 2001, 106, 141-142.	1.4	3
244	Specific Immunotherapy for Non-Hodgkin's Lymphoma. <i>Laboratory Medicine</i> , 2001, 32, 609-616.	1.2	0
245	Evaluation on a Six-Dose Treatment of Anti CD 20 Monoclonal Antibody in Patients with Refractory Follicular Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 159-162.	1.0	5
246	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. <i>Leukemia and Lymphoma</i> , 2001, 42, 1329-1337.	1.3	28
247	Recombinant immunotoxins in targeted cancer cell therapy. <i>Advances in Cancer Research</i> , 2001, 81, 93-124.	5.0	50
248	Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. <i>Blood</i> , 2001, 97, 101-106.	1.4	506
249	A phase II study of the bispecific antibody MDX-H210 (anti-HER2 \bar{A} — CD64) with GM-CSF in HER2+ advanced prostate cancer. <i>British Journal of Cancer</i> , 2001, 85, 152-156.	6.4	94
250	A Systematic Overview of Chemotherapy Effects in Indolent Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 2001, 40, 213-223.	1.8	32
251	Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. <i>Rheumatology</i> , 2001, 40, 205-211.	1.9	483
252	Monotherapy with Rituximab Induces Rapid Remission of Recurrent Cold Agglutinin-Mediated Hemolytic Anemia in a Patient with Indolent Lympho-Plasmacytic Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 1405-1408.	1.3	32
253	High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. <i>Leukemia and Lymphoma</i> , 2001, 42, 1255-1264.	1.3	0
254	Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal Antibody. <i>Acta Dermato-Venereologica</i> , 2001, 81, 207-208.	1.3	35

#	ARTICLE	IF	CITATIONS
255	Chemotherapy with Irinotecan (CPT-11), a Topoisomerase-I Inhibitor, for Refractory and Relapsed Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 577-586.	1.3	8
256	Advances in the management of patients with non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 43-52.	2.4	4
257	Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 731-738.	1.3	93
258	Komplette Remission eines langjährig therapierefraktären sekundär hochmalignen Non-Hodgkin-Lymphoms nach Therapie mit Bendamustin und CD 20-Ak (Rituximab). <i>Tumor Diagnostik Und Therapie</i> , 2001, 22, 15-19.	0.1	1
259	Antibody therapy of lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 953-961.	1.8	13
260	Rituximab in the Treatment of Refractory Follicular Lymphoma - Six Doses Are Better Than Four. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 313-316.	1.8	11
261	Monoclonal antibody therapy. <i>Advances in Protein Chemistry</i> , 2001, 56, 369-421.	4.4	11
262	Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced by Paclitaxel, Gemcitabine, and Vinorelbine. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 621-630.	1.0	41
263	In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 1303-1312.	1.3	25
264	High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer. <i>Human Gene Therapy</i> , 2002, 13, 1483-1493.	2.7	34
265	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. <i>Blood</i> , 2002, 99, 4336-4342.	1.4	257
266	A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. <i>British Journal of Cancer</i> , 2002, 86, 811-818.	6.4	32
267	Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa. <i>Journal of the National Cancer Institute</i> , 2002, 94, 718-732.	6.3	17
268	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. <i>Annals of Oncology</i> , 2002, 13, 928-943.	1.2	127
269	Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3885-3890.	1.6	105
270	Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin's Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. <i>Journal of Clinical Oncology</i> , 2002, 20, 4649-4654.	1.6	62
271	Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	1.6	1,069
272	Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. <i>Bone Marrow Transplantation</i> , 2002, 29, 871-872.	2.4	41

#	ARTICLE	IF	CITATIONS
273	Immunophenotypic Variability of B-Cell Non-Hodgkin Lymphoma. American Journal of Clinical Pathology, 2002, 117, 615-620.	0.7	24
274	Immune-based therapies: A review of clinical endpoints used in trials of selected immunologic agents, by the Forum for Collaborative HIV Research. HIV Clinical Trials, 2002, 3, 58-88.	2.0	2
275	Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma. Journal of Clinical Oncology, 2002, 20, 3545-3557.	1.6	104
276	Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma. Hematology American Society of Hematology Education Program, 2002, 2002, 241-262.	2.5	43
277	Rituximab in Lymphoma with Life Threatening Haemolysis. Leukemia and Lymphoma, 2002, 43, 1711-1712.	1.3	1
278	CHOP plus Rituximab â€” Balancing Facts and Opinion. New England Journal of Medicine, 2002, 346, 280-282.	27.0	45
279	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplantation, 2002, 29, 769-775.	2.4	44
280	Rituximab: clinical development and future directions. Expert Opinion on Biological Therapy, 2002, 2, 97-110.	3.1	36
281	Real-Time t(14;18)(q32;q21) PCR Assay Combined with High-Resolution Capillary Electrophoresis: A Novel and Rapid Approach that Allows Accurate Quantitation and Size Determination of bcl-2/JH Fusion Sequences. Modern Pathology, 2002, 15, 448-453.	5.5	16
282	Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2002, 43, 149-151.	1.3	60
283	Engineering Antibodies for Therapy. Current Pharmaceutical Biotechnology, 2002, 3, 237-256.	1.6	85
286	In vivo purging and relapse prevention following ASCT. Bone Marrow Transplantation, 2002, 29, S5-S9.	2.4	9
287	Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2002, 29, S14-S17.	2.4	16
288	Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia, 2002, 16, 693-699.	7.2	60
289	Application of Recombinant Antibodies in Cancer Patients. , 2003, 207, 27-54.		0
290	Advances in the treatment of non-Hodgkin's lymphoma. Annals of Oncology, 2002, 13, 211-216.	1.2	9
291	Stevensâ€™Johnson syndrome after treatment with rituximab. Annals of Oncology, 2002, 13, 1948-1950.	1.2	96
292	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology, 2002, 13, 523-530.	1.2	42

#	ARTICLE	IF	CITATIONS
293	Progress and Promise in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2002, 7, 217-225.	3.7	23
294	Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4261-4267.	1.6	388
296	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 1278-1287.	1.6	59
297	Cancer Vaccines. <i>Oncologist</i> , 2002, 7, 20-33.	3.7	253
299	6.è æ¶²ā ā«āāāā,ā...ç—«ç™,æ³•. The Journal of the Japanese Society of Internal Medicine, 2002, 91, 1998-2002.o.o		0
300	Radioimmunotherapy in non-Hodgkin lymphoma. <i>Current Opinion in Oncology</i> , 2002, 14, 484-489.	2.4	6
301	CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications. <i>Journal of Immunotherapy</i> , 2002, 25, 72-81.	2.4	123
302	Rituximab for Aggressive Non-Hodgkin's Lymphomas Relapsing After or Refractory to Autologous Stem Cell Transplantation. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 371-376.	2.0	23
303	Using Unconjugated Antibodies as an Immunotherapeutic Approach to Treatment of B-cell Neoplasms. <i>Journal of Infusion Nursing</i> , 2002, 25, 266-273.	2.3	0
304	Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 67-74.	1.4	149
305	The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. <i>Blood</i> , 2002, 99, 1038-1043.	1.4	350
306	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002, 99, 856-862.	1.4	155
307	Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 1092-1094.	1.4	84
308	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. <i>Blood</i> , 2002, 99, 754-758.	1.4	1,819
309	Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2002, 100, 768-773.	1.4	472
310	Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. <i>Blood</i> , 2002, 100, 1922-1923.	1.4	32
311	Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2002, 100, 1923-1925.	1.4	6
312	Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, S1-S4.	2.4	10

#	ARTICLE	IF	CITATIONS
314	Treatment of Waldenström's Macroglobulinemia With Rituximab. <i>Journal of Clinical Oncology</i> , 2002, 20, 2327-2333.	1.6	248
315	Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3262-3269.	1.6	624
316	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	27.0	4,928
318	High-dose treatment with autologous haemopoietic progenitor cell support for large B-cell, follicular and mantle-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 467-480.	1.7	5
319	Antibody-based therapy of non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 449-465.	1.7	10
320	New agents in the treatment of acute lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 771-790.	1.7	8
321	Mitoxantrone/Ifosfamide/Etoposide Salvage Regimen with Rituximab for In Vivo Purging in Patients with Relapsed Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 111-116.	2.1	8
322	Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 163-166.	2.1	71
324	Efficacy of plant-produced recombinant antibodies against HCG. <i>Human Reproduction</i> , 2002, 17, 2054-2061.	0.9	76
325	Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 544-549.	2.0	12
326	Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 2335-2341.	1.3	40
327	Monoclonal Antibody Therapy of Haematological Malignancies. <i>BioDrugs</i> , 2002, 16, 283-301.	4.6	10
328	Rituximab and other emerging monoclonal antibody therapies for lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 289-302.	2.4	10
329	Monotherapy with the anti-cd20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. <i>Transplantation Proceedings</i> , 2002, 34, 1178-1181.	0.6	16
330	Strategy against micrometastasis of epithelial cancer: Detection and elimination. <i>Science Bulletin</i> , 2002, 47, 1415.	1.7	1
331	Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 3115-3120.	1.4	200
332	Monoclonal antibody therapies in leukemias. <i>Seminars in Hematology</i> , 2002, 39, 12-19.	3.4	34
333	CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 441-443.	1.2	28

#	ARTICLE	IF	CITATIONS
334	Current treatment of follicular non-Hodgkin's lymphoma. European Journal of Cancer, 2002, 38, 1167-1172.	2.8	26
335	Correlation of Red Marrow Radiation Dosimetry with Myelotoxicity: Empirical Factors Influencing the Radiation-Induced Myelotoxicity of Radiolabeled Antibodies, Fragments and Peptides in Pre-Clinical and Clinical Settings. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 445-464.	1.0	30
336	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. Journal of Urology, 2002, 168, 2615-2623.	0.4	11
337	Emerging technology and future developments in flow cytometry. Hematology/Oncology Clinics of North America, 2002, 16, 477-495.	2.2	2
338	Intensive therapies in follicular non-Hodgkin lymphomas. Blood, 2002, 100, 1141-1152.	1.4	56
339	Targeted $\hat{\pm}$ particle immunotherapy for myeloid leukemia. Blood, 2002, 100, 1233-1239.	1.4	430
340	Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood, 2002, 100, 2257-2259.	1.4	244
341	Rituximab in Combination with Chop Improves Survival in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma. Tumori, 2002, 88, S26-S28.	1.1	7
342	First Isolation of West Nile virus from a Patient with Encephalitis in the United States. Emerging Infectious Diseases, 2002, 8, 1367-1371.	4.3	102
343	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. Journal of Clinical Oncology, 2002, 20, 1278-1287.	1.6	79
344	Molecular Targets in Cancer Therapy and Their Impact on Cancer Management. Oncology, 2002, 63, 1-5.	1.9	11
345	Update in Hematology. Annals of Internal Medicine, 2002, 136, 136.	3.9	32
346	Emerging information on the use of rituximab in chronic lymphocytic leukemia. Seminars in Oncology, 2002, 29, 70-74.	2.2	52
347	Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. Seminars in Oncology, 2002, 29, 48-55.	2.2	14
348	Rituximab: Ongoing and future clinical development. Seminars in Oncology, 2002, 29, 105-112.	2.2	152
349	Advances in classification and therapy of indolent B-cell malignancies. Seminars in Oncology, 2002, 29, 98-104.	2.2	21
350	Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal) Tj ETQq0 0 0 rgBTj /Overlock 10 Tf 50	2.2	64
351	Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia. Seminars in Oncology, 2002, 29, 75-80.	2.2	12

#	ARTICLE	IF	CITATIONS
352	Rituximab in the treatment of diffuse large B-cell lymphomas. <i>Seminars in Oncology</i> , 2002, 29, 30-35.	2.2	51
353	Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. <i>Seminars in Oncology</i> , 2002, 29, 25-29.	2.2	36
354	Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. <i>Seminars in Oncology</i> , 2002, 29, 10-24.	2.2	37
355	Rituximab: Mechanism of action and resistance. <i>Seminars in Oncology</i> , 2002, 29, 2-9.	2.2	297
356	Increasing treatment options in indolent non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 2-6.	2.2	7
357	Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon- γ and granulocyte-macrophage colony stimulating factor. <i>Seminars in Oncology</i> , 2002, 29, 7-10.	2.2	31
358	Immunochemotherapy in indolent non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 11-17.	2.2	26
359	Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2002, 29, 18-22.	2.2	94
360	Improving outcomes in transplantation. <i>Seminars in Oncology</i> , 2002, 29, 23-26.	2.2	7
361	Challenges in treating hematologic malignancies. <i>Seminars in Oncology</i> , 2002, 29, 30-39.	2.2	6
362	Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. <i>European Journal of Haematology</i> , 2002, 68, 243-246.	2.2	31
363	Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. <i>European Journal of Haematology</i> , 2002, 69, 21-26.	2.2	26
364	Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. <i>European Journal of Haematology</i> , 2002, 69, 129-134.	2.2	99
365	Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14. <i>European Journal of Haematology</i> , 2002, 69, 321-323.	2.2	4
366	Use of EBV PCR for the Diagnosis and Monitoring of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Patients. <i>American Journal of Transplantation</i> , 2002, 2, 946-954.	4.7	70
367	Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. <i>American Journal of Hematology</i> , 2002, 70, 181-185.	4.1	5
368	Rituximab for the treatment of type II mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2002, 46, 2252-2254.	6.7	56
369	Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: Comment on the article by Ray et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 2262-2263.	6.7	31

#	ARTICLE	IF	CITATIONS
370	Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 2257-2258.	6.7	34
376	Anti-tumor necrosis factor therapy and <i>Listeria monocytogenes</i> infection: Report of two cases. Arthritis and Rheumatism, 2002, 46, 2255-2257.	6.7	83
377	Criteria for TUNEL labeling in determining apoptosis in human osteoarthritis cartilage: Comment on the article by Aigner et al. Arthritis and Rheumatism, 2002, 46, 2260-2261.	6.7	18
378	Synovial lymphocyte responses to microbiologic antigen stimulation indicate the etiology of undifferentiated and reactive arthritis, and possibly of rheumatoid arthritis: Comment on the article by Schnarr et al. Arthritis and Rheumatism, 2002, 46, 2259-2260.	6.7	1
379	On my knees (Instructions to Authors). Arthritis and Rheumatism, 2002, 46, 2264-2264.	6.7	0
380	Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer, 2002, 98, 561-566.	5.1	19
381	Monoclonal Antibody Therapy for B-Cell Lymphoma. International Journal of Hematology, 2002, 76, 385-393.	1.6	34
382	Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma. International Journal of Hematology, 2002, 76, 394-400.	1.6	8
383	Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. International Journal of Hematology, 2002, 76, 411-419.	1.6	23
384	Heavy chain disease. Current Treatment Options in Oncology, 2002, 3, 247-254.	3.0	31
385	Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin's Lymphoma. Current Treatment Options in Oncology, 2002, 3, 275-282.	3.0	27
386	Vaccine therapies for Non-Hodgkin's Lymphoma. Current Treatment Options in Oncology, 2002, 3, 307-315.	3.0	12
388	Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Annals of Hematology, 2002, 81, 26-32.	1.8	76
389	Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Annals of Hematology, 2002, 81, 405-406.	1.8	13
390	Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Annals of Hematology, 2002, 81, 736-738.	1.8	13
391	Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Journal of Cancer Research and Clinical Oncology, 2002, 128, 161-166.	2.5	33
392	Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology, 2002, 128, 484-492.	2.5	37
393	Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. British Journal of Dermatology, 2002, 146, 144-147.	1.5	39

#	ARTICLE	IF	CITATIONS
394	Skin as a Potential Organ for Ectopic Monoclonal Antibody Production11The authors declared not to have a conflict of interest.. Journal of Investigative Dermatology, 2002, 118, 288-294.	0.7	11
395	A sequence of immunochemotherapy with Rituximab, mobilization of <i>in vivo</i> purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. British Journal of Haematology, 2002, 116, 229-235.	2.5	54
396	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. British Journal of Haematology, 2002, 117, 828-834.	2.5	131
397	Differentiation between non-Hodgkin's lymphoma recurrence and second primary lymphoma by VDJ rearrangement analysis. British Journal of Haematology, 2002, 118, 809-812.	2.5	14
398	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma*. British Journal of Haematology, 2002, 119, 125-127.	2.5	58
399	Flow cytometry and the study of cerebrospinal fluid in leukaemic patients: additional facts. British Journal of Haematology, 2002, 116, 725-725.	2.5	4
400	Reversible abnormal chromatin clumping in granulocytes from six transplant patients treated with mycophenolate mofetil: a rare adverse effect mimicking abnormal chromatin clumping syndrome. British Journal of Haematology, 2002, 116, 726-727.	2.5	7
401	Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. British Journal of Haematology, 2002, 116, 727-728.	2.5	31
402	Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after mabthera. British Journal of Haematology, 2002, 117, 248-248.	2.5	14
403	Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplantation, 2002, 30, 229-234.	2.4	15
404	CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia, 2002, 16, 1735-1744.	7.2	77
405	Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia, 2002, 16, 2004-2015.	7.2	58
406	Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia, 2002, 16, 2092-2095.	7.2	126
407	Antibody evolution beyond Nature. Nature Biotechnology, 2002, 20, 1189-1190.	17.5	38
408	Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies. Stem Cells, 2002, 20, 215-229.	3.2	49
409	Biodistribution and kinetics of ¹³¹ I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1276-1282.	6.4	42
410	Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?. Journal of Clinical Immunology, 2002, 22, 124-130.	3.8	64
411	Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. Journal of Neuro-Oncology, 2002, 59, 213-216.	2.9	63

#	ARTICLE	IF	CITATIONS
412	Recombinant Antibodies for the Diagnosis and Treatment of Cancer. Molecular Biotechnology, 2003, 25, 1-18.	2.4	12
414	Induction of Complete Remission of Hypoplastic Leukemia with Antithymocyte Globulin. International Journal of Hematology, 2003, 77, 277-281.	1.6	4
415	Immunotherapy for Lymphomas. International Journal of Hematology, 2003, 77, 444-455.	1.6	29
416	Innovative strategies in lymphoma therapy. Wiener Klinische Wochenschrift, 2003, 115, 462-470.	1.9	2
417	New strategies in radioimmunotherapy for lymphoma. Current Oncology Reports, 2003, 5, 364-371.	4.0	7
418	B cell depletion therapy in systemic lupus erythematosus. Current Rheumatology Reports, 2003, 5, 350-356.	4.7	63
419	Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunology, Immunotherapy, 2003, 52, 257-280.	4.2	46
420	Human antiglobulin response to foreign antibodies: therapeutic benefit?. Cancer Immunology, Immunotherapy, 2003, 52, 309-316.	4.2	52
421	Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Cancer Chemotherapy and Pharmacology, 2003, 52, 90-96.	2.3	1
422	Spezifische Immuntherapien zur Behandlung von Krebs im Kindesalter. Monatsschrift Fur Kinderheilkunde, 2003, 151, 646-653.	0.1	0
423	Therapy of non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, S28-S36.	6.4	32
424	Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma. International Journal of Clinical Oncology, 2003, 8, 212-223.	2.2	12
425	Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. Seminars in Cancer Biology, 2003, 13, 223-231.	9.6	13
426	Immunotherapy with anti-CD20 compounds. Seminars in Cancer Biology, 2003, 13, 211-222.	9.6	17
427	History of antibody therapy for non-Hodgkin's lymphoma. Seminars in Oncology, 2003, 30, 1-5.	2.2	38
428	Future directions in radioimmunotherapy for B-cell lymphoma. Seminars in Oncology, 2003, 30, 29-34.	2.2	21
429	Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly. Seminars in Oncology, 2003, 30, 21-27.	2.2	24
430	First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology, 2003, 30, 9-15.	2.2	24

#	ARTICLE	IF	CITATIONS
431	Rituximab plus chemotherapy in follicular and mantle cell lymphomas. <i>Seminars in Oncology</i> , 2003, 30, 16-20.	2.2	64
432	The mechanisms of action of rituximab in the elimination of tumor cells. <i>Seminars in Oncology</i> , 2003, 30, 3-8.	2.2	186
433	Rituximab in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2003, 30, 34-39.	2.2	24
434	Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. <i>Seminars in Oncology</i> , 2003, 30, 248-252.	2.2	33
435	CD22 as a target of passive immunotherapy. <i>Seminars in Oncology</i> , 2003, 30, 253-257.	2.2	61
436	Radioimmunotherapy for Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 258-261.	2.2	8
437	Waldenstrom's macroglobulinemia: A retrospective analysis of 40 patients from 1972 to 2001. <i>Seminars in Oncology</i> , 2003, 30, 236-238.	2.2	5
438	Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. <i>Seminars in Oncology</i> , 2003, 30, 434-447.	2.2	32
439	Rituximab in B-Cell chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2003, 30, 483-492.	2.2	50
440	CD22-directed monoclonal antibody therapy for lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 457-464.	2.2	27
441	Antibodies for the treatment of diffuse large cell lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 448-456.	2.2	15
442	Alemtuzumab therapy in B-cell lymphoproliferative disorders. <i>Seminars in Oncology</i> , 2003, 30, 493-501.	2.2	31
443	Overview of non-Hodgkin's lymphoma: Biology, staging, and treatment. <i>Seminars in Oncology</i> , 2003, 30, 3-9.	2.2	20
444	Radioimmunotherapy for non-Hodgkin's lymphomas: A historical perspective. <i>Seminars in Oncology</i> , 2003, 30, 10-21.	2.2	10
445	A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. <i>Seminars in Oncology</i> , 2003, 30, 22-30.	2.2	14
446	Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. <i>Hematological Oncology</i> , 2003, 21, 99-108.	1.7	7
447	Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. <i>American Journal of Hematology</i> , 2003, 73, 37-40.	4.1	11
448	The relationship of Fc γ R1IIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 455-459.	6.7	420

#	ARTICLE	IF	CITATIONS
449	Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 2146-2154.	6.7	424
450	Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. Leukemia Research, 2003, 27, 1097-1099.	0.8	4
451	Monoclonal antibody therapy for lymphoma. Blood Reviews, 2003, 17, 143-152.	5.7	34
452	Central lymphatic irradiation for stage Iâ€“III follicular lymphoma: report from a single-institutional prospective study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 316-320.	0.8	21
453	Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child. Pediatric Transplantation, 2003, 7, 153-156.	1.0	12
454	Anti-CD20 monoclonal antibody (rituximab) therapy in a child with refractory chronic autoimmune haemolytic anaemia. Internal Medicine Journal, 2003, 33, 544-545.	0.8	4
455	Delayed-onset neutropenia associated with rituximab therapy. British Journal of Haematology, 2003, 121, 913-918.	2.5	125
456	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 122, 457-464.	2.5	73
457	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 123, 271-277.	2.5	30
458	Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. British Journal of Haematology, 2003, 123, 850-857.	2.5	49
459	Clinical use of rituximab in haematological malignancies. British Journal of Cancer, 2003, 89, 1389-1394.	6.4	50
460	Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2003, 31, 775-782.	2.4	14
461	Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2003, 32, 673-679.	2.4	105
462	Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia, 2003, 17, 900-909.	7.2	132
463	Costimulatory signals distinctively affect CD20- and B-cell-antigen-receptor-mediated apoptosis in Burkitt's lymphoma/leukemia cells. Leukemia, 2003, 17, 1164-1174.	7.2	22
464	Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia, 2003, 17, 1658-1664.	7.2	58
465	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene, 2003, 22, 6005-6012.	5.9	103
466	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22, 7359-7368.	5.9	690

#	ARTICLE	IF	CITATIONS
467	Immunotherapy: past, present and future. <i>Nature Medicine</i> , 2003, 9, 269-277.	30.7	540
468	Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. <i>Blood Reviews</i> , 2003, 17, 25-31.	5.7	25
469	Unique Aspects of Supportive Care Using Monoclonal Antibodies in Cancer Treatment. <i>Supportive Cancer Therapy</i> , 2003, 1, 38-48.	0.3	38
470	Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. <i>Cytotherapy</i> , 2003, 5, 131-138.	0.7	57
471	Introducción al tratamiento oncológico: indicaciones e intención de los tratamientos. <i>Gaceta Medica De Bilbao</i> , 2003, 100, 133-138.	0.0	0
472	Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1340-1346.	3.0	149
473	Rituximab. <i>Drugs</i> , 2003, 63, 803-843.	10.9	412
475	Initial Trials of Anti-CD80 Monoclonal Antibody (Galiximab) Therapy for Patients with Relapsed or Refractory Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 3, 257-259.	2.1	32
476	Use of Ibritumomab Tiuxetan Anti-CD20 Radioimmunotherapy in a Non-Hodgkin's Lymphoma Patient Previously Treated with a Yttrium-90 Labeled Anti-CD22 Monoclonal Antibody. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 56-59.	2.1	11
477	Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 169-175.	2.1	19
478	Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, S5-S12.	2.1	6
479	Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma. <i>Cancer Investigation</i> , 2003, 21, 241-252.	1.3	17
481	Factors Predicting the Response to Rituximab in Indolent Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 19-21.	2.1	1
482	Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. <i>Journal of Clinical Oncology</i> , 2003, 21, 1746-1751.	1.6	330
483	B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 55ii-59.	0.9	78
484	Anti-CD20 Therapy for Chronic Lymphocytic Leukemia-associated Autoimmune Diseases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1951-1955.	1.3	83
485	Targeted therapies for the treatment of cancer. <i>American Journal of Surgery</i> , 2003, 186, 264-268.	1.8	62
486	Radioimmunotherapy of non-Hodgkin lymphomas. <i>Blood</i> , 2003, 101, 391-398.	1.4	165

#	ARTICLE	IF	CITATIONS
487	Non-Hodgkin lymphoma. Lancet, The, 2003, 362, 139-146.	13.7	122
488	Ligand-targeted liposomal anticancer drugs. Progress in Lipid Research, 2003, 42, 439-462.	11.6	387
489	Rituximab therapy for multisystem autoimmune diseases in pediatric patients. Journal of Pediatrics, 2003, 143, 598-604.	1.8	53
490	Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. Journal of Pediatrics, 2003, 143, 670-673.	1.8	22
491	Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. Journal of the American Academy of Dermatology, 2003, 49, 281-287.	1.2	28
492	Monoclonal Antibody Therapy for Cancer. Annual Review of Medicine, 2003, 54, 343-369.	12.2	175
493	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003, 101, 6-14.	1.4	549
494	Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biology of Blood and Marrow Transplantation, 2003, 9, 505-511.	2.0	204
495	Indolent B-Cell Malignancies: Immune Recognition and Antiself. Leukemia and Lymphoma, 2003, 44, S77-S83.	1.3	0
496	Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Research, 2003, 5, S12.	2.0	57
497	Spotlight on Rituximab in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia1. American Journal of Cancer, 2003, 2, 283-289.	0.4	0
498	Monoclonal Antibodies: The Good, The Bad, and The Ugly. Journal of Hematotherapy and Stem Cell Research, 2003, 12, 3-6.	1.8	0
499	Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder. Leukemia and Lymphoma, 2003, 44, 889-890.	1.3	30
500	Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2003, 44, 477-481.	1.3	29
501	Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?. Leukemia and Lymphoma, 2003, 44, 1309-1315.	1.3	15
502	An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology, 2003, 14, 520-535.	1.2	261
503	Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2003, 21, 1263-1270.	1.6	278
504	Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2003, 21, 3051-3059.	1.6	245

#	ARTICLE	IF	CITATIONS
505	Treatment of IgM antibody associated polyneuropathies using rituximab. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 485-489.	1.9	257
506	Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients. Journal of Clinical Oncology, 2003, 21, 897-906.	1.6	215
507	Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1926-1930.	7.1	144
508	Rational approaches to human cancer immunotherapy. Journal of Leukocyte Biology, 2003, 73, 3-29.	3.3	109
509	Alternative Concepts of Suicide Gene Therapy for Graft-versus-Host Disease after Adoptive Immunotherapy. Acta Haematologica, 2003, 110, 132-138.	1.4	2
510	Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opinion on Drug Safety, 2003, 2, 467-473.	2.4	9
511	Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology, 2003, 21, 2466-2473.	1.6	71
512	Radioimmunotherapy with ¹³¹ I-Rituximab: What We Know and What We Don't Know. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 489-495.	1.0	7
513	Anthrax toxin: structures, functions and tumour targeting. Expert Opinion on Biological Therapy, 2003, 3, 843-853.	3.1	54
514	EpCAM: A New Therapeutic Target for an Old Cancer Antigen. Cancer Biology and Therapy, 2003, 2, 320-325.	3.4	141
515	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. British Journal of Cancer, 2003, 89, 36-42.	6.4	68
516	Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2003, 21, 1874-1881.	1.6	69
517	Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as "in vivo purge" and consolidative immunotherapy following autologous stem cell transplantation. Annals of Oncology, 2003, 14, 758-765.	1.2	31
518	ABCs of Radioisotopes Used for Radioimmunotherapy: ¹ ±- and ¹² -Emitters. Leukemia and Lymphoma, 2003, 44, S107-S113.	1.3	15
519	T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct. Journal of Immunology, 2003, 170, 4397-4402.	0.8	183
520	Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Annals of Oncology, 2003, 14, i5-i10.	1.2	93
521	Herpesvirus Infections in Organ Transplant Recipients. Vaccine Journal, 2003, 10, 1-7.	3.1	48
522	Ibritumomab Tiuxetan: The Cancer Smart Bomb. Journal of the American Pharmacists Association: JAPhA, 2003, 43, 437-438.	1.5	0

#	ARTICLE	IF	CITATIONS
523	Hematologic Malignancies. , 2003, , 487-506.		0
524	Rituximab (Rituxan®/MabThera®): the first decade (1993–2003). Expert Review of Anticancer Therapy, 2003, 3, 767-779.	2.4	57
525	Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature. Oncology Research and Treatment, 2003, 26, 351-354.	1.2	44
526	Successful Rituximab Therapy for Hemolytic Anemia Associated with Relapsed Splenic Marginal Zone Lymphoma with Leukemic Phase. Leukemia and Lymphoma, 2003, 44, 2165-2166.	1.3	20
527	Biology and Treatment of Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2003, 2003, 153-175.	2.5	96
528	Induction of Long-Term Remission of a Relapsed Childhood “Acute Lymphoblastic Leukemia With Rituximab Chimeric Anti-CD20 Monoclonal Antibody and Autologous Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2003, 25, 327-329.	0.6	33
529	Advances in the therapy of chronic lymphocytic leukemia. Current Opinion in Hematology, 2003, 10, 297-305.	2.5	6
530	Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. Anti-Cancer Drugs, 2003, 14, 809-815.	1.4	9
531	Immunotherapy of lymphoma: update and review of the literature. Current Opinion in Oncology, 2003, 15, 363-370.	2.4	4
532	In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood, 2003, 101, 949-954.	1.4	333
533	An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood, 2003, 101, 1071-1079.	1.4	144
534	Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 2003, 101, 466-468.	1.4	393
535	Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood, 2003, 101, 3818-3826.	1.4	361
536	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	1.4	391
537	Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood, 2003, 101, 3857-3861.	1.4	278
538	Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood, 2003, 102, 810-813.	1.4	143
539	Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 2003, 102, 3514-3520.	1.4	125
540	Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood, 2003, 102, 407-408.	1.4	97

#	ARTICLE	IF	CITATIONS
541	Rituximab in relapsed or refractory hairy cell leukemia. Blood, 2003, 102, 3906-3911.	1.4	155
542	No clinical evidence for CD4+ cell depletion caused by rituximab. Blood, 2003, 102, 408-409.	1.4	17
543	Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. Blood, 2003, 102, 2309-2310.	1.4	2
544	Is sperm protein 17 a useful target for tumor immunotherapy?. Blood, 2003, 102, 2308-2309.	1.4	12
545	Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 2003, 101, 420-424.	1.4	145
546	Targeted drugs in oncology: New names, new mechanisms, new paradigm. American Journal of Health-System Pharmacy, 2003, 60, 1233-1243.	1.0	6
547	Monoclonal antibodies in the treatment of cancer, part 1. American Journal of Health-System Pharmacy, 2003, 60, 1531-1548.	1.0	34
548	Therapeutic Idiotypic Vaccines for Non-Hodgkin's Lymphoma. Advances in Pharmacology, 2004, 51, 271-293.	2.0	8
549	Radioimmunotherapy of non-Hodgkin's lymphoma: Clinical development of the Zevalin regimen. Biotechnology Annual Review, 2004, 10, 265-295.	2.1	19
550	Antibody Therapy of Lymphoma. Advances in Pharmacology, 2004, 51, 229-253.	2.0	8
551	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Leukemia and Lymphoma, 2004, 45, 937-944.	1.3	29
552	Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs, 2004, 13, 577-607.	4.1	6
553	An update on the management of chronic lymphocytic leukaemia. Expert Opinion on Pharmacotherapy, 2004, 5, 1535-1554.	1.8	4
554	Monoclonal antibody therapy of B cell lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 375-385.	3.1	20
555	Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Review of Anticancer Therapy, 2004, 4, 18-26.	2.4	27
556	Heterogeneity in the Multiple Myeloma Tumor Clone. Leukemia and Lymphoma, 2004, 45, 857-871.	1.3	8
557	Cardiac Toxicity During Rituximab Administration. Leukemia and Lymphoma, 2004, 45, 203-204.	1.3	18
558	Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease. Human Gene Therapy, 2004, 15, 63-76.	2.7	94

#	ARTICLE	IF	CITATIONS
559	Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. <i>Annals of Oncology</i> , 2004, 15, 1109-1114.	1.2	50
560	Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy. <i>Expert Reviews in Molecular Medicine</i> , 2004, 6, 1-17.	3.9	25
561	Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 2654-2661.	1.6	130
562	Bexxar Â® : Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma. <i>Oncologist</i> , 2004, 9, 160-172.	3.7	68
563	Rituximab-Dependent Cytotoxicity by Natural Killer Cells. <i>Cancer Research</i> , 2004, 64, 4664-4669.	0.9	395
564	The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7792-7798.	7.0	142
565	Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9051-9056.	7.1	34
566	The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy. <i>Journal of Experimental Medicine</i> , 2004, 199, 1659-1669.	8.5	586
567	Clinical Trials for Malignant Lymphoma in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 369-378.	1.3	19
568	Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2004, 10, 2253-2264.	7.0	155
569	Monoclonal Antibody Therapy in Lymphoid Leukemias. <i>Advances in Pharmacology</i> , 2004, 51, 127-167.	2.0	2
570	Radioimmunotherapy With Tositumomab and Iodine-131 Tositumomab for Low-Grade Non-Hodgkin Lymphoma: Nursing Implications. <i>Oncology Nursing Forum</i> , 2004, 31, 1119-1126.	1.2	0
571	Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates. <i>Clinical Cancer Research</i> , 2004, 10, 7842-7851.	7.0	122
572	Treatment of a Patient with Chronic Immune Thrombocytopenic Purpura with Rituximab and Monitoring by Flow Cytometric Analysis. <i>Acta Haematologica</i> , 2004, 111, 221-224.	1.4	6
573	Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format. <i>Journal of Biological Chemistry</i> , 2004, 279, 53907-53914.	3.4	113
574	Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1469-1479.	1.6	109
575	Efficiency of <i>in vivo</i> purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. <i>Annals of Oncology</i> , 2004, 15, 504-510.	1.2	45
576	The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3. <i>Journal of Immunology</i> , 2004, 173, 6009-6016.	0.8	2

#	ARTICLE	IF	CITATIONS
577	Handbook of Cancer Vaccines. , 2004, , .		5
578	Treatment of SLE with Anti-CD20 Monoclonal Antibody. , 2004, 8, 193-205.		39
579	Empowering Targeted Therapy: Lessons from Rituximab. Science Signaling, 2004, 2004, pe30-pe30.	3.6	25
580	Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2004, 10, 5327-5334.	7.0	221
581	Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes. Molecular Therapy, 2004, 9, 577-586.	8.2	78
582	A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. British Journal of Cancer, 2004, 90, 985-990.	6.4	162
583	Gold Standard or Wrong Standard?. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 271-272.	1.0	5
584	Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. Journal of Clinical Oncology, 2004, 22, 4711-4716.	1.6	327
585	Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2004, 10, 2868-2878.	7.0	168
586	Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. Annual Review of Medicine, 2004, 55, 477-503.	12.2	203
587	Radiation Safety Guidelines for Radioimmunotherapy With Yttrium 90 Ibritumomab Tiuxetan. Clinical Journal of Oncology Nursing, 2004, 8, 31-34.	0.6	7
588	Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Annals of Oncology, 2004, 15, 821-830.	1.2	99
589	The Natural History of CLL. , 2004, , 3-54.		1
590	Fludarabine-induced hemolytic anemia: successful treatment by rituximab. The Hematology Journal, 2004, 5, 81-83.	1.4	20
591	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Annals of Oncology, 2004, 15, 1691-1698.	1.2	102
592	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. The Hematology Journal, 2004, 5, 467-471.	1.4	23
593	Idiotype Vaccines in the Treatment of B-Cell Non-Hodgkin's Lymphoma. Cancer Investigation, 2004, 22, 97-105.	1.3	10
594	Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. Journal of Clinical Oncology, 2004, 22, 4717-4724.	1.6	190

#	ARTICLE	IF	CITATIONS
595	Treatment of primary cutaneous follicular centre lymphoma with rituximab: A report of two cases. <i>Australasian Journal of Dermatology</i> , 2004, 45, 34-37.	0.7	14
596	Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. <i>Cancer Science</i> , 2004, 95, 608-613.	3.9	74
597	Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. <i>British Journal of Haematology</i> , 2004, 127, 519-530.	2.5	39
598	Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 33, 921-923.	2.4	84
599	A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 34, 175-179.	2.4	19
600	A novel recombinant bispecific single-chain antibody, bscWue-1 Å— CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. <i>Leukemia</i> , 2004, 18, 636-644.	7.2	11
601	Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. <i>Leukemia</i> , 2004, 18, 616-623.	7.2	83
602	The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. <i>Leukemia</i> , 2004, 18, 1215-1222.	7.2	49
603	Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. <i>British Journal of Cancer</i> , 2004, 91, 1391-1398.	6.4	44
604	Antibodies to CD20 and MHC class II antigen bound to B-lymphoma cells accumulate in shed cytoplasmic fragments. <i>British Journal of Cancer</i> , 2004, 91, 1500-1507.	6.4	6
605	Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses. <i>American Journal of Transplantation</i> , 2004, 4, 1357-1360.	4.7	56
606	Safety of rituximab therapy during the first trimester of pregnancy: a case history. <i>European Journal of Haematology</i> , 2004, 72, 292-295.	2.2	127
607	Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. <i>European Journal of Haematology</i> , 2004, 73, 258-262.	2.2	70
608	A revival of bispecific antibodies. <i>Trends in Biotechnology</i> , 2004, 22, 238-244.	9.3	162
609	Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. <i>Journal of Immunological Methods</i> , 2004, 289, 97-109.	1.4	48
610	Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. <i>Journal of Immunological Methods</i> , 2004, 294, 37-42.	1.4	6
611	Advancing Therapy For Chronic Lymphocytic Leukemia—the Role Of Rituximab. <i>Seminars in Oncology</i> , 2004, 31, 22-26.	2.2	11
612	New Treatment Approaches To Indolent Non-Hodgkin's Lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 27-32.	2.2	16

#	ARTICLE	IF	CITATIONS
613	Advances in follicular lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 66-71.	2.2	14
614	Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. <i>Pathology International</i> , 2004, 54, 667-674.	1.3	22
615	What Is New in Lymphoma?. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 260-272.	329.8	37
616	Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia. <i>Medical Oncology</i> , 2004, 21, 297-304.	2.5	6
617	Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone. <i>International Journal of Hematology</i> , 2004, 79, 311-321.	1.6	13
618	Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas: Results of a Japanese Phase II Study. <i>International Journal of Hematology</i> , 2004, 80, 267-277.	1.6	40
619	A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma: Japan Clinical Oncology Group Study 9002. <i>International Journal of Hematology</i> , 2004, 80, 341-350.	1.6	15
620	A Novel Approach for Cancer Immunotherapy: Tumor Cells with Anchored Superantigen SEA Generate Effective Antitumor Immunity. <i>Journal of Clinical Immunology</i> , 2004, 24, 294-301.	3.8	20
621	Apoptosis Induced by Molecular Targeting Therapy in Hematological Malignancies. <i>Acta Haematologica</i> , 2004, 111, 107-123.	1.4	16
622	Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. <i>Pediatric Nephrology</i> , 2004, 19, 794-797.	1.7	170
623	Immunotherapy of cancer: from vision to standard clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 367-74.	2.5	32
625	CD64 Surface Expression on Neutrophils and Monocytes Is Significantly Up-Regulated after Stimulation with Granulocyte Colony-Stimulating Factor during CHOP Chemotherapy for Patients with Non-Hodgkin's Lymphoma. <i>International Journal of Hematology</i> , 2004, 79, 55-62.	1.6	21
628	Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 110-117.	4.2	81
629	Remarkable response to rituximab in a patient with atypical CD20 ++ mantle cell lymphoma of the bone marrow leading to severe pancytopenia. <i>Annals of Hematology</i> , 2004, 83, 316-318.	1.8	3
630	Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. <i>Annals of Hematology</i> , 2004, 83, 319-321.	1.8	28
631	Satellite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-X. <i>Annals of Hematology</i> , 2004, 83, S59-S137.	1.8	156
632	Epratuzumab in non-hodgkin's lymphomas. <i>Current Treatment Options in Oncology</i> , 2004, 5, 283-288.	3.0	15
633	Advances in the treatment of indolent lymphomas. <i>Reports of Practical Oncology and Radiotherapy</i> , 2004, 9, 169-172.	0.6	0

#	ARTICLE	IF	CITATIONS
634	Rituximab as immunotherapy following autologous stem cell transplantation (ASCT) in a 17-year-old boy with diffuse large B cell lymphoma – a case report. Reports of Practical Oncology and Radiotherapy, 2004, 9, 179-182.	0.6	0
635	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 2004, 59, 234-242.	2.3	98
636	The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatric Transplantation, 2004, 8, 9-21.	1.0	39
637	B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis and Rheumatism, 2004, 50, 2580-2589.	6.7	729
638	Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. American Journal of Hematology, 2004, 77, 303-310.	4.1	34
639	The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer, 2004, 101, 883-893.	4.1	31
640	Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leukemia Research, 2004, 28, 429-442.	0.8	51
641	Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias. Leukemia and Lymphoma, 2004, 45, 205-219.	1.3	52
642	Effectiveness of Fludarabine, Idarubicin and Cyclophosphamide (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2004, 45, 1815-1819.	1.3	7
643	Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 2004, 103, 777-783.	1.4	192
644	Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression. Leukemia and Lymphoma, 2004, 45, 2057-2061.	1.3	39
645	90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 1323-1331.	3.1	0
646	From the bench to the bedside: ways to improve rituximab efficacy. Blood, 2004, 104, 2635-2642.	1.4	494
647	Rituximab-Induced Acute Pulmonary Fibrosis. Mayo Clinic Proceedings, 2004, 79, 949-953.	3.0	51
649	Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia. Journal of Immunology, 2004, 172, 3280-3288.	0.8	322
650	Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/Oncology Clinics of North America, 2004, 18, 895-913.	2.2	12
651	Optimizing the Clinical Benefit of Rituximab in Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, 149-151.	2.1	1
652	Lymphomes folliculaires. EMC - Hematologie, 2004, 1, 83-105.	0.1	1

#	ARTICLE	IF	CITATIONS
653	Suicide gene therapy and the control of graft-vs-host disease. Best Practice and Research in Clinical Haematology, 2004, 17, 453-463.	1.7	3
654	A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL). Leukemia and Lymphoma, 2004, 45, 2269-2273.	1.3	61
655	Managing Immunogenic Responses to Infliximab. Drugs, 2004, 64, 1767-1777.	10.9	67
656	Treatment Options in Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2004, 5, 155-162.	2.1	5
657	Factors Associated with Toxicity and Response to Yttrium 90â€“Labeled Ibritumomab Tiuxetan in Patients with Indolent Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, S16-S21.	2.1	10
658	Ongoing Trials with Yttrium 90â€“Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, S27-S32.	2.1	11
659	Refractory Chronic Lymphocytic Leukemia. American Journal of Cancer, 2004, 3, 163-178.	0.4	3
660	Second Primary Lymphoma or Recurrence: A Dilemma Solved by VDJ Rearrangement Analysis. Leukemia and Lymphoma, 2004, 45, 1539-1543.	1.3	20
661	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Current Opinion in Pharmacology, 2004, 4, 398-402.	3.5	79
662	Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics. Cancer Letters, 2004, 208, 235-242.	7.2	10
663	FLT3 Inhibitors. European Journal of Cancer, 2004, 40, 707-721.	2.8	63
664	Monoclonal antibodies in the treatment of colorectal cancer. European Journal of Cancer, 2004, 40, 1292-1301.	2.8	74
665	Targeted therapy â€“ How successful has it been?. European Journal of Cancer, 2004, 40, 2016-2021.	2.8	1
666	Rituximab therapy for life-threatening immune hemolytic anemia in a liver transplant recipient: a case report. Transplantation Proceedings, 2004, 36, 1492-1493.	0.6	8
667	Targeted therapy for malignant gliomas. Journal of Clinical Neuroscience, 2004, 11, 807-818.	1.5	25
668	Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncology, The, 2004, 5, 292-302.	10.7	299
669	Non-Hodgkin lymphoma: an update. Lancet Oncology, The, 2004, 5, 341-353.	10.7	177
670	Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Seminars in Hematology, 2004, 41, 234-245.	3.4	18

#	ARTICLE	IF	CITATIONS
671	Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). <i>Seminars in Nuclear Medicine</i> , 2004, 34, 4-9.	4.6	42
673	In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. <i>Human Antibodies</i> , 2004, 13, 55-62.	1.5	78
674	Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1. <i>Transplantation</i> , 2004, 77, 542-548.	1.0	247
675	Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. <i>Current Opinion in Hematology</i> , 2004, 11, 419-425.	2.5	8
676	Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody). <i>Archives of Dermatology</i> , 2004, 140, 91-6.	1.4	128
677	Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. <i>American Journal of Kidney Diseases</i> , 2004, 44, 757-761.	1.9	21
678	Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. <i>Anti-Cancer Drugs</i> , 2004, 15, 189-201.	1.4	4
679	Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. <i>Blood</i> , 2004, 103, 1763-1769.	1.4	67
680	Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection. <i>Blood</i> , 2004, 103, 1625-1631.	1.4	53
681	FcγRIIIa and FcγRIIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004, 103, 1472-1474.	1.4	203
682	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004, 103, 3516-3520.	1.4	33
683	Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. <i>Blood</i> , 2004, 103, 1846-1854.	1.4	60
684	Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 227-236.	1.4	131
685	Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. <i>Blood</i> , 2004, 103, 4416-4423.	1.4	531
686	Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. <i>Blood</i> , 2004, 103, 2925-2928.	1.4	249
687	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	1.4	1,552
688	Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. <i>Blood</i> , 2004, 104, 3705-3711.	1.4	126
689	Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004, 104, 2667-2674.	1.4	285

#	ARTICLE	IF	CITATIONS
690	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004, 104, 3064-3071.	1.4	558
691	Erratum for vol. 102, p. 2173. <i>Blood</i> , 2004, 103, 4423-4423.	1.4	0
692	Successful Treatment of Primary Cardiac Lymphoma With Monoclonal CD20 Antibody (Rituximab). <i>Circulation Journal</i> , 2004, 68, 172-173.	1.6	31
693	Anticorps monoclonal anti-CD20 et traitement des maladies auto-immunes. <i>Revue De Medecine Interne</i> , 2004, 25, 752-754.	1.0	0
694	Clinical Flow Cytometry. , 2004, , 239-257.		2
695	Orbital Lymphoma. , 2005, , 133-140.		4
696	Pharmacokinetic Behavior of Rituximab. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 785-792.	2.0	84
697	CD20-Negative T-Cell-Rich B-Cell Lymphoma as a Progression of a Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Treated With Rituximab. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1399-1403.	3.7	18
698	Current status of therapeutic vaccines for non-Hodgkin's lymphoma. <i>Current Opinion in Oncology</i> , 2005, 17, 432-440.	2.4	34
699	Rituximab: Clinical Development of the First Therapeutic Antibody for Cancer. , 2005, , 211-229.		1
702	Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?. <i>Nuclear Medicine Communications</i> , 2005, 26, 1045-1047.	1.1	6
703	Combination therapy for adult T-cell leukemia in xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. <i>Blood</i> , 2005, 105, 1231-1236.	1.4	30
704	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon- γ -inducible gene expression, without significant toxicity. <i>Blood</i> , 2005, 105, 489-495.	1.4	155
705	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005, 105, 1417-1423.	1.4	896
706	An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. <i>Blood</i> , 2005, 105, 3972-3978.	1.4	83
707	Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. <i>Blood</i> , 2005, 105, 4576-4582.	1.4	152
708	Leukemic cell death induced by antithymocyte globulin. <i>Leukemia Research</i> , 2005, 29, 821-827.	0.8	12
709	Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 194-201.	0.8	28

#	ARTICLE	IF	CITATIONS
710	Follicular lymphoma: time for a re-think?. Blood Reviews, 2005, 19, 165-178.	5.7	36
711	Infections associated with purine analogs and monoclonal antibodies. Blood Reviews, 2005, 19, 253-273.	5.7	19
712	Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology/Hematology, 2005, 54, 11-29.	4.4	201
713	A Case of Interstitial Pneumonia Induced by Rituximab Therapy. International Journal of Hematology, 2005, 81, 169-170.	1.6	33
714	Pharmacokinetics and concentrationâ€“effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opinion on Biological Therapy, 2005, 5, S37-S47.	3.1	108
715	Cost-Effectiveness Analysis of Rituximab Combined with CHOP for Treatment of Diffuse Large B-Cell Lymphoma. Value in Health, 2005, 8, 462-470.	0.3	40
716	Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder*. Clinical Transplantation, 2005, 19, 644-652.	1.6	21
717	Current approaches to treatment of antibody-mediated rejection. Pediatric Transplantation, 2005, 9, 408-415.	1.0	93
718	Diffuse large B-cell lymphoma on the back of a patient with AIDS: Successful treatment by the CD20 monoclonal antibody rituximab. International Journal of Dermatology, 2005, 44, 976-978.	1.0	1
719	Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma. British Journal of Dermatology, 2005, 152, 541-544.	1.5	46
720	Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. British Journal of Dermatology, 2005, 153, 167-173.	1.5	64
721	Immunotherapy in multiple myeloma - possibility or probability?. British Journal of Haematology, 2005, 130, 344-362.	2.5	36
722	Monoclonal antibody therapy of cancer. Nature Biotechnology, 2005, 23, 1147-1157.	17.5	1,068
723	Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20) Tj ETQq1 1 0.784314 rgBT /Overlock Oncogene, 2005, 24, 2121-2143.	5.9	258
724	Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacologica Sinica, 2005, 26, 649-658.	6.1	86
725	B cell depletion in autoimmune rheumatic diseases. Autoimmunity Reviews, 2005, 4, 436-441.	5.8	19
726	T cells armed with anti-CD3 Å— anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Experimental Hematology, 2005, 33, 452-459.	0.4	57
727	Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. Seminars in Oncology, 2005, 32, 19-26.	2.2	21

#	ARTICLE	IF	CITATIONS
728	Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174. American Journal of Transplantation, 2005, 5, 50-57.	4.7	81
729	Pulmonary parenchymal infiltrates in a patient with CD20-positive multiple myeloma. European Journal of Haematology, 2005, 74, 61-65.	2.2	12
730	Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice. BMC Cancer, 2005, 5, 103.	2.6	20
731	Delayed-Onset Grade 4 Neutropenia Associated with Rituximab Therapy in a Patient with Lymphoma: Case Report and Literature Review. Pharmacotherapy, 2005, 25, 1151-1155.	2.6	14
732	The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma. Cancer, 2005, 108, 10-20.	4.1	25
733	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer, 2005, 104, 2743-2752.	4.1	45
734	Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study. Arthritis and Rheumatism, 2005, 52, 2740-2750.	6.7	462
735	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. American Journal of Hematology, 2005, 78, 275-280.	4.1	121
736	Expression and characterisation of recombinant human CD48 and isolation of a human anti-CD48 monoclonal antibody by phage display. Journal of Chemical Technology and Biotechnology, 2005, 80, 782-795.	3.2	4
737	Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transplantation, 2005, 11, 839-842.	2.4	13
738	Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1225-1233.	6.4	16
739	Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Cancer Immunology, Immunotherapy, 2005, 54, 867-879.	4.2	15
740	A Deimmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunology, Immunotherapy, 2005, 54, 1172-1179.	4.2	20
741	Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Annals of Hematology, 2005, 84, 545-547.	1.8	13
742	Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Annals of Hematology, 2005, 84, 526-531.	1.8	5
745	Current status of cancer therapy with radiolabeled monoclonal antibody. Annals of Nuclear Medicine, 2005, 19, 355-365.	2.2	44
746	Prolymphocytic leukemia. Current Treatment Options in Oncology, 2005, 6, 197-208.	3.0	16
747	Follicular lymphoma: Management options in the era of targeted therapy. Current Treatment Options in Oncology, 2005, 6, 297-308.	3.0	5

#	ARTICLE	IF	CITATIONS
748	Advances in the treatment of chronic lymphocytic leukemia. Current Oncology Reports, 2005, 7, 333-338.	4.0	3
749	New developments in immunotherapy for non-Hodgkin's lymphoma. Current Oncology Reports, 2005, 7, 364-371.	4.0	10
750	Targeted Therapy for Hematologic Malignancies. Cancer Control, 2005, 12, 82-90.	1.8	8
751	Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies. , 2005, , 677-709.		0
752	Successful Treatment of Primary Cardiac Lymphoma With Atrioventricular Nodal Block. International Heart Journal, 2005, 46, 927-931.	1.0	20
753	Non-Hodgkin-Lymphome. , 2005, , 1133-1147.		0
754	Therapeutic Monoclonal Antibodies in Oncology. Journal of the Royal Society of Medicine, 2005, 98, 146-152.	2.0	26
755	Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates. Hematology American Society of Hematology Education Program, 2005, 2005, 335-339.	2.5	17
757	Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2005, 65, 942-945.	0.9	78
758	Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology, 2005, 44, 1462-1464.	1.9	24
759	Monoclonal Antibodies in the Treatment of Leukemia. Current Molecular Medicine, 2005, 5, 663-675.	1.3	6
760	Cerebrospinal fluid diffusion of Zevalin® after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement. Annals of Oncology, 2005, 16, 1710-1711.	1.2	1
761	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology, 2005, 23, 5027-5033.	1.6	874
762	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. Journal of Clinical Oncology, 2005, 23, 1979-1983.	1.6	265
763	Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies. Clinical Cancer Research, 2005, 11, 7075s-7079s.	7.0	19
764	The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice. Journal of Immunology, 2005, 174, 4389-4399.	0.8	204
765	Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy. Clinical Cancer Research, 2005, 11, 7146s-7150s.	7.0	33
766	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106, 3725-3732.	1.4	1,221

#	ARTICLE	IF	CITATIONS
767	Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15178-15183.	7.1	111
768	Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. Journal of Clinical Oncology, 2005, 23, 694-704.	1.6	140
769	Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma. Journal of Clinical Oncology, 2005, 23, 4390-4398.	1.6	143
770	Update on rituximab. Annals of the Rheumatic Diseases, 2005, 64, iv55-iv57.	0.9	29
771	Generation of Rituximab Polymer May Cause Hyper-Cross-linkingâ€“Induced Apoptosis in Non-Hodgkin's Lymphomas. Clinical Cancer Research, 2005, 11, 5971-5980.	7.0	69
772	MHC Class Iâ€“Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells. Clinical Cancer Research, 2005, 11, 7516-7522.	7.0	39
773	Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model. Clinical Cancer Research, 2005, 11, 5984-5992.	7.0	167
774	Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology, 2005, 23, 1103-1108.	1.6	187
775	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005, 106, 1538-1543.	1.4	390
776	Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma. Annals of Oncology, 2005, 16, ii99-ii104.	1.2	8
777	Persistent Panhypogammaglobulinemia After CHOP-Rituximab for HIV-Related Lymphoma. Journal of Clinical Oncology, 2005, 23, 247-248.	1.6	54
778	Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkinâ€™s Lymphomas. Journal of Clinical Oncology, 2005, 23, 7565-7573.	1.6	226
780	Reactivation of hepatitis B virus with rituximab. Expert Opinion on Drug Safety, 2005, 4, 599-608.	2.4	130
781	Protein Therapeutics. , 2005, , 429-446.		0
782	Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncology, 2005, 1, 297-306.	2.4	19
783	Antibodies for Targeted Cancer Therapy â€“ Technical Aspects and Clinical Perspectives. Pathobiology, 2005, 72, 279-286.	3.8	38
784	How does B cell depletion therapy work, and how can it be improved?. Annals of the Rheumatic Diseases, 2005, 64, iv77-iv80.	0.9	26
785	A review of tositumomab and I131tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opinion on Biological Therapy, 2005, 5, 577-588.	3.1	14

#	ARTICLE	IF	CITATIONS
786	Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisal. Expert Review of Clinical Immunology, 2005, 1, 47-62.	3.0	32
787	Lymphocyte therapy of renal cell carcinoma. Expert Review of Anticancer Therapy, 2005, 5, 1041-1051.	2.4	11
788	Primary central nervous system lymphoma. Expert Review of Neurotherapeutics, 2005, 5, 63-70.	2.8	3
789	Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly. Oncologist, 2005, 10, 602-612.	3.7	56
790	Targeted therapy for epithelial ovarian cancer. Expert Opinion on Therapeutic Targets, 2005, 9, 501-513.	3.4	6
791	Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 6325-6332.	1.6	53
792	Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. Journal of Clinical Oncology, 2005, 23, 712-719.	1.6	242
793	Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2005, 23, 2240-2247.	1.6	127
794	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 4079-4088.	1.6	899
795	Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 379-390.	1.0	29
796	Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin's Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2005, 23, 1500-1506.	1.6	39
797	Optimizing Rituximab in B-Cell Lymphoma. Journal of Clinical Oncology, 2005, 23, 1056-1058.	1.6	10
798	Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2005, 23, 1088-1095.	1.6	315
799	Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 5044-5051.	1.6	164
800	Immunotherapy of hematological malignancies: what is new?. Annals of Oncology, 2005, 16, ii53-ii62.	1.2	5
801	Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives. Journal of Clinical Oncology, 2005, 23, 6394-6399.	1.6	80
802	B cell reductive therapy in the treatment of autoimmune diseases: A focus on monoclonal antibody treatment of rheumatoid arthritis. Hematology, 2005, 10, 521-527.	1.5	2
803	Effective Treatment of Indolent Non-Hodgkin's Lymphomas with Mitoxantrone, Chlorambucil and Prednisone. Oncology Research and Treatment, 2005, 28, 73-78.	1.2	9

#	ARTICLE	IF	CITATIONS
805	Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example. Hematology American Society of Hematology Education Program, 2005, 2005, 321-328.	2.5	12
806	Therapeutic monoclonal antibodies in oncology. Journal of the Royal Society of Medicine, 2005, 98, 146-152.	2.0	25
807	AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient. Lancet Oncology, The, 2005, 6, 629-631.	10.7	6
808	Treatment of Non-Hodgkin's Lymphoma (NHL) With Radiolabeled Antibodies (mAbs). Seminars in Nuclear Medicine, 2005, 35, 202-211.	4.6	31
809	Non-Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 1087-1097.	3.0	214
810	Medical Biomethods Handbook. , 2005, , .		3
811	Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on Favldâ„¢. Expert Opinion on Biological Therapy, 2005, 5, 841-852.	3.1	31
812	Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opinion on Biological Therapy, 2005, 5, 1225-1243.	3.1	13
813	Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leukemia and Lymphoma, 2005, 46, 1775-1784.	1.3	36
814	Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology, 2005, 23, 705-711.	1.6	184
815	Treatment of Elderly Cancer Patients with Chemotherapy. Cancer Investigation, 2005, 23, 537-547.	1.3	10
816	Toward Personalized Immunotherapy for Non-Hodgkin Lymphoma. BioDrugs, 2005, 19, 289-297.	4.6	4
817	The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma. BioDrugs, 2005, 19, 309-322.	4.6	17
818	Post-Transplant Lymphoproliferative Disorder in Children. Paediatric Drugs, 2005, 7, 55-65.	3.1	44
819	Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?. Leukemia and Lymphoma, 2005, 46, 71-75.	1.3	18
821	Treatment of primary cutaneous B-cell lymphoma with rituximab. Journal of the American Academy of Dermatology, 2005, 52, 847-853.	1.2	89
822	Tolerability and safety of rituximab (MabThera®). Cancer Treatment Reviews, 2005, 31, 456-473.	7.7	442
823	Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's Lymphoma. Drug Resistance Updates, 2005, 8, 27-41.	14.4	9

#	ARTICLE	IF	CITATIONS
826	Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfusion and Apheresis Science, 2005, 32, 33-44.	1.0	21
827	CD52 Expression in Waldenström's Macroglobulinemia: Implications for Alemtuzumab Therapy and Response Assessment. Clinical Lymphoma and Myeloma, 2005, 5, 278-281.	2.1	29
828	The clinical course of follicular lymphoma. Best Practice and Research in Clinical Haematology, 2005, 18, 1-10.	1.7	42
829	Monoclonal antibodies in the treatment of indolent lymphomas. Best Practice and Research in Clinical Haematology, 2005, 18, 69-80.	1.7	10
830	Conventional allograft and autograft in low grade lymphoma. Best Practice and Research in Clinical Haematology, 2005, 18, 113-128.	1.7	3
831	Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. Best Practice and Research in Clinical Haematology, 2005, 18, 81-95.	1.7	13
832	Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology, 2005, 116, 721-729.	2.9	34
833	Utilisation thérapeutique des anticorps monoclonaux en hématologie. EMC - Hematologie, 2005, 2, 276-285.	0.1	1
834	Population Pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial. Journal of Clinical Pharmacology, 2005, 45, 792-801.	2.0	181
835	Diagnosis and Management of Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 1564-1577.	1.6	225
836	Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. American Journal of Cancer, 2005, 4, 279-292.	0.4	4
837	Cancer immunity. , 2005, , 129-148.		0
838	A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and 90Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2005, 20, 457-466.	1.0	33
839	B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Research and Therapy, 2005, 7, S19.	3.5	55
840	Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Research and Therapy, 2006, 8, R129.	3.5	212
841	Review of clinical radioimmunotherapy. Expert Review of Anticancer Therapy, 2006, 6, 445-461.	2.4	50
843	Nanoparticle-Aptamer Bioconjugates for Targeted Antineoplastic Drug Delivery. American Journal of Drug Delivery, 2006, 4, 123-130.	0.6	4
844	Unraveling the Complex Relationship Between Cancer Immunity and Autoimmunity: Lessons from Melanoma and Vitiligo. Advances in Immunology, 2006, 90, 215-241.	2.2	52

#	ARTICLE	IF	CITATIONS
845	Spotlight on Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia1. BioDrugs, 2006, 20, 253-257.	4.6	12
846	Anticorps monoclonal anti-CD20 (rituximab) dans les maladies h�matologiques et les affections auto-immunes. Reanimation: Journal De La Soci�te De Reanimation De Langue Francaise, 2006, 15, 270-277.	0.1	3
847	Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opinion on Biological Therapy, 2006, 6, 943-949.	3.1	25
848	Late-onset neutropenia following rituximab. Leukemia and Lymphoma, 2006, 47, 965-966.	1.3	27
850	Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leukemia and Lymphoma, 2006, 47, 1830-1840.	1.3	27
851	Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leukemia and Lymphoma, 2006, 47, 1013-1017.	1.3	124
852	Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2006, 47, 1306-1314.	1.3	11
853	Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature. Leukemia and Lymphoma, 2006, 47, 1683-1685.	1.3	29
854	High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Annals of Oncology, 2006, 17, 1424-1427.	1.2	76
855	SUCCESSFUL AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH RITUXIMAB ADMINISTRATION FOR PEDIATRIC DIFFUSE LARGE B-CELL LYMPHOMA. Pediatric Hematology and Oncology, 2006, 23, 19-24.	0.8	6
856	Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy, 2006, 6, 1175-1186.	2.4	35
857	Drug Insight: rituximab in renal disease and transplantation. Nature Clinical Practice Nephrology, 2006, 2, 221-230.	2.0	114
860	Monoclonal antibody as therapy for malignant lymphomas. Comptes Rendus - Biologies, 2006, 329, 241-254.	0.2	46
861	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 1105-1129.	3.0	56
862	Monoclonal Antibody Therapy for Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1125-1136.	2.2	9
863	B Cells in Health and Disease. Mayo Clinic Proceedings, 2006, 81, 377-384.	3.0	38
864	Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Clinical Leukemia, 2006, 1, 46-56.	0.2	0
865	Vaccine- and Immune-Based Therapy in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 220-229.	2.2	10

#	ARTICLE	IF	CITATIONS
866	B Cell-Targeted Therapy for Rheumatoid Arthritis. <i>Drugs</i> , 2006, 66, 625-639.	10.9	34
867	Rituximab. <i>Drugs</i> , 2006, 66, 791-820.	10.9	92
868	B-Cell-Targeted Therapy for Systemic Lupus Erythematosus. <i>Drugs</i> , 2006, 66, 1933-1948.	10.9	88
869	Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 423-426.	1.4	11
870	Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 115-124.	1.4	6
871	Treatment of Non-Hodgkin's Lymphoma: A Look over the Past Decade. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, S7-S13.	1.4	30
872	Targeting Lymphoma Cells and Their Microenvironment with Novel Antibodies. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, S33-S40.	1.4	3
873	Therapeutic lymphoma vaccines: importance of T-cell immunity. <i>Expert Review of Vaccines</i> , 2006, 5, 381-394.	4.4	18
874	Radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 655-668.	1.7	36
875	Monoclonal antibody combinations in CLL: evolving strategies. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 781-793.	1.7	7
876	Impact of Biologic Agents on Infectious Diseases. <i>Infectious Disease Clinics of North America</i> , 2006, 20, 931-961.	5.1	30
877	Yttrium 90 ibritumomab tiuxetan in lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 967-977.	1.3	21
878	Rituximab-induced Elimination of Acquired Angioedema Due to C1-Inhibitor Deficiency. <i>American Journal of Medicine</i> , 2006, 119, e3-e5.	1.5	58
879	Nonâ€“Transplant-Related Treatment Options in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 53-58.	2.0	1
880	Analyses andÂ perspectives inÂ cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 621-628.	5.6	4
881	Le point surÂ lesÂ anticorps autorisÃ©s enÂ imagerie etÂ enÂ immunothÃ©rapie. <i>Immuno-Analyse Et Biologie Specialisee</i> , 2006, 21, 255-263.	0.0	0
882	Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate Î±-particle radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 2006, 33, 271-279.	0.6	55
883	Transplantation of the highly human leukocyte antigenâ€“sensitized patient: long-term outcomes and future directions. <i>Transplantation Reviews</i> , 2006, 20, 146-156.	2.9	14

#	ARTICLE	IF	CITATIONS
884	Cancer therapy with engineered monoclonal antibodies. Update on Cancer Therapeutics, 2006, 1, 147-157.	0.4	11
885	Tumor antigen targets and tumor immunotherapy. Frontiers in Bioscience - Landmark, 2006, 11, 337.	3.0	12
886	Regression of Extensive Colonic Extranodal Marginal Zone B Cell Lymphoma after Treatment with Rituximab. The Korean Journal of Hematology, 2006, 41, 66.	0.7	2
887	A Case of Autoimmune Hemolytic Anemia Treated with Rituximab in a Child. The Korean Journal of Hematology, 2006, 41, 321.	0.7	3
890	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood, 2006, 107, 2639-2642.	1.4	204
891	The infectious consequences of rituximab addition to fludarabine-containing regimens. Blood, 2006, 107, 3013-3014.	1.4	5
892	Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood, 2006, 108, 705-710.	1.4	32
893	CD32B, the human inhibitory Fc-γ ₃ receptor IIb, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood, 2006, 108, 2384-2391.	1.4	82
894	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 2006, 108, 3295-3301.	1.4	559
896	æŠ—ä½““âĒ»è—→ã©ç¼4çŠ¶ãæŠ—ä½““â-¥ãĳã©±•æœ». Kagaku To Seibutsu, 2006, 44, 459-465.	0.0	0
899	Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies. Current Pharmaceutical Design, 2006, 12, 111-128.	1.9	19
901	Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia. Current Drug Targets, 2006, 7, 1313-1327.	2.1	7
902	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2006, 29, 558-568.	2.4	145
903	Radioimmunotherapy of Non-Hodgkins Lymphomas. Current Drug Targets, 2006, 7, 1293-1300.	2.1	24
904	Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid Rafts. Journal of Immunotherapy, 2006, 29, 536-544.	2.4	23
905	The Fc Portion of UIV3, an Anti-CD54 Monoclonal Antibody, Is Critical for its Antitumor Activity in SCID Mice With Human Multiple Myeloma or Lymphoma Cell Lines. Journal of Immunotherapy, 2006, 29, 489-498.	2.4	13
906	Optimised Fc variants with enhanced effector function. Expert Opinion on Therapeutic Patents, 2006, 16, 1449-1452.	5.0	1
908	Principles of maintenance therapy. Leukemia Research, 2006, 30, S3-S10.	0.8	10

#	ARTICLE	IF	CITATIONS
909	Rituximab maintenance therapy in indolent NHL: a clinical review. <i>Leukemia Research</i> , 2006, 30, S11-S15.	0.8	11
910	Safety of rituximab maintenance therapy in follicular lymphomas. <i>Leukemia Research</i> , 2006, 30, S16-S21.	0.8	43
911	Patient benefits of maintenance immunotherapy. <i>Leukemia Research</i> , 2006, 30, S22-S26.	0.8	8
912	Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. <i>Transplant International</i> , 2006, 19, 259-269.	1.6	70
913	MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 482-488.	1.9	21
914	Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. <i>Clinical Transplantation</i> , 2006, 20, 179-187.	1.6	39
915	Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. <i>British Journal of Dermatology</i> , 2006, 155, 1197-1200.	1.5	76
916	Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device. <i>British Journal of Haematology</i> , 2006, 132, 42-55.	2.5	27
917	Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. <i>British Journal of Haematology</i> , 2006, 133, 3-18.	2.5	29
918	The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. <i>British Journal of Haematology</i> , 2006, 134, 157-170.	2.5	30
919	Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. <i>Cancer Science</i> , 2006, 97, 305-312.	3.9	28
920	Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. <i>Haemophilia</i> , 2006, 12, 7-18.	2.1	101
921	Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2006, 94, 1770-1776.	6.4	33
922	Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2006, 38, 433-436.	2.4	55
923	Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. <i>Journal of Perinatology</i> , 2006, 26, 252-255.	2.0	89
924	Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. <i>Leukemia</i> , 2006, 20, 1096-1102.	7.2	20
925	Current controversies in follicular lymphoma. <i>Blood Reviews</i> , 2006, 20, 179-200.	5.7	12
926	Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S15-S22.	0.8	13

#	ARTICLE	IF	CITATIONS
927	Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. <i>Leukemia Research</i> , 2006, 30, 625-631.	0.8	89
928	Fcγ3 receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. <i>Seminars in Immunopathology</i> , 2006, 28, 351-364.	4.0	57
929	Late-Onset Neutropenia in Patients Treated with Rituximab for Non-Hodgkin's Lymphoma. <i>International Journal of Hematology</i> , 2006, 84, 242-247.	1.6	40
930	Successful Treatment of Helicobacter Pylori-Negative Gastric MALT Lymphoma With Rituximab. <i>Digestive Diseases and Sciences</i> , 2006, 51, 775-778.	2.3	10
931	Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. <i>Journal of Neuro-Oncology</i> , 2006, 81, 197-199.	2.9	48
933	Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. <i>Clinical and Experimental Medicine</i> , 2006, 6, 1-12.	3.6	42
935	Auger radiation targeted into DNA: a therapy perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1352-1363.	6.4	156
936	Monoclonal antibody therapy of chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 188-196.	4.2	44
937	Immune defects in patients with chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 197-209.	4.2	117
938	Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1451-1458.	4.2	43
939	Update on management of infections in cancer and stem cell transplant patients. <i>Annals of Hematology</i> , 2006, 85, 345-356.	1.8	37
940	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. <i>Annals of Hematology</i> , 2006, 85, 257-262.	1.8	16
941	CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 35-39.	2.3	60
943	Follicular lymphoma international prognostic index. <i>Current Treatment Options in Oncology</i> , 2006, 7, 270-275.	3.0	26
944	Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. <i>Current Treatment Options in Oncology</i> , 2006, 7, 276-284.	3.0	4
945	New aspects of the treatment of chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 251-257.	2.3	0
946	Advances in the treatment of chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 43-48.	2.3	1
947	Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action. <i>American Journal of Transplantation</i> , 2006, 6, 859-866.	4.7	515

#	ARTICLE	IF	CITATIONS
948	The therapeutic use of rituximab in non-Hodgkin's lymphoma. European Journal of Haematology, 2007, 78, 5-14.	2.2	3
949	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. European Journal of Haematology, 2006, 77, 300-303.	2.2	47
950	Potential adverse events with biologic response modifiers. Autoimmunity Reviews, 2006, 5, 471-485.	5.8	24
951	Infectious Complications of Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 240-249.	2.2	185
952	Initial Therapy for Patients With Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 202-209.	2.2	17
953	Monoclonal Antibody Therapy for B-Cell Malignancies. Seminars in Oncology, 2006, 33, 2-14.	2.2	43
954	Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. Journal of Immunological Methods, 2006, 317, 90-99.	1.4	67
955	B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. , 2006, 112, 57-70.		40
956	Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. Ca-A Cancer Journal for Clinicians, 2006, 56, 226-243.	329.8	207
957	The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and Rheumatism, 2006, 54, 1390-1400.	6.7	951
958	Development of antibody-based therapeutics for oncology indications. Drug Development Research, 2006, 67, 699-728.	2.9	3
959	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 2006, 106, 1569-1580.	4.1	503
960	Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-hodgkin lymphoma. Cancer, 2006, 106, 2412-2420.	4.1	85
961	Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Cancer, 2006, 107, 686-695.	4.1	35
962	Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer, 2006, 107, 2512-2520.	4.1	77
963	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer, 2006, 107, 2826-2832.	4.1	44
964	Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma. Cancer, 2006, 107, 2817-2825.	4.1	20
965	Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematological Oncology, 2006, 24, 47-55.	1.7	19

#	ARTICLE	IF	CITATIONS
966	Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2006, 24, 234-237.	1.7	43
967	Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. <i>International Journal of Cancer</i> , 2006, 119, 1303-1311.	5.1	104
968	Immune thrombocytopenic purpura following liver transplantation: A case series and review of the literature. <i>Liver Transplantation</i> , 2006, 12, 781-791.	2.4	30
969	The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2006, 81, 631-633.	4.1	13
970	Delayed Reduction in Left Ventricular Function following Treatment of Non-Hodgkin's Lymphoma with Chemotherapy and Rituximab, Unrelated to Acute Infusion Reaction. <i>Cardiology</i> , 2006, 105, 184-187.	1.4	23
971	AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 811-826.	0.5	33
972	Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. <i>Rheumatology</i> , 2006, 45, 1505-1513.	1.9	69
973	Current and Investigational Therapies for Patients with CLL. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 285-294.	2.5	16
976	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. <i>Current Pharmaceutical Design</i> , 2006, 12, 73-91.	1.9	24
977	Haematology. <i>Journal of the Royal Army Medical Corps</i> , 2006, 152, 250-265.	0.8	0
978	Recombinant Antibodies in Cancer Therapy. <i>Current Protein and Peptide Science</i> , 2006, 7, 165-170.	1.4	6
979	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1657-1686.	2.1	12
980	Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 174-180.	1.6	36
981	Phase II Trial of Idiotypic Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. <i>Journal of Clinical Oncology</i> , 2006, 24, 3107-3112.	1.6	85
982	Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity. <i>Clinical Cancer Research</i> , 2006, 12, 4027-4035.	7.0	217
983	A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 7046-7053.	7.0	100
984	Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 83-131.	2.2	41
985	Follicular lymphoma: today's treatments and tomorrow's targets. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1273-1290.	1.8	7

#	ARTICLE	IF	CITATIONS
986	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3121-3127.	1.6	1,203
987	Current treatment strategies in follicular lymphomas. <i>Annals of Oncology</i> , 2006, 17, x155-x159.	1.2	5
988	The Anti-“Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2006, 66, 1799-1808.	0.9	37
989	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4123-4128.	1.6	199
990	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6056-6063.	7.0	52
991	The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes. <i>Journal of Immunology</i> , 2006, 176, 2600-2609.	0.8	203
992	The biology and treatment of chronic lymphocytic leukemia. <i>Annals of Oncology</i> , 2006, 17, x144-x154.	1.2	23
993	Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites. <i>Leukemia and Lymphoma</i> , 2006, 47, 2388-2399.	1.3	2
994	Update: Recombinant Antibodies: From the Laboratory to the Clinic. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 285-304.	1.0	23
995	A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry. <i>Immunological Investigations</i> , 2006, 35, 93-114.	2.0	118
996	Editorial: Radioimmunotherapy, a New Breakthrough in the Treatment of Follicular Non-Hodgkin's Lymphoma: The European Perspective. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 1-4.	1.0	12
997	REFRACTORINESS TO RITUXIMAB MONOTHERAPY IN A CHILD WITH RELAPSED/REFRACTORY BURKITT NON-HODGKIN LYMPHOMA. <i>Pediatric Hematology and Oncology</i> , 2006, 23, 25-31.	0.8	6
998	Rituximab therapy in monoclonal IgM-related neuropathies. <i>Leukemia and Lymphoma</i> , 2006, 47, 859-864.	1.3	51
999	Sensitivity Analysis of Cost Factors for Various Therapy Options in the Treatment of Follicular Lymphoma. <i>Oncology Research and Treatment</i> , 2006, 29, 258-264.	1.2	4
1000	Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2006, 177, 7435-7443.	0.8	141
1001	Direct Antilymphoma Activity of Novel, First-Generation "Antibody Mimics" that Bind HLA-DR10-Positive Non-Hodgkin's Lymphoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 645-654.	1.0	11
1002	Ibritumomab tiuxetan for non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 861-869.	2.4	18
1003	Epratuzumab in the therapy of oncological and immunological diseases. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1341-1353.	2.4	54

#	ARTICLE	IF	CITATIONS
1004	Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 3880-3886.	1.6	148
1005	Tailoring antibodies for radionuclide delivery. Expert Opinion on Drug Delivery, 2006, 3, 53-70.	5.0	86
1006	Multicenter Phase II Clinical Study of Iodine-131- ¹³¹ I-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2006, 24, 4418-4425.	1.6	89
1007	Monoclonal antibodies in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1231-1238.	2.4	6
1008	Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?. Nature Clinical Practice Rheumatology, 2006, 2, 408-409.	3.2	3
1009	Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Review of Neurotherapeutics, 2006, 6, 1267-1274.	2.8	12
1010	Recent Advances and Current Challenges in Tumor Immunology and Immunotherapy. Molecular Therapy, 2007, 15, 1065-1071.	8.2	29
1011	Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2007, 99, 706-714.	6.3	344
1012	Cancer du sujet Ã©gÃ©. , 2007, , .		1
1013	Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas. Cancer Research, 2007, 67, 5921-5928.	0.9	43
1014	Targeting IFN- γ to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities. Journal of Immunology, 2007, 179, 6881-6888.	0.8	46
1015	Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 2007, 25, 1986-1992.	1.6	471
1016	Safe Administration of Iodine-131 Tositumomab After Repeated Infusion-Related Reactions to Rituximab. Oncologist, 2007, 12, 338-340.	3.7	6
1017	Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen. Journal of Immunology, 2007, 179, 2815-2823.	0.8	127
1018	Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Review of Anticancer Therapy, 2007, 7, 257-273.	2.4	24
1019	Nursing Guidelines for Managing Infections in Patients With Chronic Lymphocytic Leukemia. Clinical Journal of Oncology Nursing, 2007, 11, 914-924.	0.6	4
1020	Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus-Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB Trial. Journal of Clinical Oncology, 2007, 25, 3350-3356.	1.6	220
1021	Introduction to B-Cell Disorders. Clinical Journal of Oncology Nursing, 2007, 11, 3-12.	0.6	1

#	ARTICLE	IF	CITATIONS
1022	The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy, 2007, 7, 1749-1762.	3.1	8
1023	Rituximab in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2007, 3, 17-26.	3.0	6
1024	TREATMENT OF FOLLICULAR LYMPHOMA “ A REVIEW. Acta Clinica Belgica, 2007, 62, 408-418.	1.2	0
1025	Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leukemia and Lymphoma, 2007, 48, 342-348.	1.3	12
1026	Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 683-690.	1.3	35
1028	A Complete Response with Rituximab in Metastatic Diffuse Large B-Cell Lymphoma of the Testis: Case Report. International Journal of Immunopathology and Pharmacology, 2007, 20, 401-403.	2.1	8
1029	BiovaxID, ¢ idiotype vaccination: active immunotherapy for follicular lymphoma. Expert Review of Vaccines, 2007, 6, 307-317.	4.4	12
1030	Anti-CD25 Targeted Killing of Bicistronically Transduced Cells: A Novel Safety Mechanism Against Retroviral Genotoxicity. Molecular Therapy, 2007, 15, 1174-1181.	8.2	6
1031	Iodine 131 tositumomab in the treatment of non-Hodgkin’s lymphoma. Future Oncology, 2007, 3, 255-262.	2.4	6
1032	Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma. JAMA Ophthalmology, 2007, 125, 1663.	2.4	77
1033	Current treatment options in follicular lymphoma: Science and bias. Leukemia and Lymphoma, 2007, 48, 2098-2109.	1.3	2
1034	Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, 2007, 16, 1799-1815.	4.1	5
1035	Effect of Antilymphoma Antibody,131I-Lym-1, on Peripheral Blood Lymphocytes in Patients with Non-Hodgkin’s Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 521-530.	1.0	2
1036	Phase I to III Trials of Anti“B Cell Therapy in Non“Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 5636s-5642s.	7.0	13
1037	Role of antibody therapy in lymphoid malignancies. British Medical Bulletin, 2007, 83, 275-290.	6.9	7
1038	Bevacizumab 5 mg/kg Can Be Infused Safely Over 10 Minutes. Journal of Clinical Oncology, 2007, 25, 2691-2695.	1.6	54
1039	Titration Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 932-937.	4.5	150
1040	Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy. Cancer Research, 2007, 67, 2872-2880.	0.9	37

#	ARTICLE	IF	CITATIONS
1041	A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. <i>Annals of Oncology</i> , 2007, 18, 364-369.	1.2	92
1042	Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 206-212.	1.7	5
1043	B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2007, 179, 1369-1380.	0.8	128
1044	Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine. <i>Cancer Research</i> , 2007, 67, 10939-10947.	0.9	86
1045	A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 5652s-5660s.	7.0	31
1046	Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. <i>Rheumatology</i> , 2007, 46, 29-36.	1.9	86
1047	The clinical use of antibodies in haematological malignancies. <i>Annals of Oncology</i> , 2007, 18, ix51-ix57.	1.2	8
1048	Toll-like Receptors in Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 5280-5289.	7.0	114
1049	Immunotherapy of Cancer. , 2007, , 211-235.		3
1050	BiovaXID [®] : a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 113-122.	3.1	23
1051	Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models. <i>Journal of Immunology</i> , 2007, 179, 4263-4271.	0.8	65
1052	A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. <i>Annals of Oncology</i> , 2007, 18, 1216-1223.	1.2	103
1053	Immunologic Approaches to Ovarian Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 2884-2893.	1.6	45
1054	Complete Response to Temozolomide Treatment in an Elderly Patient With Recurrent Primary Central Nervous System Lymphoma-Case Report-. <i>Neurologia Medico-Chirurgica</i> , 2007, 47, 229-232.	2.2	6
1055	Small Intestinal Follicular Lymphoma with Multiple Tumor Formations Diagnosed by Double-Balloon Enteroscopy. <i>Internal Medicine</i> , 2007, 46, 705-709.	0.7	22
1057	Rituximab maintenance therapy: a step forward in follicular lymphoma. <i>Haematologica</i> , 2007, 92, 826-833.	3.5	30
1058	Rituximab for the treatment of autoimmune cytopenias. <i>Haematologica</i> , 2007, 92, 1589-1596.	3.5	30
1059	B Cell-Ablative Therapy: Where are We Now?. <i>International Journal of Immunopathology and Pharmacology</i> , 2007, 20, 655-659.	2.1	2

#	ARTICLE	IF	CITATIONS
1060	Clinical Response of Severe Mechanobullous Epidermolysis Bullosa Acquisita to Combined Treatment With Immunoabsorption and Rituximab (Anti-CD20 Monoclonal Antibodies). Archives of Dermatology, 2007, 143, 192-8.	1.4	81
1061	How I treat indolent lymphoma. Blood, 2007, 109, 4617-4626.	1.4	100
1062	Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood, 2007, 109, 4980-4987.	1.4	33
1063	Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood, 2007, 109, 4171-4173.	1.4	98
1064	Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood, 2007, 110, 2569-2577.	1.4	136
1065	Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood, 2007, 110, 4037-4046.	1.4	94
1067	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. The Cochrane Library, 2010, 2010, CD003805.	2.8	62
1068	Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. Current Opinion in Hematology, 2007, 14, 360-368.	2.5	14
1069	Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma. Journal of Immunotherapy, 2007, 30, 64-74.	2.4	27
1070	One Step Generation of Fully Chimeric Antibodies Using C β 1- and C β Mutant Mice. Journal of Immunotherapy, 2007, 30, 338-349.	2.4	7
1071	Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. Journal of Immunotherapy, 2007, 30, 455-467.	2.4	29
1072	Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica, 2007, 92, 66-71.	3.5	98
1073	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. Mayo Clinic Proceedings, 2007, 82, 692-699.	3.0	32
1074	Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. International Journal of Oncology, 0, , .	3.3	2
1075	The curability of follicular lymphoma. Transfusion and Apheresis Science, 2007, 37, 31-35.	1.0	8
1076	Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults. American Journal of Geriatric Pharmacotherapy, 2007, 5, 247-262.	3.0	15
1077	Expression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cells. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 21-29.	2.6	27
1078	Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario. Cancer Treatment Reviews, 2007, 33, 161-176.	7.7	60

#	ARTICLE	IF	CITATIONS
1079	Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2). Journal of the American Academy of Dermatology, 2007, 56, e55-e79.	1.2	101
1080	Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology, 2007, 44, 1331-1341.	2.2	176
1081	Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology, 2007, 44, 3823-3837.	2.2	500
1082	Standard Approaches to Relapsed Indolent Non-Hodgkinâ€™s Lymphoma. Seminars in Hematology, 2007, 44, S12-S17.	3.4	0
1083	Overcoming Rituximab Resistance: The US Clinical Experience With Bendamustine. Seminars in Hematology, 2007, 44, S27-S31.	3.4	1
1084	New Agents in Development for Non-Hodgkinâ€™s Lymphoma. Seminars in Hematology, 2007, 44, S18-S21.	3.4	0
1085	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkinâ€™s Lymphoma. Seminars in Hematology, 2007, 44, S2-S6.	3.4	1
1086	Therapy for patients with follicular lymphoma. European Journal of Cancer, Supplement, 2007, 5, 438-439.	2.2	0
1087	Emerging concepts in monocloal antibody therapy. European Journal of Cancer, Supplement, 2007, 5, 442-443.	2.2	0
1088	Apoptosis, Senescence, and Cancer. , 2007, , .		8
1090	General Principles of Tumor Immunotherapy. , 2007, , .		3
1091	Rituximab-related viral infections in lymphoma patients. Leukemia and Lymphoma, 2007, 48, 1307-1312.	1.3	235
1092	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leukemia and Lymphoma, 2007, 48, 1931-1939.	1.3	92
1093	Bortezomib Sensitizes Nonâ€™Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factorâ€™Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2. Clinical Cancer Research, 2007, 13, 5528s-5534s.	7.0	38
1094	Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leukemia and Lymphoma, 2007, 48, 944-956.	1.3	14
1095	Head and Neck Manifestations of Systemic Disease. , 0, , .		3
1096	Hepatitis B virus reactivation induced by Yttrium-90-ibritumomab-tiuxetan. Leukemia and Lymphoma, 2007, 48, 1866-1868.	1.3	11
1097	The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2007, 48, 1961-1967.	1.3	16

#	ARTICLE	IF	CITATIONS
1098	Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy. Hematology, 2007, 12, 361-370.	1.5	80
1099	Lym-1-Induced Apoptosis of Non-Hodgkin's Lymphomas Produces Regression of Transplanted Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 342-356.	1.0	8
1100	Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization. Leukemia and Lymphoma, 2007, 48, 1875-1877.	1.3	11
1101	Long-term treatment with rituximab is feasible in selected patients with B-CLL: Response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leukemia and Lymphoma, 2007, 48, 905-911.	1.3	14
1102	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2007, 13, 6168-6174.	7.0	111
1103	Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond. Hematology American Society of Hematology Education Program, 2007, 2007, 233-242.	2.5	93
1104	Use of CFSE to Monitor <i>Ex Vivo</i> Regulatory T-cell Suppression of CD4 ⁺ and CD8 ⁺ T-cell Proliferation within Unseparated Mononuclear Cells from Malignant and Non-Malignant Human Lymph Node Biopsies. Immunological Investigations, 2007, 36, 629-648.	2.0	20
1105	Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. Rheumatic Disease Clinics of North America, 2007, 33, 741-754.	1.9	12
1106	Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab. Mayo Clinic Proceedings, 2007, 82, 692-699.	3.0	31
1107	Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. Cancer Research, 2007, 67, 3927-3935.	0.9	96
1108	Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Molecular Oncology, 2007, 1, 42-54.	4.6	48
1109	Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. Journal of Clinical Pharmacology, 2007, 47, 1119-1128.	2.0	126
1110	Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Drugs, 2007, 67, 333-350.	10.9	102
1111	Efficacy and Safety of Rituximab Combined with ESHAP Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 406-412.	1.4	19
1112	Maintenance Therapy in Lymphoma. Clinical Lymphoma and Myeloma, 2007, 7, 507-513.	1.4	22
1113	Targeted Therapies for Non-Hodgkin Lymphoma: Rationally Designed Combinations. Clinical Lymphoma and Myeloma, 2007, 7, S192-S198.	1.4	4
1114	CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 2424-2436.	1.3	32
1115	B-cell depletion in the treatment of mixed cryoglobulinemia. Digestive and Liver Disease, 2007, 39, S116-S121.	0.9	15

#	ARTICLE	IF	CITATIONS
1116	Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Digestive and Liver Disease, 2007, 39, S122-S128.	0.9	32
1117	Chemoimmunotherapy of chronic lymphocytic leukemia. Best Practice and Research in Clinical Haematology, 2007, 20, 479-498.	1.7	17
1118	Lymphomes et autres tumeurs h�matologiques. , 2007, , 179-206.		1
1119	Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value. Core Evidence, 0, .	4.7	0
1120	Biological Macromolecules. , 2007, , 431-447.		1
1122	Improvement of Sj�gren's syndrome after two infusions of rituximab (anti-CD20). Arthritis and Rheumatism, 2007, 57, 310-317.	6.7	280
1123	Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematological Oncology, 2007, 25, 127-131.	1.7	96
1124	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer, 2007, 110, 121-128.	4.1	41
1125	Management of symptomatic, untreated chronic lymphocytic leukemia. Blood Reviews, 2007, 21, 143-156.	5.7	8
1126	Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. Critical Reviews in Oncology/Hematology, 2007, 62, 43-52.	4.4	109
1127	Use of Rituximab in Patients with Follicular Lymphoma. Clinical Oncology, 2007, 19, 38-49.	1.4	11
1128	Emerging Therapies for Multiple Sclerosis. Neurotherapeutics, 2007, 4, 676-692.	4.4	24
1129	Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatric Blood and Cancer, 2007, 48, 339-344.	1.5	32
1130	Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene, 2007, 26, 3704-3713.	5.9	93
1131	Rituximab therapy in malignant lymphoma. Oncogene, 2007, 26, 3603-3613.	5.9	203
1132	Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab. Oncogene, 2007, 26, 3614-3628.	5.9	90
1133	Building better magic bullets â improving unconjugated monoclonal antibody therapy for cancer. Nature Reviews Cancer, 2007, 7, 701-706.	28.4	72
1134	Septic polyarthritis with Ureaplasma urealyticum in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment. Bone Marrow Transplantation, 2007, 40, 597-598.	2.4	34

#	ARTICLE	IF	CITATIONS
1135	Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplantation, 2007, 40, 973-978.	2.4	23
1136	Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Research, 2007, 17, 89-99.	12.0	51
1137	Intraocular rituximab. Eye, 2007, 21, 1453-1454.	2.1	8
1138	Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transplant International, 2007, 20, 102-105.	1.6	91
1139	Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome. Pediatric Transplantation, 2007, 11, 552-556.	1.0	5
1140	Current management of follicular lymphomas. British Journal of Haematology, 2007, 136, 191-202.	2.5	27
1141	Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 2007, 136, 451-461.	2.5	251
1142	Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. British Journal of Haematology, 2007, 137, 409-415.	2.5	55
1143	Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. British Journal of Haematology, 2007, 138, 502-505.	2.5	30
1144	High activity ⁹⁰ Y-rituximab tiuxetan (Zevalin [®]) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. British Journal of Haematology, 2007, 139, 590-599.	2.5	45
1145	Partial remission of a newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. International Journal of Laboratory Hematology, 2007, 29, 469-473.	1.3	13
1146	Efficacy of Anti-CD20 Treatment in Patients with Rheumatoid Arthritis Resistant to a Combination of Methotrexate/Anti-TNF Therapy. Scandinavian Journal of Immunology, 2007, 66, 476-483.	2.7	38
1147	Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes. Cancer Science, 2007, 98, 1368-1372.	3.9	5
1148	Off-label uses of rituximab in dermatology. Dermatologic Therapy, 2007, 20, 277-287.	1.7	32
1149	B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clinical Immunology, 2007, 122, 139-145.	3.2	167
1150	Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clinical Immunology, 2007, 122, 62-74.	3.2	215
1151	Successful Induction of Remission With Rituximab for Relapse of ANCA-Associated Vasculitis Post-Kidney Transplant: Report of Two Cases. American Journal of Transplantation, 2007, 7, 2821-2825.	4.7	38
1152	The therapeutic use of rituximab in non-Hodgkin's lymphoma. European Journal of Haematology, 2007, 78, 5-14.	2.2	84

#	ARTICLE	IF	CITATIONS
1153	Prolonged remission of pure white cell aplasia (PWCA), in a patient with CLL, induced by rituximab and maintained by continuous oral cyclosporin. <i>European Journal of Haematology</i> , 2007, 79, 271-273.	2.2	12
1154	Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin's Lymphoma. <i>Seminars in Radiation Oncology</i> , 2007, 17, 176-183.	2.2	24
1155	Evaluation of a peptide ELISA for the detection of rituximab in serum. <i>Journal of Immunological Methods</i> , 2007, 325, 127-139.	1.4	65
1156	Rituximab: first monoclonal antibody for severe, active RA. <i>The Prescriber</i> , 2007, 18, 19-28.	0.3	2
1157	The management of posttransplant lymphoproliferative disorder. <i>Medical Oncology</i> , 2007, 24, 125-136.	2.5	54
1158	Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. <i>Rheumatology International</i> , 2007, 28, 179-183.	3.0	10
1159	Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma—role of radioimmunotherapy. <i>Annals of Hematology</i> , 2007, 86, 81-87.	1.8	35
1160	Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. <i>Annals of Hematology</i> , 2007, 86, 639-645.	1.8	15
1161	Primary follicular lymphoma of the cervix uteri: a review. <i>Annals of Hematology</i> , 2007, 86, 623-630.	1.8	28
1162	Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 129-134.	2.3	107
1164	Rituximab maintenance therapy in follicular lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 213-218.	2.3	3
1165	Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 225-231.	2.3	1
1166	Rituximab maintenance in indolent lymphoma: Indications and controversies. <i>Current Oncology Reports</i> , 2007, 9, 378-383.	4.0	4
1167	The Future of Biologic Agents in the Treatment of Sjögren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 292-297.	6.5	38
1168	An overview of cancer multidrug resistance: a still unsolved problem. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 3145-3167.	5.4	375
1169	Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 411-423.	4.2	192
1170	Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 µl) blood samples. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 1027-1035.	2.3	59
1172	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. <i>Current Allergy and Asthma Reports</i> , 2008, 8, 63-68.	5.3	14

#	ARTICLE	IF	CITATIONS
1173	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Current Hematologic Malignancy Reports, 2008, 3, 187-193.	2.3	7
1174	Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Current Oncology Reports, 2008, 10, 420-426.	4.0	2
1175	Radioimmunotherapy â€“ still experimental? Rational, proven indications and future trends. Memo - Magazine of European Medical Oncology, 2008, 1, 193-203.	0.5	3
1176	Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkinâ€™s lymphoma. Medical Oncology, 2008, 25, 437-442.	2.5	29
1177	Androgen regulation of multidrug resistanceâ€™associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate, 2008, 68, 1421-1429.	2.3	70
1178	Durable complete responses from therapy with combined epratuzumab and rituximab. Cancer, 2008, 113, 2714-2723.	4.1	102
1179	Controversies in the front-line management of chronic lymphocytic leukemia. Leukemia Research, 2008, 32, 679-688.	0.8	10
1180	Follicular lymphomas. Critical Reviews in Oncology/Hematology, 2008, 66, 248-261.	4.4	44
1181	Effects of ultrasound on apoptosis induced by anti-CD20 antibody in CD20-positive B lymphoma cells. Ultrasonics Sonochemistry, 2008, 15, 463-471.	8.2	12
1182	Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. New England Journal of Medicine, 2008, 359, 613-626.	27.0	412
1183	Rituximab in advanced rheumatoid arthritis. Future Prescriber, 2008, 7, 5-10.	0.1	0
1184	Recommendations for the use of rituximab (antiâ€™CD20 antibody) in the treatment of autoimmune bullous skin diseases^{ÂŠ}. JDDG - Journal of the German Society of Dermatology, 2008, 6, 366-373.	0.8	144
1185	Empfehlungen fÃ¼r den Einsatz von Rituximab (anti-CD20-AntikÃ¶rper) bei bullÃ¶sen Autoimmundermatosen. JDDG - Journal of the German Society of Dermatology, 2008, 6, ---.	0.8	0
1186	B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses. Journal of Investigative Dermatology, 2008, 128, 2859-2869.	0.7	113
1187	Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer, 2008, 8, 473-480.	28.4	1,064
1188	Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery, 2008, 7, 21-39.	46.4	1,678
1189	Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human l-type amino-acid transporter 1. Cancer Science, 2008, 99, 1000-1007.	3.9	30
1190	Chronic lymphocytic leukaemia cells are efficiently killed by an antiâ€™CD20 monoclonal antibody selected for improved engagement of FcÎ³RIIIA/CD16. British Journal of Haematology, 2008, 140, 635-643.	2.5	115

#	ARTICLE	IF	CITATIONS
1191	Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent <i>in situ</i> hybridization in 510 patients. British Journal of Haematology, 2008, 141, 36-40.	2.5	79
1192	Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. British Journal of Haematology, 2008, 141, 631-640.	2.5	43
1193	Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. British Journal of Haematology, 2008, 142, 179-191.	2.5	28
1194	Rituximab in the treatment of autoimmune haematological disorders. British Journal of Haematology, 2008, 143, 294-294.	2.5	4
1195	Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. British Journal of Haematology, 2008, 143, 672-680.	2.5	10
1196	The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. British Journal of Clinical Pharmacology, 2008, 66, 6-19.	2.4	56
1197	Responses to Rituximab Vary Among Follicular Lymphoma B Cells of Different Maturation Stages. Scandinavian Journal of Immunology, 2008, 68, 159-168.	2.7	6
1198	Features of Rituximab-Induced Killing of B Lymphocytes. Scandinavian Journal of Immunology, 2008, 68, 118-119.	2.7	2
1199	Newer monoclonal antibodies for hematological malignancies. Experimental Hematology, 2008, 36, 755-768.	0.4	75
1200	Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity. Clinical Immunology, 2008, 128, 155-163.	3.2	9
1201	A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation. American Journal of Transplantation, 2008, 8, 2607-2617.	4.7	139
1202	B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. Journal of Neuroimmunology, 2008, 204, 1-12.	2.3	26
1203	The Use of Galiximab in Non-Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2008, 8, 277-282.	1.4	12
1204	Epstein-Barr Virus-Induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy. Clinical Lymphoma and Myeloma, 2008, 8, 356-358.	1.4	7
1205	Considerations with Newer Regimens for Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2008, 8, S128-S136.	1.4	2
1206	The NF- κ B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leukemia and Lymphoma, 2008, 49, 1982-1994.	1.3	25
1207	CD70 as a therapeutic target in human malignancies. Expert Opinion on Therapeutic Targets, 2008, 12, 341-351.	3.4	56
1208	Molecular Biomethods Handbook. Springer Protocols, 2008, , .	0.3	13

#	ARTICLE	IF	CITATIONS
1209	Targeted Cancer Therapy. , 2008, , .		11
1210	Quelques perspectives concernant le traitement des lymphomes par Zevalin® À partir de l'évaluation de l'expérience niçoise. Medecine Nucleaire, 2008, 32, 85-95.	0.2	0
1211	Monoclonal antibodies in the treatment of lymphoid malignancies. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 267-271.	2.5	8
1212	It is the antigen(s), stupid! and other lessons from over a decade of vaccitherapy of human cancer. Seminars in Immunology, 2008, 20, 296-300.	5.6	26
1213	Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases. Vaccine, 2008, 26, 241-249.	3.8	3
1214	Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic Malignancies. , 2008, , 203-229.		0
1215	High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2008, 14, 50-58.	2.0	94
1216	Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index. Biology of Blood and Marrow Transplantation, 2008, 14, 36-42.	2.0	65
1217	Antibody Therapy for Chronic Lymphocytic Leukemia. Seminars in Hematology, 2008, 45, 95-103.	3.4	33
1218	Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma. Seminars in Hematology, 2008, 45, 85-89.	3.4	6
1219	Monoclonal Antibodies for the Treatment of Hematologic Malignancies: Schedule and Maintenance Therapy. Seminars in Hematology, 2008, 45, 75-84.	3.4	9
1220	Novel and Engineered Anti-B-Cell Monoclonal Antibodies for Non-Hodgkin's Lymphoma. Seminars in Hematology, 2008, 45, 126-132.	3.4	16
1221	Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 4473-4479.	1.6	333
1222	Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology, 2008, 26, 204-210.	1.6	271
1224	Approved monoclonal antibodies for cancer therapy. Expert Opinion on Biological Therapy, 2008, 8, 1151-1158.	3.1	65
1225	Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas. Hematology/Oncology Clinics of North America, 2008, 22, 903-940.	2.2	5
1226	Ab therapy of AML: native anti-CD33 Ab and drug conjugates. Cytotherapy, 2008, 10, 7-12.	0.7	8
1227	Follicular Lymphoma: Clinical Features and Treatment. Hematology/Oncology Clinics of North America, 2008, 22, 863-882.	2.2	35

#	ARTICLE	IF	CITATIONS
1228	Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress. Journal of Clinical Oncology, 2008, 26, 1774-1777.	1.6	187
1229	Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leukemia and Lymphoma, 2008, 49, 227-236.	1.3	41
1230	B-Cell-Targeted Therapy for SystemicÂLupus Erythematosus. BioDrugs, 2008, 22, 239-249.	4.6	28
1231	Treatment of follicular lymphoma: current status. Leukemia and Lymphoma, 2008, 49, 7-17.	1.3	12
1232	Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma. Cancer Investigation, 2008, 26, 431-433.	1.3	36
1233	Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opinion on Biological Therapy, 2008, 8, 759-768.	3.1	76
1234	Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology, 2008, 47, 735-737.	1.9	66
1235	Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis. Journal of Immunology, 2008, 181, 822-832.	0.8	116
1236	Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving. Journal of Immunology, 2008, 181, 2916-2924.	0.8	86
1237	Immunopharmacology. , 2008, , .		6
1238	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncology, 2008, 4, 569-577.	2.4	27
1239	Severe Prolonged Immunosuppression following Fludarabine and Rituximab Combination Therapy. Chemotherapy, 2008, 54, 242-244.	1.6	7
1240	A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma. Annual Review of Medicine, 2008, 59, 237-250.	12.2	174
1241	Use of rituximab in multiple sclerosis: current progress and future perspectives. Expert Review of Clinical Immunology, 2008, 4, 573-582.	3.0	4
1242	Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 7088-7094.	7.0	88
1243	Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study. Journal of Clinical Oncology, 2008, 26, 3614-3620.	1.6	137
1244	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane. Journal of Immunology, 2008, 180, 7028-7038.	0.8	211
1245	Does Rituximab Really Induce Hepatitis C Virus Reactivation?. Journal of Clinical Oncology, 2008, 26, 4695-4696.	1.6	17

#	ARTICLE	IF	CITATIONS
1246	Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab. <i>Rheumatology</i> , 2008, 47, 734-735.	1.9	10
1247	Rituximab treatment of idiopathic membranous nephropathy. <i>Kidney International</i> , 2008, 73, 117-125.	5.2	219
1248	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. <i>PLoS Medicine</i> , 2008, 5, e64.	8.4	115
1249	New monoclonal antibodies for non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2008, 19, iv60-iv62.	1.2	5
1250	Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1724-1731.	0.9	187
1251	Innovative Leukemia and Lymphoma Therapy. , 0, , .		0
1252	Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression. <i>Clinical Cancer Research</i> , 2008, 14, 1550-1560.	7.0	107
1253	Development of Novel Tetraivalent Anti-CD20 Antibodies with Potent Antitumor Activity. <i>Cancer Research</i> , 2008, 68, 2400-2408.	0.9	69
1254	GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 1681-1692.	1.3	19
1255	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	7.0	149
1256	Purine-Rich Box-1 Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells. <i>Cancer Research</i> , 2008, 68, 7512-7519.	0.9	34
1257	Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice. <i>Journal of Immunology</i> , 2008, 180, 361-371.	0.8	322
1258	Antibody-based cancer therapy. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 441-452.	5.0	1
1259	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 68-74.	1.3	13
1260	Signaling in Human B-Lymphoma Rafts. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2008, 8, 366-374.	0.5	0
1261	A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment. <i>Journal of Dermatological Treatment</i> , 2008, 19, 368-370.	2.2	6
1262	Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 179-185.	0.7	76
1263	Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2725-2731.	1.6	77

#	ARTICLE	IF	CITATIONS
1264	Recombinant antibodies for cancer therapy. Expert Opinion on Biological Therapy, 2008, 8, 1123-1141.	3.1	27
1265	Development of Common Variable Immunodeficiency in an 8-year-old Boy Treated with Rituximab for Idiopathic Thrombocytopenia. Pediatric Asthma, Allergy and Immunology, 2008, 21, 99-104.	0.2	4
1266	Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. Leukemia and Lymphoma, 2008, 49, 102-112.	1.3	60
1267	Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: Analysis of remission induction and stem cell mobilization. Leukemia and Lymphoma, 2008, 49, 1337-1344.	1.3	8
1268	Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood, 2008, 111, 1504-1511.	1.4	33
1269	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood, 2008, 112, 711-720.	1.4	97
1270	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 2008, 111, 5486-5495.	1.4	247
1271	Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood, 2008, 112, 3312-3321.	1.4	81
1272	Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 2008, 112, 2261-2271.	1.4	628
1273	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood, 2008, 112, 830-835.	1.4	81
1274	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood, 2008, 112, 4824-4831.	1.4	304
1276	15. Treatment of Malignant Lymphoma. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 2315-2320.	0.0	0
1277	15. Treatment of Malignant Lymphoma. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 112b-112b.	0.0	0
1278	SV40 Infection Associated With Rituximab Treatment After Kidney Transplantation in Nonhuman Primates. Transplantation, 2008, 85, 893-902.	1.0	12
1279	B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus. Future Rheumatology, 2008, 3, 59-68.	0.2	2
1280	The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Current Opinion in Pediatrics, 2008, 20, 17-22.	2.0	38
1281	Antibodies and Hematologic Malignancies. Cancer Journal (Sudbury, Mass), 2008, 14, 184-190.	2.0	3
1282	Pharmacokinetic Properties of Rituximab. Reviews on Recent Clinical Trials, 2008, 3, 22-30.	0.8	18

#	ARTICLE	IF	CITATIONS
1283	Rituximab in the treatment of non-Hodgkin's lymphoma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 619.	3.2	24
1284	Tumor targeting using liposomal antineoplastic drugs. <i>International Journal of Nanomedicine</i> , 0, , 21.	6.7	107
1285	Macroglobulinemia de Waldenström - remissão completa após tratamento com rituximabe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2008, 30, .	0.7	0
1286	Prediction of Clinical Outcome in Patients with Idiopathic Thrombocytopenic Purpura by Evaluating Bone Marrow Clot CD20+ B Lymphocytes and Morphological Changes of Megakaryocytes. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2008, 48, 11-15.	0.8	2
1287	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2009, , 225.	3.2	0
1288	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. <i>OncoTargets and Therapy</i> , 2009, 2, 229.	2.0	4
1289	131I- ¹²⁵ Tositumomab in Lymphoma. <i>Current Oncology</i> , 2009, 16, 32-47.	2.2	9
1290	Expanded use of rituximab in the management of non-Hodgkin lymphoma. <i>OncoTargets and Therapy</i> , 2009, 2, 189.	2.0	4
1292	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 37-46.	1.3	39
1293	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotinut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3036-3043.	1.6	132
1294	Rapid Infusion Rituximab Changing Practice for Patient Care. <i>Journal of Oncology Pharmacy Practice</i> , 2009, 15, 183-186.	0.9	29
1295	Immunotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. <i>Journal of Clinical Oncology</i> , 2009, 27, 6101-6108.	1.6	182
1296	Mobilization of hematopoietic stem cells into the peripheral blood. <i>Expert Review of Hematology</i> , 2009, 2, 717-733.	2.2	30
1297	Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX. <i>Journal of Immunology</i> , 2009, 183, 749-758.	0.8	230
1298	Rituximab and chemotherapy in diffuse large B-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 719-726.	2.4	11
1299	Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. <i>British Journal of Cancer</i> , 2009, 101, 1758-1768.	6.4	26
1300	Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5023-5030.	1.6	96
1301	CpG ODN Enhances the Efficacy of Rituximab in Non-Hodgkin Lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 858-864.	3.8	3

#	ARTICLE	IF	CITATIONS
1302	Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1607-1614.	1.6	264
1303	Ten years of rituximab in NHL. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 223-235.	2.4	79
1304	Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 6446-6453.	7.0	297
1306	Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1083-1088.	4.5	76
1307	Targeting CD70 for Human Therapeutic Use. <i>Advances in Experimental Medicine and Biology</i> , 2009, 647, 108-119.	1.6	34
1308	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. <i>Journal of Clinical Oncology</i> , 2009, 27, 3346-3353.	1.6	154
1310	Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1500-1508.	5.0	68
1311	Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. <i>Human Antibodies</i> , 2009, 18, 47-73.	1.5	43
1312	New and Experimental Skin-Directed Therapies for Cutaneous Lymphomas. <i>Skin Pharmacology and Physiology</i> , 2009, 22, 322-334.	2.5	22
1313	Understanding and circumventing resistance to anticancer monoclonal antibodies. <i>MAbs</i> , 2009, 1, 222-229.	5.2	47
1314	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. <i>Hematology</i> , 2009, 14, 187-197.	1.5	1
1315	Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient. <i>Expert Review of Hematology</i> , 2009, 2, 173-182.	2.2	5
1316	New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 805-819.	4.1	17
1317	Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. <i>Immunotherapy</i> , 2009, 1, 1015-1024.	2.0	1
1318	Prevention of hepatitis B virus reactivation under rituximab therapy. <i>Immunotherapy</i> , 2009, 1, 1053-1061.	2.0	14
1319	Ocrelizumab: a step forward in the evolution of B-cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 889-895.	3.1	58
1320	Treatment of lymphoma with adoptively transferred T cells. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1407-1425.	3.1	13
1321	The preparation of radiolabeled monoclonal antibodies for human use. <i>Human Antibodies</i> , 2009, 18, 145-156.	1.5	4

#	ARTICLE	IF	CITATIONS
1322	A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. <i>Rheumatology</i> , 2009, 48, 447-448.	1.9	20
1323	Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2009, 15, 4038-4045.	7.0	53
1324	CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells. <i>Clinical Cancer Research</i> , 2009, 15, 2739-2746.	7.0	63
1325	Rituximab Therapy for Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 734-744.	4.5	80
1326	Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. <i>Journal of Immunotherapy</i> , 2009, 32, 689-702.	2.4	336
1327	Applications of monoclonal antibodies for the treatment of hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 207-220.	3.1	15
1328	Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions. <i>Clinical Cancer Research</i> , 2009, 15, 6582-6594.	7.0	59
1329	Antibody-based therapy of leukaemia. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e29.	3.9	34
1330	<i>In vivo</i> Model of Follicular Lymphoma Resistant to Rituximab. <i>Clinical Cancer Research</i> , 2009, 15, 851-857.	7.0	36
1331	Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 265-280.	3.4	61
1332	Serum Immunoglobulins and Risk of Infection: How Low Can You Go?. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 18-29.	3.4	112
1333	Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 1999, 63, 325-331.	2.2	5
1334	FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. <i>European Journal of Haematology</i> , 2009, 82, 143-147.	2.2	23
1335	Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13 deficiency: a report of four cases and a systematic review of the literature. <i>European Journal of Haematology</i> , 2009, 83, 365-372.	2.2	75
1336	Comparison of Combination Plasmapheresis/IVIg/ Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection. <i>American Journal of Transplantation</i> , 2009, 9, 1099-1107.	4.7	264
1337	Immunogenicity of rituximab in patients with severe pemphigus. <i>Clinical Immunology</i> , 2009, 132, 334-341.	3.2	90
1338	Immunotherapy of cancer. <i>European Journal of Pharmacology</i> , 2009, 625, 41-54.	3.5	85
1339	Rituximab-associated acute thrombocytopenia: An underdiagnosed phenomenon. <i>American Journal of Hematology</i> , 2009, 84, 247-250.	4.1	59

#	ARTICLE	IF	CITATIONS
1340	Myelodysplasia and copper deficiency induced by denture paste. American Journal of Hematology, 2009, 84, 612-612.	4.1	2
1341	Postvaccination hyperhemolysis coinciding with remission of Epstein Barr virus (EBV)-associated immune thrombocytopenic purpura (ITP). American Journal of Hematology, 2009, 84, 612-613.	4.1	5
1342	Pneumatic tube -pseudo tumor lysis syndrome-in chronic lymphocytic leukemia. American Journal of Hematology, 2009, 84, 613-614.	4.1	16
1343	An unusual presentation of extramedullary biphenotypic lymphoblastic lymphoma. American Journal of Hematology, 2009, 84, 616-617.	4.1	6
1344	Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. American Journal of Hematology, 2009, 84, 614-616.	4.1	13
1345	Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology, 2009, 65, 286-293.	5.3	274
1346	Opportunistic infections and other risks with newer multiple sclerosis therapies. Annals of Neurology, 2009, 65, 367-377.	5.3	51
1347	Chronic lymphocytic leukemia. Cancer, 2009, 115, 3830-3841.	4.1	11
1348	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer, 2009, 115, 5210-5217.	4.1	78
1349	A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2009, 60, 2156-2168.	6.7	322
1350	Immunomodulation in the treatment of haematological malignancies. Clinical and Experimental Medicine, 2009, 9, 81-92.	3.6	7
1351	Targeting the B cell in vasculitis. Pediatric Nephrology, 2009, 24, 1267-1275.	1.7	15
1352	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. International Journal of Hematology, 2009, 89, 326-331.	1.6	8
1353	Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. International Journal of Hematology, 2009, 90, 253-260.	1.6	48
1354	Chronic Lymphocytic Leukemia: New Concepts and Emerging Therapies. Current Treatment Options in Oncology, 2009, 10, 16-32.	3.0	8
1355	Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Current Colorectal Cancer Reports, 2009, 5, 120-125.	0.5	0
1356	Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma. Current Oncology Reports, 2009, 11, 363-370.	4.0	4
1357	Targeted therapy for chronic lymphocytic leukemia. Targeted Oncology, 2009, 4, 11-21.	3.6	13

#	ARTICLE	IF	CITATIONS
1359	Side effects and venous access issues with immune tolerance therapy. <i>Haemophilia</i> , 2009, 15, 494-500.	2.1	6
1360	Japanese phase II study of ⁹⁰ Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. <i>Cancer Science</i> , 2009, 100, 158-164.	3.9	35
1361	Engineered therapeutic antibodies with improved effector functions. <i>Cancer Science</i> , 2009, 100, 1566-1572.	3.9	159
1362	Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. <i>Cancer Science</i> , 2009, 100, 1951-1956.	3.9	8
1363	Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. <i>Cancer Science</i> , 2009, 100, 2411-2418.	3.9	39
1364	Haemolytic anaemia following rituximab treatment in a patient with pemphigus vulgaris. <i>British Journal of Dermatology</i> , 2009, 161, 205-206.	1.5	5
1365	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009, 145, 816-824.	2.5	66
1366	Rituximab in non-haematological disorders of adults and its mode of action. <i>British Journal of Haematology</i> , 2009, 146, 233-246.	2.5	47
1367	CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. <i>Clinical and Experimental Immunology</i> , 2009, 155, 249-256.	2.6	41
1368	Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases – lessons from B cell-depletion therapy. <i>Clinical and Experimental Immunology</i> , 2009, 157, 191-197.	2.6	49
1369	Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 561-573.	2.4	19
1370	Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. <i>Leukemia</i> , 2009, 23, 59-70.	7.2	42
1371	Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. <i>Leukemia</i> , 2009, 23, 457-466.	7.2	13
1372	A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. <i>Leukemia</i> , 2009, 23, 912-918.	7.2	26
1373	Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. <i>Leukemia</i> , 2009, 23, 1320-1328.	7.2	30
1374	Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 121-126.	2.4	42
1375	Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 701-708.	2.4	66
1376	Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 679-684.	2.4	18

#	ARTICLE	IF	CITATIONS
1377	Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?. Bone Marrow Transplantation, 2009, 44, 559-569.	2.4	8
1378	Serum autoantibodies as biomarkers for early cancer detection. FEBS Journal, 2009, 276, 6880-6904.	4.7	272
1379	Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology, 2009, 14, 696-699.	1.6	44
1380	Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor. Geriatrics and Gerontology International, 2009, 9, 197-199.	1.5	14
1381	Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australasian Journal of Dermatology, 2009, 50, 202-206.	0.7	28
1382	Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transplant Infectious Disease, 2009, 11, 167-170.	1.7	37
1383	Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundamental and Clinical Pharmacology, 2009, 23, 601-608.	1.9	26
1384	Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified. Leukemia Research, 2009, 33, e13-e16.	0.8	19
1385	Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leukemia Research, 2009, 33, 792-797.	0.8	21
1386	CpG Oligodeoxynucleotides as TLR9 Agonists. BioDrugs, 2009, 23, 361-375.	4.6	89
1387	Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 498-503.	1.6	168
1388	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15
1389	Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects. Cancer Treatment Reviews, 2009, 35, 653-661.	7.7	28
1390	Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. European Journal of Surgical Oncology, 2009, 35, 527-531.	1.0	48
1391	Siglecs as targets for therapy in immune-cell-mediated disease. Trends in Pharmacological Sciences, 2009, 30, 240-248.	8.7	173
1393	Advanced-Stage Follicular Lymphoma in the Rituximab Era. Drugs, 2009, 69, 1727-1737.	10.9	1
1394	Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review. Clinical Lymphoma and Myeloma, 2009, 9, S179-S185.	1.4	38
1395	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Molecular Cancer, 2009, 8, 115.	19.2	71

#	ARTICLE	IF	CITATIONS
1396	R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. <i>Journal of Hematology and Oncology</i> , 2009, 2, 14.	17.0	28
1397	New targets for the treatment of follicular lymphoma. <i>Journal of Hematology and Oncology</i> , 2009, 2, 50.	17.0	17
1398	Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging. <i>Journal of Physical Chemistry C</i> , 2009, 113, 20252-20258.	3.1	21
1399	Improvement of Rituximab Efficiency in Chronic Lymphocytic Leukemia by CpG-Mediated Upregulation of CD20 Expression Independently of PU.1. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 721-728.	3.8	14
1400	The TLR9 Ligand CpG Promotes the Acquisition of <i>Plasmodium falciparum</i> -Specific Memory B Cells in Malaria-Naive Individuals. <i>Journal of Immunology</i> , 2009, 182, 3318-3326.	0.8	73
1401	The late adverse events of rituximab therapy “rare but there!”. <i>Leukemia and Lymphoma</i> , 2009, 50, 1083-1095.	1.3	116
1402	Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2009, 50, 357-365.	1.3	104
1403	A Simple and Safe Method for ¹³¹ I Radiolabeling of Rituximab for Myeloablative High-Dose Radioimmunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 103-110.	1.0	13
1404	Rituximab therapy in nephrotic syndrome due to AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 178-180.	3.0	3
1405	Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. <i>Leukemia and Lymphoma</i> , 2009, 50, 873-885.	1.3	49
1406	Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Lancet Oncology</i> , The, 2009, 10, 816-824.	10.7	433
1407	Monoclonal antibodies for cancer immunotherapy. <i>Lancet</i> , The, 2009, 373, 1033-1040.	13.7	270
1408	Biology and treatment of follicular lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 533-547.	2.2	11
1409	Longitudinal changes in rheumatoid arthritis after rituximab administration assessed by quantitative and dynamic contrast-enhanced 3-T MR imaging: preliminary findings. <i>European Radiology</i> , 2009, 19, 2217-2224.	4.5	9
1410	Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 949-971.	2.2	49
1411	Critical care management of cancer patients: cause for optimism and need for objectivity. <i>Current Opinion in Oncology</i> , 2009, 21, 318-326.	2.4	84
1412	Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma. <i>Journal of Immunotherapy</i> , 2009, 32, 622-631.	2.4	36
1414	Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009, 113, 3765-3772.	1.4	116

#	ARTICLE	IF	CITATIONS
1415	Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. <i>Blood</i> , 2009, 113, 4352-4361.	1.4	77
1416	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	1.4	99
1417	Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009, 113, 1412-1421.	1.4	79
1418	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , 2009, 113, 3773-3780.	1.4	133
1419	Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. <i>Blood</i> , 2009, 113, 4144-4152.	1.4	196
1420	Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. <i>Blood</i> , 2009, 113, 3809-3812.	1.4	141
1421	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. <i>Blood</i> , 2009, 114, 957-964.	1.4	150
1422	CD20-targeted tetrameric interferon- γ , a novel and potent immunocytokine for the therapy of B-cell lymphomas. <i>Blood</i> , 2009, 114, 3864-3871.	1.4	59
1424	Research Advances in Neuroblastoma Immunotherapy. <i>Current Pediatric Reviews</i> , 2009, 5, 112-117.	0.8	3
1425	Front-line management of diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2010, 22, 642-645.	2.4	27
1426	Monoclonal Antibody Therapy in Haematological Malignancies. <i>Current Clinical Pharmacology</i> , 2010, 5, 148-159.	0.6	7
1427	A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell Lymphoma. <i>Journal of Immunotherapy</i> , 2010, 33, 178-184.	2.4	10
1428	Late-Onset Neutropenia After Rituximab Treatment. <i>Medicine (United States)</i> , 2010, 89, 308-318.	1.0	137
1429	Successful Treatment with Rituximab in a Patient with Stiff-Person Syndrome Complicated by Dysthyroid Ophthalmopathy. <i>Internal Medicine</i> , 2010, 49, 237-241.	0.7	44
1430	Therapy of B-cell malignancies by anti- α -HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. <i>Blood</i> , 2010, 115, 5180-5190.	1.4	43
1431	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. <i>Blood</i> , 2010, 115, 3745-3755.	1.4	40
1432	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. <i>Blood</i> , 2010, 116, 926-934.	1.4	183
1433	Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. <i>Blood</i> , 2010, 115, 2864-2871.	1.4	105

#	ARTICLE	IF	CITATIONS
1434	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, 2010, 115, 5191-5201.	1.4	292
1435	Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease. AAPS Journal, 2010, 12, 33-43.	4.4	254
1436	Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies. AAPS Journal, 2010, 12, 592-601.	4.4	31
1437	A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunology, Immunotherapy, 2010, 59, 257-265.	4.2	40
1438	Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology, 2010, 89, 255-262.	1.8	187
1439	Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma. Annals of Hematology, 2010, 89, 263-272.	1.8	16
1440	Bendamustine: something old, something new. Cancer Chemotherapy and Pharmacology, 2010, 66, 413-423.	2.3	58
1442	Current immunochemotherapy strategies in follicular lymphoma. Advances in Therapy, 2010, 27, 704-713.	2.9	5
1443	A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy. Clinical Journal of Gastroenterology, 2010, 3, 254-258.	0.8	2
1444	Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic Research, 2010, 46, 192-205.	2.9	13
1445	Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. International Journal of Hematology, 2010, 91, 501-508.	1.6	52
1446	Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology, 2010, 92, 12-24.	1.6	15
1447	Challenges in the Frontline Treatment of Patients With Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2010, 5, 45-51.	2.3	3
1448	Maintenance and Consolidation Strategies in Non-Hodgkin's Lymphoma: A Review of the Data. Current Oncology Reports, 2010, 12, 395-401.	4.0	5
1449	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investigational New Drugs, 2010, 28, 561-574.	2.6	22
1450	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Journal of Immunological Methods, 2010, 360, 30-38.	1.4	25
1451	Is Rituximab Safe to Use in Kidney Transplant Patients?. American Journal of Transplantation, 2010, 10, 8-9.	4.7	10
1452	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. European Journal of Haematology, 2010, 85, 502-507.	2.2	22

#	ARTICLE	IF	CITATIONS
1453	Consensus conference on the use of 90â€”Yttriumâ€”labeled rituximab therapy in clinical practice. A project of the Italian Society of Hematology. American Journal of Hematology, 2010, 85, 147-155.	4.1	5
1454	VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience. Archives of Gerontology and Geriatrics, 2010, 51, 209-215.	3.0	7
1455	Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. Leukemia Research, 2010, 34, 307-311.	0.8	10
1456	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. Leukemia Research, 2010, 34, e140-e141.	0.8	1
1457	Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. Blood Reviews, 2010, 24, 69-82.	5.7	13
1458	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. Value in Health, 2010, 13, 703-711.	0.3	25
1459	Antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement. International Journal of Evidence-Based Healthcare, 2010, 8, 18-27.	0.5	1
1460	Development of novel humanized antiâ€”CD20 antibodies based on affinity constant and epitope. Cancer Science, 2010, 101, 201-209.	3.9	39
1461	Phase I study of inotuzumab ozogamicin (CMCâ€”544) in Japanese patients with follicular lymphoma pretreated with rituximabâ€”based therapy. Cancer Science, 2010, 101, 1840-1845.	3.9	55
1462	Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent Bâ€”cell nonâ€”Hodgkin lymphoma: 7â€”year followâ€”up results. Cancer Science, 2010, 101, 2579-2585.	3.9	14
1463	The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. British Journal of Haematology, 2010, 149, 3-13.	2.5	134
1464	Weekly <i>versus</i> twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrâ€”m macroglobulinaemia. British Journal of Haematology, 2010, 151, 346-353.	2.5	63
1465	Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia, 2010, 24, 500-511.	7.2	17
1466	Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology, 2010, 10, 317-327.	22.7	1,056
1467	Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Management and Research, 2010, 2, 71.	1.9	4
1470	Management of non-Hodgkin's lymphoma in older adults. , 2010, , 274-287.		0
1471	Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Therapeutics and Clinical Risk Management, 2010, 7, 1.	2.0	8
1472	In Vivo, Multimodal Imaging of B Cell Distribution and Response to Antibody Immunotherapy in Mice. PLoS ONE, 2010, 5, e10655.	2.5	21

#	ARTICLE	IF	CITATIONS
1473	Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 943-946.	1.8	2
1474	The spectrum of use of rituximab in chronic lymphocytic leukemia. <i>OncoTargets and Therapy</i> , 2010, 3, 227.	2.0	6
1475	Ofatumumab: a novel monoclonal anti-CD20 antibody. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 51.	0.7	28
1476	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). <i>Journal of Blood Medicine</i> , 2010, 1, 115.	1.7	1
1477	Galiximab: a review. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 451-458.	3.1	23
1478	Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. <i>Annals of Oncology</i> , 2010, 21, 1699-1705.	1.2	16
1479	High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3709-3716.	1.6	106
1480	Utility of Influenza Vaccination for Oncology Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 2481-2490.	1.6	96
1481	A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and Fc γ RI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells. <i>Journal of Immunology</i> , 2010, 184, 1210-1217.	0.8	38
1482	Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 6293-6302.	0.9	7
1483	Hepatitis B Reactivation and Rituximab in the Oncology Practice. <i>Oncologist</i> , 2010, 15, 1113-1121.	3.7	23
1484	Rituximab (Rituxan). <i>American Journal of Neuroradiology</i> , 2010, 31, 1178-1180.	2.4	21
1485	Immunoglobulin G Fc Receptor Fc γ RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 279-284.	1.6	112
1486	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2085-2093.	1.6	306
1487	A Review: The Use of Rituximab in Neuromuscular Diseases. <i>Journal of Clinical Neuromuscular Disease</i> , 2010, 12, 91-102.	0.7	16
1488	Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma. <i>Archive of Oncology</i> , 2010, 18, 23-29.	0.2	1
1489	Rituximab Administration and Reactivation of HBV. <i>Hepatitis Research and Treatment</i> , 2010, 2010, 1-8.	2.0	21
1490	Evolution of anti- CD20 monoclonal antibody therapeutics in oncology. <i>MAbs</i> , 2010, 2, 14-19.	5.2	89

#	ARTICLE	IF	CITATIONS
1491	Impact of Rituximab Treatment on ^{90}Y -labeled Rituximab Dosimetry for Patients with Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2010, 51, 150-157.	5.0	11
1492	Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas. <i>Expert Review of Vaccines</i> , 2010, 9, 1251-1256.	4.4	11
1493	Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. <i>Leukemia and Lymphoma</i> , 2010, 51, 747-755.	1.3	52
1494	Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 494-506.	2.0	34
1495	Managing Infections in Patients With Hematological Malignancies. , 2010, , .		1
1496	Rituximab Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2188-2198.	4.5	247
1497	Investigational Immunotherapeutics for B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2010, 28, 884-892.	1.6	22
1498	Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. <i>Human Antibodies</i> , 2010, 19, 7-13.	1.5	28
1499	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. <i>Annals of Oncology</i> , 2010, 21, 1870-1876.	1.2	119
1500	Antibodies in cancer immunotherapy. <i>Cancer Biomarkers</i> , 2010, 6, 291-305.	1.7	2
1501	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation. <i>Annals of Oncology</i> , 2010, 21, 1891-1897.	1.2	12
1502	Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-14.	3.3	20
1503	Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies. <i>Current Drug Targets</i> , 2010, 11, 790-800.	2.1	10
1504	Medical Treatment of Hyperthyroidism: State of the Art. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 678-684.	1.2	42
1506	The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2010, 51, 376-389.	1.3	34
1507	Diversity in antibody-based approaches to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 20-27.	1.3	15
1508	Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 41-49.	1.3	6
1509	Rituximab add-on therapy for breakthrough relapsing multiple sclerosis. <i>Neurology</i> , 2010, 74, 1860-1867.	1.1	192

#	ARTICLE	IF	CITATIONS
1510	A Bispecific Antibody-IFN γ 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. Cancer Research, 2010, 70, 7600-7609.	0.9	41
1511	Emerging biotherapies for Sjögren's syndrome. Expert Opinion on Emerging Drugs, 2010, 15, 269-282.	2.4	14
1512	Innovative Uses of Rituximab in Dermatology. Dermatologic Clinics, 2010, 28, 547-557.	1.7	19
1513	Infectious Complications Associated with Immunomodulating Biologic Agents. Infectious Disease Clinics of North America, 2010, 24, 285-306.	5.1	78
1514	Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica, 2010, 95, 329-332.	3.5	44
1515	Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica, 2010, 95, 135-143.	3.5	228
1516	Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura. Journal of the Neurological Sciences, 2010, 288, 178-181.	0.6	8
1517	Role of Antibodies in Cancer Treatment (An Overview). , 2010, , 135-152.		3
1518	Rituximab. Drugs, 2010, 70, 1445-1476.	10.9	163
1519	Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics, 2010, 49, 493-507.	3.5	564
1520	Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 379-384.	0.4	11
1521	A Decade of Progress in Lymphoma: Advances and Continuing Challenges. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 414-423.	0.4	43
1522	Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S27-S33.	0.4	3
1523	Infusion Reactions. Clinical Journal of Oncology Nursing, 2010, 14, E10-E21.	0.6	165
1524	Targeted Therapies in Cancer. BioDrugs, 2010, 24, 77-88.	4.6	36
1525	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	27.0	1,471
1526	The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia and Lymphoma, 2010, 51, 983-994.	1.3	80
1527	Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opinion on Biological Therapy, 2010, 10, 439-449.	3.1	16

#	ARTICLE	IF	CITATIONS
1528	Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2010, 23, 133-143.	1.7	16
1529	Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Letters, 2010, 292, 208-214.	7.2	12
1530	Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Letters, 2010, 294, 66-73.	7.2	6
1531	Chemoimmunotherapy of chronic lymphocytic leukemia. Nature Reviews Clinical Oncology, 2010, 7, 521-532.	27.6	55
1532	Management of Sjögren's Syndrome. , 2010, , 134-156.		4
1533	Experience with maintenance rituximab after chemotherapy in patients with low-grade lymphoma. Community Oncology, 2010, 7, 414-417.	0.2	1
1534	Rituximab-Associated Infections. Seminars in Hematology, 2010, 47, 187-198.	3.4	230
1535	Rituximab in Indolent Lymphomas. Seminars in Hematology, 2010, 47, 133-142.	3.4	31
1536	Rituximab in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2010, 47, 156-169.	3.4	41
1537	Rituximab-Associated Neutropenia. Seminars in Hematology, 2010, 47, 180-186.	3.4	80
1538	Rituximab: Mechanism of Action. Seminars in Hematology, 2010, 47, 115-123.	3.4	629
1539	Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a Paradigm. Seminars in Nuclear Medicine, 2010, 40, 136-144.	4.6	7
1540	Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1756-1765.	1.6	437
1541	Prognostic Factors in Follicular Lymphoma. Journal of Clinical Oncology, 2010, 28, 2902-2913.	1.6	136
1542	Non-Hodgkin's Lymphoma in the Elderly. Drugs and Aging, 2010, 27, 211-238.	2.7	7
1543	I-131 tositumomab. Expert Opinion on Biological Therapy, 2010, 10, 1271-1278.	3.1	14
1545	Autologous transplant of follicular lymphoma in the era of rituximab. Leukemia and Lymphoma, 2010, 51, 967-974.	1.3	11
1546	Rituximab in hematopoietic cell transplantation. Expert Opinion on Biological Therapy, 2010, 10, 971-982.	3.1	5

#	ARTICLE	IF	CITATIONS
1547	A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. <i>Acta Oncol</i> ³ <i>gica</i> , 2010, 49, 3-12.	1.8	30
1548	Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 459-462.	1.4	8
1549	New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. <i>Leukemia and Lymphoma</i> , 2010, 51, 1596-1611.	1.3	3
1550	Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1230-1238.	1.3	12
1551	Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1381-1394.	3.1	28
1552	Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 443-455.	2.4	3
1553	The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dong. <i>Leukemia and Lymphoma</i> , 2011, 52, 550-551.	1.3	1
1554	The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoproliferative neoplastic disorders. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 551-557.	3.1	8
1555	Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. <i>Journal of Immunology</i> , 2011, 186, 1840-1848.	0.8	841
1556	Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. <i>Expert Review of Hematology</i> , 2011, 4, 619-625.	2.2	68
1557	Investigational drugs in thrombotic thrombocytopenic purpura. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1087-1098.	4.1	9
1558	Effect of rituximab on human <i>in vivo</i> antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1295-1302.e5.	2.9	91
1559	Dual-Targeting Bispecific Antibodies as New Therapeutic Modalities for Cancer. <i>Molecular Medicine and Medicinal</i> , 2011, , 373-408.	0.4	1
1560	The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF- κ B/Snail/RKIP/PTEN resistance loop in B-NHL cells: Role in sensitization to TRAIL apoptosis. <i>International Journal of Oncology</i> , 2011, 38, 1683-94.	3.3	25
1561	Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and <i>in vivo</i> activity. <i>Nanomedicine</i> , 2011, 6, 1575-1591.	3.3	18
1562	Enterovirus 71 meningoencephalitis complicating rituximab therapy. <i>Journal of the Neurological Sciences</i> , 2011, 305, 149-151.	0.6	28
1563	Cancer Cell Culture. <i>Methods in Molecular Biology</i> , 2011, , .	0.9	37
1565	New antibody drug treatments for lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 623-640.	3.1	15

#	ARTICLE	IF	CITATIONS
1566	Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 1-64.	1.0	120
1567	Infectious Complications Associated with Immunomodulating Biologic Agents. Hematology/Oncology Clinics of North America, 2011, 25, 117-138.	2.2	34
1568	Treatment strategies in advanced stage follicular lymphoma. Best Practice and Research in Clinical Haematology, 2011, 24, 187-201.	1.7	11
1569	Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results. Journal of Clinical Oncology, 2011, 29, 1864-1875.	1.6	42
1570	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leukemia and Lymphoma, 2011, 52, 1-14.	1.3	16
1571	Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia. , 2011, , 221-271.		3
1572	Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology, 2011, 50, 1390-1394.	1.9	167
1573	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncology, The, 2011, 12, 773-784.	10.7	98
1574	Rituximab. Drugs, 2011, 71, 885-895.	10.9	4
1575	Radioimmunotherapy for CD20-positive B-cell non-Hodgkin's lymphoma. Community Oncology, 2011, 8, 24-31.	0.2	1
1576	Brentuximab Vedotin (SGN-35). Clinical Cancer Research, 2011, 17, 6428-6436.	7.0	333
1577	Development of Rituximab-Resistant B-NHL Clones: An In Vitro Model for Studying Tumor Resistance to Monoclonal Antibody-Mediated Immunotherapy. Methods in Molecular Biology, 2011, 731, 407-419.	0.9	3
1578	Allergic reactions to chemotherapy. , 2011, , 10-15.		0
1579	IMMUNOMODULATORS AND THE "BIOLOGICS" IN CUTANEOUS EMERGENCIES. , 0, , 34-49.		0
1580	CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis. Human Antibodies, 2011, 20, 29-35.	1.5	28
1581	Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer. Critical Reviews in Therapeutic Drug Carrier Systems, 2011, 28, 293-356.	2.2	5
1582	Therapeutic Monoclonal Antibodies. Keio Journal of Medicine, 2011, 60, 37-46.	1.1	43
1583	Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection. Journal of Pharmacy and Pharmaceutical Sciences, 2011, 14, 227.	2.1	18

#	ARTICLE	IF	CITATIONS
1584	Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 277.	3.0	40
1585	Interferon- γ and Anti-Fibroblast Growth Factor Receptor 1 Monoclonal Antibody Suppress Hepatic Cancer Cells In Vitro and In Vivo. <i>PLoS ONE</i> , 2011, 6, e19618.	2.5	11
1586	Rituximab Treatment in Hepatitis C Infection: An In Vitro Model to Study the Impact of B Cell Depletion on Virus Infectivity. <i>PLoS ONE</i> , 2011, 6, e25789.	2.5	7
1587	Neutropenia associated with rituximab therapy. <i>Current Opinion in Hematology</i> , 2011, 18, 49-54.	2.5	31
1588	New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia. <i>Mini-Reviews in Medicinal Chemistry</i> , 2011, 11, 508-518.	2.4	3
1589	The future of anti-CD20 monoclonal antibodies: are we making progress?. <i>Blood</i> , 2011, 117, 2993-3001.	1.4	117
1590	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	1.4	30
1591	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	4.9	161
1592	Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 563-571.	4.9	0
1593	Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. <i>Cancer Science</i> , 2011, 102, 432-438.	3.9	25
1594	Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study. <i>Cancer Science</i> , 2011, 102, 1698-1705.	3.9	21
1595	A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 152, 570-578.	2.5	38
1596	A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity <i>in vitro</i> and lymphoma growth inhibition <i>in vivo</i> . <i>British Journal of Haematology</i> , 2011, 155, 426-437.	2.5	67
1597	Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma. <i>Veterinary and Comparative Oncology</i> , 2011, 9, 95-105.	1.8	11
1598	Immunosuppressive monoclonal antibodies: current and next generation. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1759-1768.	6.0	17
1599	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. <i>Joint Bone Spine</i> , 2011, 78, 241-245.	1.6	39
1600	Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. <i>Leukemia and Lymphoma</i> , 2011, 52, 994-1002.	1.3	50
1601	The impact of Fc γ 3 receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. <i>Blood</i> , 2011, 118, 4657-4662.	1.4	61

#	ARTICLE	IF	CITATIONS
1602	Immunomodulating antibodies and drugs for the treatment of hematological malignancies. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 97-109.	5.9	17
1603	Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. <i>Journal of Gastroenterology</i> , 2011, 46, 9-16.	5.1	84
1604	Rituximab and minimal change nephrotic syndrome: a therapeutic option. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 641-647.	1.6	20
1605	The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. <i>Rheumatology International</i> , 2011, 31, 1493-1499.	3.0	70
1606	Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 300-305.	2.0	6
1607	Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 75-85.	4.2	31
1608	Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2011, 90, 1145-1151.	1.8	40
1609	Isolation of human Fab antibodies specific for the low-affinity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells. <i>Immunology Letters</i> , 2011, 136, 213-220.	2.5	1
1610	Stratégie diagnostique devant la découverte d'une hypogammaglobulinémie en rhumatologie. <i>Revue Du Rhumatisme (Edition Française)</i> , 2011, 78, 122-127.	0.0	2
1611	Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. <i>International Journal of Hematology</i> , 2011, 93, 91-98.	1.6	87
1612	Rituximab in chronic lymphocytic leukemia. <i>Advances in Therapy</i> , 2011, 28, 534-554.	2.9	12
1613	Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 207-215.	2.3	7
1614	Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. <i>BMC Cancer</i> , 2011, 11, 87.	2.6	27
1615	Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. <i>American Journal of Hematology</i> , 2011, 86, 278-291.	4.1	21
1616	Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 3182-3186.	4.1	13
1617	Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. <i>Hematological Oncology</i> , 2011, 29, 5-9.	1.7	27
1618	Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2011, 128, 2192-2201.	5.1	40
1619	State of the art treatment of chronic lymphocytic leukaemia. <i>Blood Reviews</i> , 2011, 25, 1-9.	5.7	48

#	ARTICLE	IF	CITATIONS
1620	Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. <i>Future Oncology</i> , 2011, 7, 963-979.	2.4	7
1621	Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 346-370.	2.1	11
1622	Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis. <i>Leukemia and Lymphoma</i> , 2011, 52, 194-204.	1.3	9
1623	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <i>Leukemia and Lymphoma</i> , 2011, 52, 374-386.	1.3	1
1624	Follicular lymphoma: still Six characters in search of an author? <i>Leukemia and Lymphoma</i> , 2011, 52, 1655-1667.	1.3	3
1625	Quantitative analysis of the CD4 T cell repertoire specific to therapeutic antibodies in healthy donors. <i>FASEB Journal</i> , 2011, 25, 2040-2048.	0.5	55
1626	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. <i>Haematologica</i> , 2011, 96, 307-314.	3.5	113
1627	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355.	1.6	124
1628	Spotlight on Rituximab in Chronic Lymphocytic Leukemia, Low-Grade or Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma. <i>BioDrugs</i> , 2011, 25, 55-61.	4.6	11
1629	Rituximab tolerability when given before or after CHOP. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 381-386.	0.9	6
1630	Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 178-185.	4.1	125
1631	Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens. <i>Journal of Immunology</i> , 2011, 186, 6044-6055.	0.8	93
1632	SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6448-6458.	7.0	155
1633	The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S4087.	1.3	8
1634	Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6085.	1.3	27
1635	Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies. <i>Clinical Cancer Research</i> , 2011, 17, 19-30.	7.0	86
1636	Added value of molecular targeted agents in oncology. <i>Annals of Oncology</i> , 2011, 22, 1703-1716.	1.2	49
1638	Rapid-Onset, Prolonged Bone Marrow Failure Following Rituximab Therapy of Follicular Lymphoma. <i>Onkologie</i> , 2011, 34, 322-324.	0.8	1

#	ARTICLE	IF	CITATIONS
1639	Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 567-573.	3.5	47
1640	Eradication of melanomas by targeted elimination of a minor subset of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2474-2479.	7.1	111
1641	Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. <i>Journal of Immunology</i> , 2011, 186, 3762-3769.	0.8	198
1642	Beyond chemotherapy: new agents for targeted treatment of lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 85-96.	27.6	73
1643	One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. <i>Experimental and Molecular Medicine</i> , 2011, 43, 539.	7.7	51
1644	Cancer radioimmunotherapy. <i>Immunotherapy</i> , 2011, 3, 349-370.	2.0	108
1645	Monoclonal antibodies in hematological malignancies: Past, present and future. <i>Journal of Cancer Research and Therapeutics</i> , 2011, 7, 399.	0.9	16
1646	Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy. <i>Toxins</i> , 2011, 3, 697-720.	3.4	67
1647	Therapy of newly diagnosed follicular lymphoma. <i>Frontiers in Oncology</i> , 2012, 2, 188.	2.8	0
1648	Resistance—the true face of biological defiance. <i>Rheumatology</i> , 2012, 51, 413-422.	1.9	3
1649	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2687-2695.	1.2	23
1650	Galiximab Signals B-NHL Cells and Inhibits the Activities of NF- κ B-Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 572-581.	4.1	20
1651	Rituximab-Based Treatment, HCV Replication, and Hepatic Flares. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-5.	3.3	42
1652	Immune-Related Disorders and Extrahepatic Diseases in Chronic HCV Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	4
1653	Incidence of Non-Neutropenic Infection (NNI) in Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma: The Effects of Rituximab Therapy. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2012, 22, 220-226.	0.1	0
1654	Neutropenia after rituximab treatment. <i>Current Opinion in Hematology</i> , 2012, 19, 32-38.	2.5	58
1655	What Is the Best Initial Therapy for a Patient With Symptomatic Low-Grade Follicular Lymphoma?. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 383-389.	2.0	5
1656	Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1918-1926.	2.0	65

#	ARTICLE	IF	CITATIONS
1657	Anti-Tumor Monoclonal Antibodies in Conjunction with β -Glucans: A Novel Anti- Cancer Immunotherapy. Current Medicinal Chemistry, 2012, 19, 4298-4305.	2.4	22
1658	Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Leukemia and Lymphoma, 2012, 53, 770-778.	1.3	5
1660	Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma. MAbs, 2012, 4, 256-266.	5.2	8
1661	Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin lymphoma. Future Oncology, 2012, 8, 359-371.	2.4	6
1662	Research Spotlight: Shining light on nuclear-targeted therapy using gold nanostar constructs. Therapeutic Delivery, 2012, 3, 1263-1267.	2.2	22
1663	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology, 2012, 3, 199-207.	2.5	7
1664	Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Medical Weekly, 2012, 142, w13511.	1.6	27
1665	Rapid-Infusion Rituximab in Lymphoma Treatment: 2-Year Experience in a Single Institution. Journal of Oncology Practice, 2012, 8, 141-143.	2.5	6
1666	Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies, 2012, 1, 172-198.	2.5	28
1667	Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma?. Cancer Journal (Sudbury, Mass), 2012, 18, 390-395.	2.0	11
1668	Rituximab Therapy and Autoimmune Disease. Current Immunology Reviews, 2012, 8, 94-100.	1.2	2
1669	Advances in the management of follicular lymphoma. Current Opinion in Oncology, 2012, 24, 742-747.	2.4	12
1670	Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica, 2012, 97, 1431-1438.	3.5	96
1671	Antibody-targeted therapy. , 0, , 563-581.		0
1672	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood, 2012, 119, 3698-3704.	1.4	125
1673	Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain. Clinical Microbiology Reviews, 2012, 25, 471-506.	13.6	337
1674	Therapeutic Antibodies Against Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 447-481.	2.2	71
1675	Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Review of Clinical Immunology, 2012, 8, 413-421.	3.0	10

#	ARTICLE	IF	CITATIONS
1676	Targeted drug delivery for cancer therapy: the other side of antibodies. <i>Journal of Hematology and Oncology</i> , 2012, 5, 70.	17.0	232
1677	Management of indolent lymphoma: Where are we now and where are we going. <i>Blood Reviews</i> , 2012, 26, 279-288.	5.7	43
1678	Immunotherapy in Clinical Medicine: Historical Perspective and Current Status. <i>Medical Clinics of North America</i> , 2012, 96, 421-431.	2.5	14
1679	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2012, 380, 848-857.	13.7	522
1680	Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, E68-71.	4.1	1
1681	Rituximab-induced direct inhibition of T-cell activation. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1233-1241.	4.2	50
1682	Positron Emission Tomography of ⁶⁴ Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL. <i>Molecular Imaging and Biology</i> , 2012, 14, 608-616.	2.6	30
1683	The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 583-619.	2.5	4
1684	Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1757-1763.	1.3	10
1685	Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 525-529.	1.0	3
1686	Chronic alloantibody mediated rejection. <i>Seminars in Immunology</i> , 2012, 24, 115-121.	5.6	47
1687	Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 221-227.	2.3	4
1688	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	1.6	287
1689	Biological agents for the treatment of uveitis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 311-328.	3.1	29
1690	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 31983-31993.	3.4	19
1691	A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. <i>Clinical Cancer Research</i> , 2012, 18, 5752-5760.	7.0	64
1692	Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. <i>Leukemia</i> , 2012, 26, 1365-1374.	7.2	48
1693	Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. <i>Immunology Letters</i> , 2012, 143, 44-52.	2.5	39

#	ARTICLE	IF	CITATIONS
1694	Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma. Journal of Clinical Epidemiology, 2012, 65, 996-1009.	5.0	6
1695	Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical Reviews in Oncology/Hematology, 2012, 84, e49-e57.	4.4	39
1696	Rituximab. BioDrugs, 2012, 26, 71-82.	4.6	15
1697	Treatment of Lymphoma with 131I-Chimeric Monoclonal Antibodies. Medical Radiology, 2012, , 527-533.	0.1	0
1698	Acupuncture and Moxibustion for Side Effects of Chemotherapy in Cancer Patients. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 153-181.	0.1	0
1699	Risks and untoward toxicities of antibody-based immunoconjugates. Advanced Drug Delivery Reviews, 2012, 64, 1782-1799.	13.7	43
1700	Cranio-maxillofacial non-Hodgkin's lymphoma: Clinical and histological presentation. Journal of Cranio-Maxillo-Facial Surgery, 2012, 40, e211-e213.	1.7	19
1701	Radioimmunotherapy in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 201-210.	1.7	15
1702	Polyclonal Rabbit Antithymocyte Globulin Induces Apoptosis and Has Cytotoxic Effects on Human Leukemic Cells. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 345-354.	0.4	13
1703	Management of patients with relapsed/refractory follicular lymphoma. Community Oncology, 2012, 9, S61-S67.	0.2	1
1704	Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transplant Immunology, 2012, 27, 107-113.	1.2	37
1705	Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology, 2012, 1, 28-37.	4.6	103
1707	Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. Journal of Clinical Oncology, 2012, 30, 4017-4025.	1.6	172
1708	Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series. Rheumatology International, 2012, 32, 3281-3284.	3.0	7
1709	Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. Haematologica, 2012, 97, 288-296.	3.5	11
1710	Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation. Case Reports in Oncology, 2012, 5, 110-113.	0.7	7
1711	Clinical immunology A prolonged progressive lymphopenia with hypogammaglobulinemia after FCR treatment of chronic lymphocytic leukemia: and literature review. Central-European Journal of Immunology, 2012, 3, 264-269.	1.2	1
1712	Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report. Open Rheumatology Journal, 2012, 6, 312-314.	0.2	6

#	ARTICLE	IF	CITATIONS
1713	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptorâ€“transduced T cells. <i>Blood</i> , 2012, 119, 2709-2720.	1.4	1,296
1714	Anti-CD20 Antibody Therapy for B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2012, 366, 2008-2016.	27.0	264
1715	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. <i>Blood</i> , 2012, 120, 1613-1623.	1.4	33
1716	High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcÎ³R1IIa polymorphism. <i>International Immunology</i> , 2012, 24, 477-483.	4.0	27
1718	The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. <i>Medical Oncology</i> , 2012, 29, 1237-1241.	2.5	38
1719	Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. <i>Annals of Hematology</i> , 2012, 91, 1007-1012.	1.8	80
1720	A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkinâ€™s lymphoma. <i>Biotechnology Letters</i> , 2012, 34, 1183-1191.	2.2	4
1721	Better response with conjugate vaccine than with polysaccharide vaccine 12â€“months after rituximab treatment in lymphoma patients. <i>British Journal of Haematology</i> , 2012, 156, 407-409.	2.5	6
1722	Ofatumumab demonstrates activity against rituximabâ€“sensitive and â€“resistant cell lines, lymphoma xenografts and primary tumour cells from patients with Bâ€“cell lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 490-498.	2.5	67
1723	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	2.5	58
1724	The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. <i>Biochemical Pharmacology</i> , 2012, 84, 451-458.	4.4	6
1725	Rituximabâ€“induced thrombocytopenia: a cohort study. <i>European Journal of Haematology</i> , 2012, 89, 256-266.	2.2	31
1726	Coiled-coil based drug-free macromolecular therapeutics: In vivo efficacy. <i>Journal of Controlled Release</i> , 2012, 157, 126-131.	9.9	71
1727	Phase I study of antiâ€“CDâ€“22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory <sc>B</sc>-cell nonâ€“H<sc>odgkin lymphoma. <i>Cancer Science</i> , 2012, 103, 933-938.	3.9	61
1728	Modelâ€“based design of rituximab dosage optimization in follicular nonâ€“Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 597-605.	2.4	20
1729	Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development. <i>Medicinal Research Reviews</i> , 2012, 32, 1197-1219.	10.5	14
1730	Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 49-61.	4.2	35
1731	Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 291-294.	1.8	10

#	ARTICLE	IF	CITATIONS
1732	Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2012, 91, 375-382.	1.8	23
1733	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551.	1.8	50
1734	The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. <i>Leukemia</i> , 2013, 27, 190-201.	7.2	58
1735	Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma. <i>Cancer</i> , 2013, 119, 99-106.	4.1	41
1736	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. <i>Journal of Translational Medicine</i> , 2013, 11, 160.	4.4	31
1737	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
1738	Balancing the Risks and Benefits of Rituximab. <i>JAMA Internal Medicine</i> , 2013, 173, 920.	5.1	3
1739	Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2013, 29, 1-10.	0.6	5
1740	Anti-CD20 monoclonal antibodies: Beyond B-cells. <i>Blood Reviews</i> , 2013, 27, 217-223.	5.7	55
1741	The Optimal Management of Follicular Lymphoma: An Evolving Field. <i>Drugs</i> , 2013, 73, 1395-1403.	10.9	6
1742	Acquired C1-inhibitor deficiency and lymphoproliferative disorders: A tight relationship. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 323-332.	4.4	59
1743	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013, 42, 1317-1330.	1.9	62
1744	Ibrutinib and novel BTK inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2013, 6, 59.	17.0	194
1745	Influenza Vaccination in Oncology Patients. <i>Current Infectious Disease Reports</i> , 2013, 15, 486-490.	3.0	11
1746	Real Time Analysis of Binding between Rituximab (Anti-CD20 Antibody) and B Lymphoma Cells. <i>Analytical Chemistry</i> , 2013, 85, 8543-8551.	6.5	25
1747	Rituximab in the treatment of non-Hodgkin's lymphoma â€“ a critical evaluation of randomized controlled trials. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 803-811.	3.1	49
1748	Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1928-1933.	1.3	9
1749	Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2013, 140, 813-818.	0.7	17

#	ARTICLE	IF	CITATION
1750	Reversal of cardiomyopathy with tocilizumab in a case of <scp>HIV</scp>â€“negative <scp>C</scp>astleman's disease. European Journal of Haematology, 2013, 91, 273-276.	2.2	12
1751	Rituximab maintenance versus retreatment in follicular lymphoma. Hematological Oncology, 2013, 31, 171-178.	1.7	5
1752	Phase I Study of a Modified Regimen of 90Yttriumâ€“Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 370-379.	1.0	2
1753	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs, 2013, 5, 826-837.	5.2	105
1754	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Research and Therapy, 2013, 15, S2.	3.5	109
1755	Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncology, 2013, 9, 1829-1839.	2.4	15
1756	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leukemia and Lymphoma, 2013, 54, 2500-2505.	1.3	58
1757	Treatment approaches to asymptomatic follicular lymphoma. Expert Review of Hematology, 2013, 6, 747-758.	2.2	0
1758	Polymerâ€“drug conjugates: Origins, progress to date and future directions. Advanced Drug Delivery Reviews, 2013, 65, 49-59.	13.7	321
1759	Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 106-111.	0.4	246
1760	RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia. Cancer Research, 2013, 73, 683-694.	0.9	53
1761	Critical analysis of the use of rituximab in mucous membrane pemphigoid: A review of the literature. Journal of the American Academy of Dermatology, 2013, 68, 499-506.	1.2	50
1762	Targeted Therapy in Chronic Lymphocytic Leukemia: Past, Present, and Future. Clinical Therapeutics, 2013, 35, 1258-1270.	2.5	37
1763	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. , 2013, , 103-119.		0
1764	Immunology of the Lymphomas. , 2013, , 919-943.		0
1765	Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy. Hematology/Oncology Clinics of North America, 2013, 27, 303-327.	2.2	9
1766	Drugâ€“conjugated antibodies for the treatment of cancer. British Journal of Clinical Pharmacology, 2013, 76, 248-262.	2.4	126
1767	Rituximab biosimilars. Expert Opinion on Biological Therapy, 2013, 13, 1049-1062.	3.1	34

#	ARTICLE	IF	CITATIONS
1768	Update on Chronic Lymphocytic Leukemia: Overview of New Agents and Comparative Analysis. Current Treatment Options in Oncology, 2013, 14, 144-155.	3.0	2
1769	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. British Journal of Clinical Pharmacology, 2013, 76, 233-247.	2.4	38
1770	The first antibody therapy for cancer: a personal experience. Expert Review of Anticancer Therapy, 2013, 13, 399-406.	2.4	2
1771	Non-Hodgkin's B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine, 2013, 238, 971-990.	2.4	52
1772	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 2013, 121, 1604-1611.	1.4	279
1773	Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. Leukemia and Lymphoma, 2013, 54, 934-939.	1.3	5
1775	Rituximab for the treatment of follicular lymphoma. Future Oncology, 2013, 9, 1283-1298.	2.4	3
1777	Generation and Preclinical Characterization of a Fc-optimized GITR-Ig Fusion Protein for Induction of NK Cell Reactivity Against Leukemia. Molecular Therapy, 2013, 21, 877-886.	8.2	17
1778	Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen. Immunotherapy, 2013, 5, 135-141.	2.0	0
1779	Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica, 2013, 98, 1259-1263.	3.5	9
1780	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2013, 98, 964-970.	3.5	11
1781	Cerebral Toxoplasmosis After Rituximab Therapy. JAMA Internal Medicine, 2013, 173, 924.	5.1	34
1783	Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan. ISRN Oncology, 2013, 2013, 1-5.	2.1	0
1784	<i>Helicobacter pylori</i> Infection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma. Mediators of Inflammation, 2013, 2013, 1-8.	3.0	26
1785	Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. OncoImmunology, 2013, 2, e26333.	4.6	145
1786	A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy, 2013, 5, 91-102.	2.0	22
1787	Developments and Challenges for mAb-Based Therapeutics. Antibodies, 2013, 2, 452-500.	2.5	110
1788	Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma. Cellular Physiology and Biochemistry, 2013, 32, 645-654.	1.6	2

#	ARTICLE	IF	CITATIONS
1789	Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2013, 190, 6681-6693.	0.8	77
1790	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	16.0	33
1791	Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 734-740.	2.4	68
1792	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-583.	1.6	142
1793	Trial watch. <i>OncolImmunology</i> , 2013, 2, e22789.	4.6	92
1794	Pixantrone: merging safety with efficacy. <i>Expert Review of Hematology</i> , 2013, 6, 25-33.	2.2	3
1795	The role of monoclonal antibodies in the treatment of lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 227-239.	3.1	4
1796	Production of recombinant immunotherapeutics for anticancer treatment. <i>Bioengineered</i> , 2013, 4, 305-312.	3.2	19
1797	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. , 2013, , .		2
1798	Follow-up Data of 10 Patients With B-cell Non-Hodgkin Lymphoma With a CD20-negative Phenotypic Change After Rituximab-containing Therapy. <i>American Journal of Surgical Pathology</i> , 2013, 37, 563-570.	3.7	20
1799	Hydroxyurea Potentiates the Caspase-Independent Killing of B-Cell Lines by Rituximab and GA101. <i>Oncology Research</i> , 2013, 20, 545-555.	1.5	3
1800	Hepatitis B virus reactivation with rituximab-containing regimen. <i>World Journal of Hepatology</i> , 2013, 5, 612.	2.0	27
1801	Human Polyomavirus Reactivation: Disease Pathogenesis and Treatment Approaches. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-27.	3.3	66
1802	The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1157.	0.2	2
1803	Rituximab for treatment of inhibitors in haemophilia A. <i>Thrombosis and Haemostasis</i> , 2014, 112, 445-458.	3.4	43
1804	Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs. <i>Molecules</i> , 2014, 19, 2135-2165.	3.8	48
1805	Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies. <i>Scientific World Journal</i> , The, 2014, 2014, 1-10.	2.1	44
1807	Trial Watch: Radioimmunotherapy for oncological indications. <i>OncolImmunology</i> , 2014, 3, e954929.	4.6	40

#	ARTICLE	IF	CITATIONS
1808	Trial Watch. Oncoimmunology, 2014, 3, e27048.	4.6	69
1809	Trial Watch. Oncoimmunology, 2014, 3, e27297.	4.6	99
1810	Sustained CD4 ⁺ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology, 2014, 3, e27357.	4.6	62
1811	A first-in-human study of the anti- α 5 β 1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 74, 1039-1046.	2.3	29
1812	No Mechanism is an Island. , 2014, , 257-267.		0
1813	Gene therapy for cancer: present status and future perspective. Molecular and Cellular Therapies, 2014, 2, 27.	0.2	185
1814	New antibody approaches to lymphoma therapy. Journal of Hematology and Oncology, 2014, 7, 58.	17.0	50
1815	Rituximab: modes of action, remaining dispute and future perspective. Future Oncology, 2014, 10, 2481-2492.	2.4	41
1816	Hypogammaglobulinaemia after rituximab treatment--incidence and outcomes. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 821-828.	0.5	115
1817	End of Rituximab Maintenance for Lowâ€Tumor Burden Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 3093-3095.	1.6	10
1818	Historical Roots of Flow Cytometry. , 2014, , 3629-3641.		0
1819	Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leukemia and Lymphoma, 2014, 55, 288-295.	1.3	11
1820	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	5.2	16
1821	Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface. International Immunology, 2014, 26, 451-465.	4.0	17
1822	Rituximab for Nonâ€Hodgkin's Lymphoma: A Story of Rapid Success in Translation. Clinical and Translational Science, 2014, 7, 82-86.	3.1	28
1823	Rituximab Extended Schedule or Re-Treatment Trial for Lowâ€Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. Journal of Clinical Oncology, 2014, 32, 3096-3102.	1.6	159
1824	Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2014, 312, 2265.	7.4	134
1825	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3 β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. Experimental Hematology and Oncology, 2014, 3, 31.	5.0	1

#	ARTICLE	IF	CITATIONS
1826	Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Medical Oncology, 2014, 31, 276.	2.5	4
1827	Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 35-40.	1.3	1
1828	Lentivector Vaccines. , 2014, , 345-361.		1
1829	Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs, 2014, 6, 1026-1037.	5.2	32
1830	Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with 90Y and 111In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkinâ€™s Lymphoma. DARU, Journal of Pharmaceutical Sciences, 2014, 22, 58.	2.0	14
1831	Theranostic applications of antibodies in oncology. Molecular Oncology, 2014, 8, 799-812.	4.6	53
1833	Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. Investigational New Drugs, 2014, 32, 75-86.	2.6	17
1834	Secondary antibody deficiency. Expert Review of Clinical Immunology, 2014, 10, 583-591.	3.0	39
1835	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. Journal of Translational Medicine, 2014, 12, 21.	4.4	14
1836	Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood, 2014, 123, 3553-3562.	1.4	78
1837	Sinonasal lymphoma: case series and review of the literature. International Forum of Allergy and Rhinology, 2014, 4, 670-674.	2.8	45
1838	From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies. Seminars in Oncology, 2014, 41, 661-666.	2.2	54
1839	Influence of <i>ex vivo</i> purging with $C</math>MACS CD34+ selection on outcome after autologous stem cell transplantation in nonâ€™H</math>odgkin lymphoma. British Journal of Haematology, 2014, 164, 555-564.$	2.5	8
1840	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.1	275
1842	Obinutuzumab for B-cell malignancies. Expert Opinion on Biological Therapy, 2014, 14, 1197-1205.	3.1	5
1843	Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance. Seminars in Oncology, 2014, 41, 667-677.	2.2	43
1845	Analyses of CD20 Monoclonal Antibodyâ€™Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies. Molecular Pharmacology, 2014, 86, 485-491.	2.3	41
1846	Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. Journal of Immunology, 2014, 193, 1519-1524.	0.8	46

#	ARTICLE	IF	CITATIONS
1847	CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. <i>Cancer Immunology Research</i> , 2014, 2, 878-889.	3.4	48
1848	Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 121, 141-149.	5.0	14
1849	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	3.2	25
1850	A drug safety evaluation of rituximab and risk of hepatitis B. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 977-987.	2.4	16
1851	Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?. <i>Clinical Cancer Research</i> , 2014, 20, 5226-5239.	7.0	17
1852	Rituximab and Immune Deficiency: Case Series and Review of the Literature. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 594-600.	3.8	91
1853	The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. <i>BMC Infectious Diseases</i> , 2014, 14, 364.	2.9	9
1854	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. <i>Annals of Hematology</i> , 2014, 93, 147-156.	1.8	6
1855	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 850-863.	6.1	199
1856	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	27.6	636
1857	Complement in monoclonal antibody therapy of cancer. <i>Immunologic Research</i> , 2014, 59, 203-210.	2.9	94
1858	The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 178.	1.9	116
1860	Optimized selection of anti-tumor recombinant antibodies from phage libraries on intact cells. <i>Molecular Immunology</i> , 2014, 57, 317-322.	2.2	12
1861	Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1019-1031.	3.1	26
1863	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-Î, as therapy for previously treated indolent non-Hodgkin lymphoma. <i>Blood</i> , 2014, 123, 3406-3413.	1.4	203
1864	Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 279-293.	0.3	7
1866	Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 41-51.	1.6	0
1867	Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study. <i>Scientific Reports</i> , 2015, 5, 14008.	3.3	16

#	ARTICLE	IF	CITATIONS
1868	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. <i>Blood</i> , 2015, 125, 949-958.	1.4	17
1869	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015, 125, 82-89.	1.4	45
1870	The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. <i>Blood</i> , 2015, 125, 3223-3229.	1.4	64
1871	Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e454-e457.	3.5	7
1872	Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. <i>Experimental Hematology and Oncology</i> , 2015, 5, 13.	5.0	86
1873	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. <i>Cancer</i> , 2015, 121, 3869-3876.	4.1	14
1874	The combination of milatuzumab, a humanized anti-CD74 antibody, and velutuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 701-710.	2.5	31
1875	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 763-775.	2.5	83
1876	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2015, 22, 469-475.	2.5	0
1877	The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 351-356.	2.0	2
1878	Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. <i>Cancer Management and Research</i> , 2015, 7, 319.	1.9	3
1879	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. <i>Frontiers in Immunology</i> , 2015, 6, 202.	4.8	130
1880	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	4.8	36
1881	Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. <i>Journal of Cancer Science & Therapy</i> , 2015, 7, 347-358.	1.7	34
1882	Harnessing the Microbiome to Enhance Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	2.2	54
1883	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-13.	1.9	59
1884	Monoclonal Antibodies for the Treatment of Cancer. , 2015, , 683-694.e3.		0
1885	Novel Pharmacodynamic Approach to Assess Obatoclox (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin's Lymphoma. <i>Clinical Cancer Drugs</i> , 2015, 2, 44-53.	0.3	0

#	ARTICLE	IF	CITATIONS
1886	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treatment Reviews, 2015, 41, 680-689.	7.7	43
1887	Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leukemia and Lymphoma, 2015, 56, 2357-2364.	1.3	13
1888	Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-“Peptide”-HLA Fusion Molecules. Molecular Cancer Therapeutics, 2015, 14, 1327-1335.	4.1	2
1889	The European Society for Medical Oncology (ESMO). Annals of Oncology, 2015, 26, vii.	1.2	0
1890	Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway. International Immunology, 2015, 27, 183-194.	4.0	10
1891	Refractory Sweet's syndrome successfully treated with rituximab. JAAD Case Reports, 2015, 1, 123-125.	0.8	12
1892	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. Expert Opinion on Drug Safety, 2015, 14, 1945-1959.	2.4	12
1893	Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology, 2015, 20, 129-136.	1.5	4
1894	Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. Journal of Autoimmunity, 2015, 57, 60-65.	6.5	245
1895	Kinetics of B, T, NK lymphocytes and isoagglutinin titers in ABO incompatible living donor liver transplantation using rituximab and basiliximab. Transplant Immunology, 2015, 32, 29-34.	1.2	19
1896	Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leukemia and Lymphoma, 2015, 56, 1659-1664.	1.3	24
1897	Chemotherapy-free treatment in patients with follicular lymphoma. Expert Review of Hematology, 2015, 8, 187-203.	2.2	8
1898	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Molecular Immunology, 2015, 67, 46-57.	2.2	100
1899	Monoclonal Antibodies for Cancer Immunotherapy. , 2015, , 293-328.		6
1900	Radiation Dosimetry Study of [89Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography. Molecular Imaging and Biology, 2015, 17, 539-547.	2.6	25
1901	Tumour Inflammatory Response: Adding Fuel to the Fire?. Current Oncology, 2015, 22, 7-9.	2.2	1
1902	Immunoreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?. Cancers, 2015, 7, 305-328.	3.7	45
1903	Molecular Therapies of Cancer. , 2015, , .		15

#	ARTICLE	IF	CITATIONS
1904	Biobetter Biologics. , 2015, , 199-217.		5
1905	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2015, , 135-183.		0
1906	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Drug Discovery, 2015, 10, 791-808.	5.0	7
1907	Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia, 2015, 29, 668-676.	7.2	95
1908	Follicular lymphoma patients with a high FLIPI score and a high tumor burden: A risk stratification model. Vojnosanitetski Pregled, 2015, 72, 26-32.	0.2	3
1909	Tumour targeting and radiation dose of radioimmunotherapy with ⁹⁰ Y-rituximab in CD20+ B-cell lymphoma as predicted by ⁸⁹ Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1304-1314.	6.4	76
1911	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγR1a Patients with Previously Treated Follicular Lymphoma. Leukemia and Lymphoma, 2015, 56, 42-48.	1.3	29
1912	Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the ² BCL inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory ²⁰ CD lymphoid malignancies. British Journal of Haematology, 2015, 170, 669-678.	2.5	80
1913	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 897-912.	4.1	12
1914	The challenging definition of naïve patient for biological drug use. Autoimmunity Reviews, 2015, 14, 543-546.	5.8	6
1915	Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia and Lymphoma, 2015, 56, 2598-2607.	1.3	24
1916	Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. Molecular Medicine Reports, 2015, 12, 147-154.	2.4	9
1917	The Expanding Role of Therapeutic Antibodies. International Reviews of Immunology, 2015, 34, 202-264.	3.3	22
1918	A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Future Oncology, 2015, 11, 1327-1342.	2.4	61
1919	Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. Molecular Pharmaceutics, 2015, 12, 1703-1716.	4.6	45
1920	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology, 2015, 9, 2043-2053.	4.6	87
1921	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica, 2015, 100, 357-362.	3.5	66
1922	Ofatumumab Exhibits Enhanced <i>In Vitro</i> and <i>In Vivo</i> Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma. Clinical Cancer Research, 2015, 21, 4391-4397.	7.0	28

#	ARTICLE	IF	CITATIONS
1923	The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry. <i>Leukemia and Lymphoma</i> , 2015, 56, 1050-1057.	1.3	14
1924	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. <i>Current Oncology Reports</i> , 2015, 17, 41.	4.0	31
1925	The evolution within us. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140235.	4.0	34
1926	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. <i>Oncolimmunology</i> , 2015, 4, e1026503.	4.6	33
1927	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. <i>Expert Review of Hematology</i> , 2015, 8, 733-742.	2.2	9
1928	Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors. <i>International Journal of Immunopathology and Pharmacology</i> , 2015, 28, 329-340.	2.1	1
1929	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 3635-3640.	1.6	163
1930	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20 ⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3467-3474.	1.6	149
1932	Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 310-316.	1.0	3
1933	The Role of Biologic Therapies in Dermatology. <i>Medical Clinics of North America</i> , 2015, 99, 1183-1194.	2.5	19
1934	Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. <i>Leukemia Research</i> , 2015, 39, 1382-1388.	0.8	30
1935	Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 578-585.	0.4	27
1936	Novel immunotherapies for hematologic malignancies. <i>Immunological Reviews</i> , 2015, 263, 90-105.	6.0	44
1937	Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. <i>European Journal of Haematology</i> , 2015, 94, 99-108.	2.2	26
1938	A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 59-74.	0.4	17
1939	Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 1611-1618.	1.3	9
1940	The status of radioimmunotherapy in CD20 ⁺ non-Hodgkin's lymphoma. <i>Targeted Oncology</i> , 2015, 10, 15-26.	3.6	18
1941	Pharmaceutical Biotechnology. , 0, , .		7

#	ARTICLE	IF	CITATIONS
1942	Monoclonal Antibodies as Therapeutic Agents. , 2016, , 157-196.		1
1943	Translational Medicine Case Studies and Reports. , 2016, , 135-156.		0
1944	LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016041.	1.3	12
1945	Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. Molecular Medicine, 2016, 22, 632-642.	4.4	25
1946	Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 89-99.	0.8	36
1947	Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 197-208.	2.2	6
1948	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology, 2016, 174, 571-581.	2.5	43
1949	A visualization method measuring the performance of biomarkers for guiding treatment decisions. Pharmaceutical Statistics, 2016, 15, 152-164.	1.3	5
1950	Chemotherapy-sparing treatment strategies for follicular lymphoma. Current Opinion in Hematology, 2016, 23, 371-376.	2.5	0
1951	Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion. American Journal of Transplantation, 2016, 16, 3139-3149.	4.7	16
1952	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology, 2016, 173, 867-875.	2.5	36
1953	Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies. Expert Review of Clinical Pharmacology, 2016, 9, 1557-1569.	3.1	17
1954	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Immunotherapy, 2016, 8, 1335-1346.	2.0	9
1955	Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics, 2016, 13, 824-832.	4.4	197
1956	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e196-e199.	3.5	15
1957	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. Leukemia and Lymphoma, 2016, 57, 1269-1280.	1.3	4
1958	Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*. Leukemia and Lymphoma, 2016, 57, 803-811.	1.3	12
1959	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leukemia and Lymphoma, 2016, 57, 1021-1032.	1.3	119

#	ARTICLE	IF	CITATIONS
1960	Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy, 2016, 8, 569-581.	2.0	14
1961	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood, 2016, 127, 79-86.	1.4	72
1963	Bacterial production and structure-functional validation of a recombinant antigen-binding fragment (Fab) of an anti-cancer therapeutic antibody targeting epidermal growth factor receptor. Applied Microbiology and Biotechnology, 2016, 100, 10521-10529.	3.6	4
1965	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	5.4	56
1966	New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leukemia Research, 2016, 49, 13-21.	0.8	29
1967	Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clinical Immunology, 2016, 172, 101-104.	3.2	21
1968	Challenges and opportunities for monoclonal antibody therapy in veterinary oncology. Veterinary Journal, 2016, 218, 40-50.	1.7	13
1969	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety, 2017, 16, 1-17.	2.4	3
1970	Management of Bleeding Patients. , 2016, , .		3
1971	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer, 2016, 122, 2996-3004.	4.1	31
1972	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends in Pharmacological Sciences, 2016, 37, 993-1008.	8.7	156
1973	Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell Lymphoma. Oncology, 2016, 91, 302-310.	1.9	14
1974	Adult Acute Lymphoblastic Leukemia. Mayo Clinic Proceedings, 2016, 91, 1645-1666.	3.0	158
1975	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. Journal of Biological Chemistry, 2016, 291, 16659-16671.	3.4	28
1977	Unintended Immunological Consequences of Biologic Therapy. Current Allergy and Asthma Reports, 2016, 16, 46.	5.3	18
1978	Inhibition of complement dependent cytotoxicity by anti-CD20 aptamers. RSC Advances, 2016, 6, 12435-12438.	3.6	4
1979	Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia. OncoImmunology, 2016, 5, e1132977.	4.6	12
1980	Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica, 2016, 101, 226-234.	3.5	31

#	ARTICLE	IF	CITATIONS
1981	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1238-1247.	4.1	11
1982	Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 182-185.	0.6	0
1983	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	3.1	21
1984	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 61-70.	2.3	5
1985	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage III Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.	0.8	35
1986	Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. <i>Supportive Care in Cancer</i> , 2016, 24, 3023-8.	2.2	2
1987	Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody. <i>Analyst</i> , The, 2016, 141, 2284-2295.	3.5	7
1988	SERS detection and targeted ablation of lymphoma cells using functionalized Ag nanoparticles. <i>Proceedings of SPIE</i> , 2016, , .	0.8	2
1989	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	7.0	26
1990	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 859-867.	3.4	15
1991	A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 235-244.	2.2	9
1992	A review of monoclonal antibody therapies in lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 72-84.	4.4	41
1993	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. <i>Journal of Leukocyte Biology</i> , 2016, 99, 87-96.	3.3	73
1994	Visceral disseminated varicella zoster virus infection after rituximab treatment for granulomatosis with polyangiitis. <i>Modern Rheumatology</i> , 2017, 27, 155-161.	1.8	21
1995	Hospitalization for Toxicity in Patients Treated With Rituximab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 125-132.	1.3	0
1996	Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. <i>Clinical Pharmacokinetics</i> , 2017, 56, 107-125.	3.5	8
1997	Use of polyclonal/monoclonal antibody therapies in transplantation. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 339-352.	3.1	9
1998	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017, 34, 324-356.	2.9	128

#	ARTICLE	IF	CITATIONS
1999	TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood, 2017, 129, 1284-1295.	1.4	44
2000	Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome. JDDG - Journal of the German Society of Dermatology, 2017, 15, 319-323.	0.8	6
2001	Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961769130.	0.6	0
2002	Intraleisionale Therapie niedrig maligner primär kutaner B-Zell-Lymphome mit Anti-CD20-Antikörper: Nebenwirkungen korrelieren mit gutem klinischen Ansprechen. JDDG - Journal of the German Society of Dermatology, 2017, 15, 319-324.	0.8	2
2003	Evaluation of changes in promoters, use of UCOES and chain order to improve the antibody production in CHO cells. Protein Expression and Purification, 2017, 132, 108-115.	1.3	13
2004	Rituximab treatment of myasthenia gravis: A systematic review. Muscle and Nerve, 2017, 56, 185-196.	2.2	204
2005	Precision medicine needs randomized clinical trials. Nature Reviews Clinical Oncology, 2017, 14, 317-323.	27.6	60
2006	Biologic response modifiers: Indications, implications, and insights. Journal of Allergy and Clinical Immunology, 2017, 139, 1445-1456.	2.9	25
2007	Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood, 2017, 129, 2616-2623.	1.4	73
2010	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
2011	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. , 2017, , 99-122.		0
2012	CAR T-cell therapy: Balance of efficacy and safety. Molecular Biology, 2017, 51, 237-250.	1.3	4
2014	Small-Molecule Inhibitors of Bruton's Tyrosine Kinase. Topics in Medicinal Chemistry, 2017, , 75-104.	0.8	2
2015	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematology, 2017, 4, e272-e282.	4.6	91
2016	A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen. Human Antibodies, 2017, 24, 45-51.	1.5	4
2017	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. Advanced Drug Delivery Reviews, 2017, 114, 285-300.	13.7	20
2018	Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma. Leukemia and Lymphoma, 2017, 58, 2845-2851.	1.3	0
2019	Chemotherapy free treatment of indolent lymphoma. Hematological Oncology, 2017, 35, 20-24.	1.7	1

#	ARTICLE	IF	CITATIONS
2020	Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity. Immunotherapy, 2017, 9, 567-577.	2.0	5
2021	Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia, 2017, 31, 2416-2425.	7.2	24
2022	Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980–2016). Human Vaccines and Immunotherapeutics, 2017, 13, 1388-1397.	3.3	21
2023	New targeted therapies for malignant lymphoma based on molecular heterogeneity. Expert Review of Hematology, 2017, 10, 39-51.	2.2	14
2024	Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method. International Immunopharmacology, 2017, 43, 23-32.	3.8	2
2025	Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunology, Immunotherapy, 2017, 66, 367-378.	4.2	12
2026	Rituximab in the treatment of pemphigus. Expert Opinion on Orphan Drugs, 2017, 5, 99-109.	0.8	1
2027	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Advances in Therapy, 2017, 34, 2232-2273.	2.9	407
2028	TNFR2: A Novel Target for Cancer Immunotherapy. Trends in Molecular Medicine, 2017, 23, 1037-1046.	6.7	102
2029	Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2828-2839.	4.1	57
2030	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood, 2017, 130, 1628-1638.	1.4	40
2031	Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opinion on Biological Therapy, 2017, 17, 1-8.	3.1	5
2032	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 834-851.	0.4	47
2033	Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. International Reviews of Immunology, 2017, 36, 352-359.	3.3	84
2034	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1429-1437.	4.9	18
2035	Featured Article: Delivery of chemotherapeutic vcMMAE using tobacco mosaic virus nanoparticles. Experimental Biology and Medicine, 2017, 242, 1405-1411.	2.4	25
2036	Obinutuzumab: what is there to learn from clinical trials?. Blood, 2017, 130, 581-589.	1.4	70
2037	Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Review of Hematology, 2017, 10, 783-799.	2.2	7

#	ARTICLE	IF	CITATIONS
2038	Treatment of membranous nephropathy: time for a paradigm shift. <i>Nature Reviews Nephrology</i> , 2017, 13, 563-579.	9.6	117
2039	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 81-88.	4.7	37
2040	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	1.4	4
2041	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 667-676.	3.0	14
2042	Targeting Oncoproteins for Molecular Cancer Therapy. , 2017, , 727-756.		0
2043	Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. <i>Clinical Oncology</i> , 2017, 29, e13-e28.	1.4	14
2044	Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 107-113.e1.	3.8	56
2045	Sortase A-Generated Highly Potent Anti-CD20-mMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas. <i>Small</i> , 2017, 13, 1602267.	10.0	45
2046	Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1564-1571.	3.8	34
2047	Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 607.	3.5	33
2048	Recent Advances in the Delivery of Chemotherapeutic Agents. , 2017, , 281-298.		6
2049	Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 117, 256-269.	4.3	4
2050	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	1.9	40
2051	Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies. <i>Acta Clinica Croatica</i> , 2017, 56, 143-155.	0.2	3
2052	RITUXIMAB DELAYS WOUND HEALING AND DECREASES WHITE BLOOD CELL COUNT IN MALE MICE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 112.	0.3	2
2053	Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. <i>Cancer Management and Research</i> , 2017, Volume 9, 131-140.	1.9	18
2054	Cell-Targeted Biologics and Emerging Targets. , 2017, , 1020-1043.e4.		0
2055	The role of novel immunotherapies in non-Hodgkin lymphoma. <i>Translational Cancer Research</i> , 2017, 6, 93-103.	1.0	26

#	ARTICLE	IF	CITATIONS
2056	How Biophysical Forces Regulate Human B Cell Lymphomas. <i>Cell Reports</i> , 2018, 23, 499-511.	6.4	30
2057	Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. <i>Pediatric Nephrology</i> , 2018, 33, 1013-1018.	1.7	19
2058	A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. <i>Clinical and Translational Science</i> , 2018, 11, 296-304.	3.1	22
2060	Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 261-274.	6.1	36
2061	Bispecific Antibody Armed T Cells to Target Cancer Cells. <i>Methods in Molecular Biology</i> , 2018, 1722, 117-126.	0.9	3
2062	Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testing. <i>Scientific Reports</i> , 2018, 8, 124.	3.3	29
2063	Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. <i>Annals of Oncology</i> , 2018, 29, 332-340.	1.2	20
2064	Rituximab in the management of acute lymphoblastic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 221-226.	3.1	20
2065	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 605-613.	4.2	4
2066	Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Oncology</i> , 2018, 29, 1354-1365.	1.2	64
2067	Pulmonary MALT lymphoma with underlying interstitial lung disease: A case report and review of the literature. <i>Journal of Oncological Science</i> , 2018, 4, 56-59.	0.1	2
2068	Immunology of the Lymphomas. , 2018, , 827-852.		1
2069	Treating relapsed follicular lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 403-410.	2.2	3
2070	Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1086-1089.	1.2	16
2071	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. , 2018, , 117-134.		0
2072	Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). <i>Pathology and Oncology Research</i> , 2018, 24, 199-205.	1.9	5
2073	Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1420-1426.	1.3	10
2074	Treatment and prognosis of stage I follicular lymphoma in the modern era – does PET matter?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1163-1171.	1.3	3

#	ARTICLE	IF	CITATIONS
2075	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. <i>Autoimmunity Reviews</i> , 2018, 17, 115-124.	5.8	48
2076	Expression of single-domain antibody in different systems. <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 539-551.	3.6	84
2077	Aptamers as potential therapeutic agents for ovarian cancer. <i>Biochimie</i> , 2018, 145, 34-44.	2.6	17
2078	Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 309-315.	3.1	32
2079	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	7.7	134
2080	Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 273-277.	0.6	6
2081	Novel agents for relapsed and refractory follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 41-48.	1.7	19
2082	A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e51-e60.	0.4	6
2083	Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). <i>Oncotarget</i> , 2018, 9, 766-773.	1.8	8
2084	1 Essentials of Medical Oncology. , 2018, , .		0
2085	Tocilizumab treatment for new onset refractory status epilepticus. <i>Annals of Neurology</i> , 2018, 84, 940-945.	5.3	134
2086	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , the, 2018, 5, e543-e553.	4.6	53
2087	HCV Infection on Lymphoid Neoplasm. <i>Journal of Infectious Disease and Therapy</i> , 2018, 06, .	0.1	0
2088	Approaches for generation of anti-leukemia specific T cells. <i>Cell Regeneration</i> , 2018, 7, 40-44.	2.6	3
2089	Cancers of the eye. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 677-690.	5.9	55
2090	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus “distinct roles of BAFF and APRIL. <i>Lupus</i> , 2018, 27, 1470-1478.	1.6	24
2091	An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 508-518.e14.	0.4	11
2092	Biosimilars Have Arrived: Rituximab. <i>Arthritis</i> , 2018, 2018, 1-6.	2.0	30

#	ARTICLE	IF	CITATIONS
2093	Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 407-414.	0.6	5
2094	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. <i>Cancer Management and Research</i> , 2018, Volume 10, 1259-1273.	1.9	109
2095	Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 177.	4.1	23
2096	Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma. , 2018, , 1288-1297.e3.		0
2097	Cancer Immunotherapy and the Immune Response in Follicular Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 219.	2.8	11
2098	Overcoming Resistance of Human Non-Hodgkinâ€™s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. <i>Cancers</i> , 2018, 10, 200.	3.7	36
2099	Selection and Characterization of Single-Stranded DNA Aptamers Binding Human B-Cell Surface Protein CD20 by Cell-SELEX. <i>Molecules</i> , 2018, 23, 715.	3.8	26
2100	Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide realâ€‘world analysis from Taiwan Cancer Registry Database. <i>Cancer Medicine</i> , 2018, 7, 3582-3591.	2.8	7
2101	Past, Present, and Future of Rituximabâ€‘The Worldâ€™s First Oncology Monoclonal Antibody Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 163.	2.8	238
2102	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 12.	2.4	3
2103	Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2018, 57, 1151-1154.	0.7	18
2104	A tale of two antibodies: obinutuzumab <i>versus</i> rituximab. <i>British Journal of Haematology</i> , 2018, 182, 29-45.	2.5	123
2105	Complement system's role in cancer and its therapeutic potential in ovarian cancer. <i>Scandinavian Journal of Immunology</i> , 2018, 88, e12672.	2.7	22
2106	Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults. <i>Contributions To Nephrology</i> , 2018, 195, 12-19.	1.1	5
2107	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. <i>Internal Medicine</i> , 2018, 57, 2247-2250.	0.7	7
2108	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	3.3	68
2109	Safety and efficacy of obinutuzumab in Chinese patients with Bâ€‘cell lymphomas: a secondary analysis of the GERSHWIN trial. <i>Cancer Communications</i> , 2018, 38, 1-9.	9.2	7
2110	Renewed interest for lowâ€‘dose radiation therapy in follicular lymphomas: From biology to clinical applications. <i>Hematological Oncology</i> , 2018, 36, 723-732.	1.7	3

#	ARTICLE	IF	CITATIONS
2111	Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. <i>FASEB Journal</i> , 2018, 32, 5063-5077.	0.5	7
2112	The Fab portion of immunoglobulin G contributes to its binding to Fc γ 3 receptor III. <i>Scientific Reports</i> , 2019, 9, 11957.	3.3	35
2113	Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation. <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 709-719.	4.1	9
2114	Targeting Biology in Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 727-738.	2.2	1
2115	Erythema Migrans: Course and Outcome in Patients Treated With Rituximab. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz292.	0.9	10
2116	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 849.	2.8	117
2117	Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 426-438.	2.3	23
2118	Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML). <i>Journal of NeuroImmune Pharmacology</i> , 2019, 14, 649-660.	4.1	10
2119	Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019, 10, 2085.	4.8	10
2120	Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma. <i>Molecular Medicine Reports</i> , 2019, 20, 3679-3690.	2.4	2
2121	Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. <i>Journal of Clinical Medicine</i> , 2019, 8, 1261.	2.4	38
2123	Commentary: Potential Therapeutic Consequences of an Acid-Sensing Ion Channel 1a-Blocking Antibody. <i>Frontiers in Pharmacology</i> , 2019, 10, 954.	3.5	4
2124	Rekombinante Antikörper. , 2019, , .		1
2125	Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 306-310.	1.3	1
2126	Novel Treatments for Lymphoma. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 903-915.	1.5	20
2127	The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis. <i>Platelets</i> , 2019, 30, 690-697.	2.3	26
2128	The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 1035.	4.8	4
2129	Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1145-1151.	1.9	30

#	ARTICLE	IF	CITATIONS
2130	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 999.	4.8	47
2131	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019, 9, 944-961.	9.4	36
2132	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2019, , 151-190.		0
2133	CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 829-843.	3.1	34
2134	<p></p>How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas<p></p>. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 71-84.	1.7	33
2135	Development of "Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. <i>Angewandte Chemie</i> , 2019, 131, 4574-4578.	2.0	6
2136	A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. <i>Protein Science</i> , 2019, 28, 900-909.	7.6	24
2137	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	1.6	277
2138	Monoclonal Antibodies in Cancer. , 2019, , 489-519.		0
2139	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. <i>International Reviews of Immunology</i> , 2019, 38, 79-91.	3.3	3
2140	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: <sc>CALGB</sc> 50901 (Alliance). <i>British Journal of Haematology</i> , 2019, 185, 53-64.	2.5	9
2141	<p></p>Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobe on malignant lymphoma cells with CD20 overexpression<p></p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 921-936.	6.7	22
2142	Development of "Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 4526-4530.	13.8	23
2143	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	3.7	15
2144	Infusion-related reactions to rituximab: frequency, mechanisms and predictors. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 383-389.	3.0	52
2145	Position of Scientific Oncological Societies Towards Biosimilar Antibodies. <i>Breast Care</i> , 2019, 14, 5-8.	1.4	3
2147	Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. <i>Methods in Molecular Biology</i> , 2019, 1881, 173-184.	0.9	1
2148	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1715-1730.	6.4	92

#	ARTICLE	IF	CITATIONS
2149	In Silico Analysis for Determination and Validation of Human CD20 Antigen 3D Structure. International Journal of Peptide Research and Therapeutics, 2019, 25, 123-135.	1.9	1
2150	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
2151	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. Clinical Pharmacokinetics, 2020, 59, 7-23.	3.5	0
2152	Proposed rituximab biosimilar BCDâ€œ020 versus reference rituximab for treatment of patients with indolent nonâ€œHodgkin lymphomas: An international multicenter randomized trial. Hematological Oncology, 2020, 38, 67-73.	1.7	9
2153	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
2154	Rituximab conjugated iron oxide nanoparticles for targeted imaging and enhanced treatment against CD20-positive lymphoma. Journal of Materials Chemistry B, 2020, 8, 895-907.	5.8	15
2156	Antibody and antibody fragments for cancer immunotherapy. Journal of Controlled Release, 2020, 328, 395-406.	9.9	63
2157	Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. Biologicals, 2020, 68, 79-91.	1.4	14
2158	The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e590-e596.	0.4	7
2160	Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients. Translational Cancer Research, 2020, 9, 5139-5146.	1.0	2
2161	Synthesis and analysis of silverâ€œcopper alloy nanoparticles of different ratios manifest anticancer activity in breast cancer cells. Cancer Nanotechnology, 2020, 11, .	3.7	13
2162	Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. Journal of Personalized Medicine, 2020, 10, 79.	2.5	10
2163	Monoclonal Antibodies in Cancer Therapy. Antibodies, 2020, 9, 34.	2.5	325
2164	Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology. Kidney360, 2020, 1, 359-367.	2.1	5
2165	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. Expert Review of Hematology, 2020, 13, 851-869.	2.2	2
2166	Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. International Journal of STD and AIDS, 2020, 31, 1426-1431.	1.1	2
2167	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Advances, 2020, 4, 4091-4101.	5.2	33
2168	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€œCoVâ€œ2â€œPandemic. HemaSphere, 2020, 4, e432.	2.7	18

#	ARTICLE	IF	CITATIONS
2169	Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000753.	4.5	25
2170	A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. <i>Blood Advances</i> , 2020, 4, 3886-3893.	5.2	26
2171	Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis. <i>Cancer Medicine</i> , 2020, 9, 5312-5319.	2.8	6
2172	Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 595-610.	27.6	124
2173	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. <i>International Journal of Cancer</i> , 2020, 147, 1979-1986.	5.1	6
2174	T cell-engaging therapies â€” BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	27.6	296
2175	A Microfluidic Single-Cell Cloning (SCC) Device for the Generation of Monoclonal Cells. <i>Cells</i> , 2020, 9, 1482.	4.1	3
2176	Initial Treatment of High Tumor Burden Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 673-687.	2.2	1
2177	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 363-381.	2.5	14
2178	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. <i>European Journal of Cancer</i> , 2020, 136, 4-6.	2.8	53
2179	Antibody Therapy Maintenance in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 689-699.	2.2	2
2180	Recurrent <i>Campylobacter</i> Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 553.	2.4	10
2181	O-GlcNAcylation of light chain serine 12 mediates rituximab production doubled by thiamet G. <i>Bioprocess and Biosystems Engineering</i> , 2020, 43, 863-875.	3.4	0
2182	Rituximab in Ocular Adnexal Lymphoma and Orbital Inflammatory Disease. <i>International Ophthalmology Clinics</i> , 2020, 60, 63-75.	0.7	1
2183	Pretargeted delivery of PI3K/mTOR small-molecule inhibitorâ€”loaded nanoparticles for treatment of non-Hodgkinâ€™s lymphoma. <i>Science Advances</i> , 2020, 6, eaaz9798.	10.3	30
2184	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 563-571.	0.4	10
2185	Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 853-858.	3.7	20
2187	Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan. <i>Cancer Science</i> , 2021, 112, 433-443.	3.9	1

#	ARTICLE	IF	CITATIONS
2188	Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. Arthritis and Rheumatology, 2021, 73, 347-354.	5.6	25
2189	Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opinion on Biological Therapy, 2021, 21, 161-181.	3.1	24
2190	Gene Therapy and Gene Editing for Cancer Therapeutics. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 116-204.	0.1	0
2191	Bleeding Associated with Thrombocytopenia. , 2021, , 141-156.		0
2192	Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a Tj ETQq0 0 0 rgBT /Overlock 10 T Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 405-416.	2.2	6
2193	A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Advances, 2021, 5, 984-993.	5.2	9
2194	Immunotherapy for Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 343-345.	1.6	6
2195	Nano-Oncologicals: A Tortoise Trail Reaching New Avenues. Advanced Functional Materials, 2021, 31, 2009860.	14.9	13
2196	Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Therapy, 2021, 28, 602-612.	4.5	9
2197	Does COVID-19 Vaccination Warrant the Classical Principle "efelein i mi vlaptin"? Medicina (Lithuania), 2021, 57, 253.	2.0	10
2198	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 209-221.	5.6	88
2199	Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of 225Ac-DOTA-rituximab using 64Cu-DOTA-rituximab. Annals of Nuclear Medicine, 2021, 35, 639-647.	2.2	10
2200	Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis. Frontiers in Neurology, 2021, 12, 637932.	2.4	3
2201	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	10.7	83
2202	BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood, 2021, 138, 1843-1854.	1.4	17
2203	Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar. BioDrugs, 2021, 35, 459-468.	4.6	5
2204	Management of relapsed follicular lymphoma. Annals of Lymphoma, 0, 5, 14-14.	4.5	4
2206	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology, 2021, 12, 681984.	4.8	32

#	ARTICLE	IF	CITATIONS
2207	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. <i>Viruses</i> , 2021, 13, 1202.	3.3	26
2208	Vaccination in Patients with Chronic Lymphocytic Leukemia: Current Problems. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2021, 20, 91-106.	0.8	1
2209	Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 55-66.	2.7	2
2210	SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case. <i>Lupus</i> , 2021, 30, 1698-1699.	1.6	1
2211	Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. <i>Frontiers in Medicine</i> , 2021, 8, 707104.	2.6	11
2212	The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 323-336.	2.4	2
2213	Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. <i>Lancet Haematology</i> , 2021, 8, e593-e604.	4.6	26
2214	Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 523-532.e8.	2.9	24
2216	A case of polymorphic dermal angitis in a B-cell chronic lymphocytic leukemia patient during rituximab therapy. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	1
2217	Production and Application of CAR T Cells: Current and Future Role of Europe. <i>Frontiers in Medicine</i> , 2021, 8, 713401.	2.6	15
2218	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	1.7	1
2219	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 26-43.	2.5	16
2220	Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. <i>Cancer Cell</i> , 2021, 39, 1297-1299.	16.8	83
2221	The tetraspan MS4A family in homeostasis, immunity, and disease. <i>Trends in Immunology</i> , 2021, 42, 764-781.	6.8	33
2222	Impact of rituximab on COVID-19 outcomes. <i>Annals of Hematology</i> , 2021, 100, 2805-2812.	1.8	46
2223	Prognostic Indicators of Survival in Sinonasal Diffuse Large B-Cell Lymphoma: A National Cancer Database Analysis. <i>Laryngoscope</i> , 2022, 132, 1515-1522.	2.0	5
2224	Role of ceramide/sphingomyelin (SM) balance regulated through SM cycle in cancer. <i>Cellular Signalling</i> , 2021, 87, 110119.	3.6	44
2225	Separation of recombinant monoclonal antibodies IgG201 from a cell culture supernatant using an integrated aqueous two-phase system with thermo-separating EOPO. <i>Separation and Purification Technology</i> , 2021, 275, 119246.	7.9	7

#	ARTICLE	IF	CITATIONS
2226	Non-Hodgkin's Lymphomas. , 0, , 443-468.		1
2227	Biopharmaceuticals as Targeting Vehicles for In situ Radiotherapy of Malignancies. , 0, , 497-535.		17
2228	Rare Thyroid Cancers. , 2006, , 393-402.		2
2229	The Indolent B-Cell Lymphomas. , 2006, 131, 89-120.		4
2230	Vaccine Therapies for Non-Hodgkin's Lymphomas. , 2006, 131, 283-315.		1
2231	Monoclonal Antibodies in the Treatment of Malignant Lymphomas. Advances in Experimental Medicine and Biology, 2008, 610, 155-176.	1.6	3
2232	Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology, 2009, , .	1.6	6
2233	Monoclonal Antibodies in Cancer Therapy. , 2007, , 453-484.		1
2234	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2013, , 143-178.		5
2235	Orbital and Ocular Adnexal Lymphoma. , 2015, , 145-153.		2
2236	Analysis of Humoral Immune Responses in Vaccine Trials. , 2004, , 543-561.		1
2238	Monoclonal antibody therapy. , 2009, , 303-406.		4
2239	Regulatory process for approval of biologicals for cancer therapy. , 2009, , 613-629.		1
2240	Antibody-Based Therapies for Solid Tumors. , 2011, , 245-256.		1
2241	Acupuncture and Moxibustion as an Evidence-based Therapy for Cancer. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , .	0.1	11
2242	Monoclonal antibody therapy. , 2003, , 329-390.		3
2243	Application of Fluorescence in Studying Therapeutic Enzymes. Advances in Experimental Medicine and Biology, 2019, 1148, 105-114.	1.6	3
2244	Non-Hodgkin's Lymphoma. , 2008, , 2371-2404.		3

#	ARTICLE	IF	CITATIONS
2245	Malignant Diseases in Human Immunodeficiency Virus Infection. , 2010, , 1765-1779.		1
2246	Follicular Lymphoma. , 2006, , 348-373.		1
2249	Chronic lymphocytic leukemia/small lymphocytic lymphoma. , 0, , 81-102.		1
2250	Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. The Hematology Journal, 2001, 2, 300-306.	1.4	69
2251	Tumor necrosis factor α release is a major biological event associated with rituximab treatment. The Hematology Journal, 2001, 2, 378-384.	1.4	88
2252	Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine+rituximab. The Hematology Journal, 2003, 4, 151-153.	1.4	4
2253	Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. The Hematology Journal, 2003, 4, 110-115.	1.4	13
2254	Recurrent psychotic episodes in a patient who received rituximab for the treatment of non-Hodgkin's lymphoma. The Hematology Journal, 2004, 5, 90-90.	1.4	3
2255	Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. , 0, .		1
2256	Correspondence. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. British Journal of Haematology, 2001, 112, 1085-1086.	2.5	38
2257	Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. American Journal of Kidney Diseases, 2004, 44, 757-761.	1.9	14
2258	High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. Leukemia and Lymphoma, 2001, 42, 1255-1264.	1.3	3
2259	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. Leukemia and Lymphoma, 2001, 42, 1329-1337.	1.3	32
2260	Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds. Journal of Drug Targeting, 2020, 28, 1018-1033.	4.4	3
2261	Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer. Current Opinion in Oncology, 1999, 11, 187.	2.4	15
2262	Treatment of follicular and other indolent lymphomas. Current Opinion in Oncology, 1999, 11, 333.	2.4	3
2263	Biologic therapy for lymphoma. Current Opinion in Oncology, 1999, 11, 343.	2.4	7
2264	Radioimmunotherapy for lymphoma. Current Opinion in Oncology, 1999, 11, 375.	2.4	41

#	ARTICLE	IF	CITATIONS
2265	Monoclonal Antibody Therapy for Genitourinary Oncology: Promise for the Future. Journal of Urology, 2002, , 2615-2623.	0.4	1
2266	Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study. Therapeutic Drug Monitoring, 2000, 22, 295-301.	2.0	60
2267	SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS. Transplantation, 1999, 68, 1588-1596.	1.0	45
2268	Hodgkin's disease and non-Hodgkin's lymphoma. Current Opinion in Hematology, 1999, 6, 205.	2.5	7
2269	Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. Current Opinion in Hematology, 1999, 6, 222.	2.5	6
2270	Chronic lymphocytic leukemia. Current Opinion in Hematology, 1999, 6, 253.	2.5	43
2271	Clinically useful monoclonal antibodies in treatment. Journal of Clinical Pathology, 2002, 55, 81-85.	2.0	36
2272	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
2273	Immunotherapy of lymphomas. Journal of Clinical Investigation, 2020, 130, 1576-1585.	8.2	32
2274	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. Journal of Clinical Investigation, 2011, 121, 4268-4280.	8.2	156
2275	Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	2.5	9
2276	Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects. Hematology American Society of Hematology Education Program, 2007, 2007, 226-232.	2.5	25
2277	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	2.5	1
2278	Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood, 2002, 100, 2257-2259.	1.4	19
2279	Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma. Blood, 2016, 128, 47-47.	1.4	2
2280	Rituxan in the Treatment of Cold Agglutinin Disease. Blood, 1998, 92, 3490-3491.	1.4	2
2281	Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood, 2000, 95, 3052-3056.	1.4	63
2282	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 2000, 95, 3900-3908.	1.4	124

#	ARTICLE	IF	CITATIONS
2283	Characterization of Epstein-Barr virusâ€“infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood, 2000, 96, 4055-4063.	1.4	80
2284	Targeting CD20: teaching an old dog new tricks. Hematology American Society of Hematology Education Program, 2019, 2019, 273-278.	2.5	6
2285	A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection. American Journal of Case Reports, 2019, 20, 1394-1397.	0.8	4
2286	Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement. PLoS ONE, 2014, 9, e100324.	2.5	62
2287	Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLoS ONE, 2017, 12, e0178544.	2.5	30
2288	Passage of Humanized Monoclonal Antibodies Across the Blood- Brain Barrier: Relevance in the Treatment of Cancer Brain Metastases?. Journal of Applied Biopharmaceutics and Pharmacokinetics, 2015, 2, 50-58.	0.1	3
2289	The Role of Rituximab in Lymphomas. Revista Brasileira De Hematologia E Hemoterapia, 2002, 24, .	0.7	1
2291	Usefulness of real-time PCR in long-term follow-up of follicular lymphoma patients.. Acta Biochimica Polonica, 2007, 54, 135-142.	0.5	4
2292	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. Oncotarget, 2016, 7, 71536-71547.	1.8	7
2293	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. Oncotarget, 2017, 8, 113895-113909.	1.8	15
2294	Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget, 2018, 9, 4020-4033.	1.8	40
2295	Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget, 2015, 6, 27816-27831.	1.8	20
2296	90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Oncotarget, 2016, 7, 7597-7609.	1.8	31
2297	Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells. Oncotarget, 2013, 4, 218-230.	1.8	26
2298	Scientific rationale for immunotherapy in lymphoma and predictors of response. Annals of Lymphoma, 0, 1, 1-1.	4.5	2
2299	Advances in the diagnosis and control of lymphomas. Salud Publica De Mexico, 2016, 58, 296-301.	0.4	3
2301	B-lymphocytes as Targets for Therapy in Chronic Cold Agglutinin Disease. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 219-227.	0.7	10
2302	Monoclonal Antibodies: Application in Radiopharmacy. Current Radiopharmaceuticals, 2014, 6, 231-248.	0.8	7

#	ARTICLE	IF	CITATIONS
2303	Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2002, 6, 1-85.	2.8	34
2304	Therapy of gastric mucosa associated lymphoid tissue lymphoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 3554.	3.3	41
2305	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2011, 17, 3881.	3.3	51
2306	<i>Helicobacter pylori</i> infection in gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 2751.	3.3	23
2307	Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab. <i>Korean Journal of Internal Medicine</i> , 2010, 25, 86.	1.7	32
2308	Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 885-893.	1.7	9
2309	The promise of targeted therapy: cancer drugs become more specific.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 551-560.	1.3	31
2310	Biologics in dermatology: An integrated review. <i>Indian Journal of Dermatology</i> , 2014, 59, 425.	0.3	22
2311	Safety and Efficacy of Radioimmunotherapy with ⁹⁰ Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. <i>Journal of Cancer Science & Therapy</i> , 2012, 04, .	1.7	2
2312	Targeted use of Alpha Particles: Current Status in Cancer Therapeutics. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2012, 03, .	0.2	9
2313	Rituximab maintenance in follicular lymphoma patients. <i>World Journal of Clinical Oncology</i> , 2011, 2, 281.	2.3	6
2314	Relapsed follicular lymphoma sequentially treated with rituximab and ⁹⁰ Y-ibritumomab tiuxetan. Case report. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2007, 151, 109-112.	0.6	3
2315	Next generation of antibody therapy for cancer. <i>Chinese Journal of Cancer</i> , 2011, 30, 293-302.	4.9	10
2316	Fatal Adenoviral Hepatitis After Rituximab Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1557-1560.	2.5	28
2318	Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature. <i>Drugs in Context</i> , 2020, 9, 1-12.	2.2	6
2319	Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. <i>PeerJ</i> , 2013, 1, e31.	2.0	27
2321	Leukemia Therapy: Mechanisms of Drug Resistance and Investigational Strategies. <i>British Journal of Medicine and Medical Research</i> , 2014, 4, 4134-4153.	0.2	1
2322	Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. <i>Pediatric Nephrology</i> , 2022, 37, 1057-1066.	1.7	15

#	ARTICLE	IF	CITATIONS
2323	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	2.5	0
2324	Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 2000, 96, 1259-1266.	1.4	7
2325	æŠ—ä½“ä«ä,~ä,«èj€æŋ²è...«ç~ñ®æ²»ç™,. Okayama Igakkai Zasshi, 2001, 113, 235-239.	0.0	0
2326	Immunomodulation Strategies in Xenotransplantation. , 2001, , 357-388.		0
2328	Non-Hodgkinâ€™s Lymphoma. , 2001, , 310-322.		0
2329	Clinical applications of monoclonal antibody therapy.. Drug Delivery System, 2001, 16, 91-95.	0.0	0
2330	Immunology of Cancer. , 2001, , 1641-1657.		0
2331	Clinical use of monoclonal antibody.. Drug Delivery System, 2001, 16, 409-418.	0.0	0
2332	Taqman PCR In The Detection And Quantification Of Chromosomal Translocations In Follicular Lymphoma, Mantle Cell Lymphoma And Chronic Myeloid Leukemia: Taqman Real-time PCR Assay. The Internet Journal of Pathology, 2002, 2, .	0.1	2
2333	Genomic drug discovery and clinical applications of DDS.. Drug Delivery System, 2002, 17, 408-418.	0.0	0
2334	Antibody-Targeted Gene Therapy. , 2002, , 81-94.		0
2335	A Case of Follicular Lymphoma with Cutaneous Infiltration.. Nishinohon Journal of Dermatology, 2002, 64, 194-199.	0.0	0
2336	Treatment of B-cell non-Hodgkin's lymphoma with anti-CD20 monoclonal antibodies.. Drug Delivery System, 2002, 17, 35-41.	0.0	0
2337	Innovations in Cancer Therapeutics. , 2002, , 93-116.		0
2338	Development of cancer therapy using antibodies.. Drug Delivery System, 2002, 17, 29-34.	0.0	1
2339	Äkute lymphatische LeukÄmie bei Älteren Patienten. , 2002, , 421-436.		0
2340	The Rise of Antibodies as Therapeutics. Lung Biology in Health and Disease, 2002, , 427-469.	0.1	0
2342	Non-Hodgkin-Lymphome. , 2003, , 1079-1093.		0

#	ARTICLE	IF	CITATIONS
2343	Drug immunoconjugates. , 2003, , 435-446.		0
2344	Non-Hodgkin's Lymphoma. , 2003, , 295-318.		0
2345	Antibody-based cancer therapy. Drug Delivery System, 2003, 18, 377-384.	0.0	0
2346	New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia. Hamatologie Und Bluttransfusion, 2003, , 153-160.	0.0	0
2347	Non-Hodgkin's Lymphoma. , 2003, , 83-99.		2
2348	Cancer biotherapy: 2003 disease-related activity. , 2003, , 615-674.		0
2349	Experimental and clinical pharmacology: Antineoplastic antibodies - clinical applications. Australian Prescriber, 2003, 26, 141-143.	1.0	2
2350	Anti-CD20 monoclonal antibody therapy for the patients with cutaneous B-cell lymphoma. Skin Cancer, 2004, 19, 80-89.	0.0	0
2351	Monoclonal Antibody Therapy in Chronic Lymphocytic Leukemia. , 2004, , 269-298.		0
2353	Maligne Lymphome. , 2004, , 1711-1774.		0
2354	Role of Radiotherapy in Lymphomas. Medical Radiology, 2004, , 229-240.	0.1	0
2355	Chemotherapy of Chronic Lymphocytic Leukemia. , 2004, , 241-254.		1
2357	Present Status and Perspectives of Antibody Therapy against Cancer. Japanese Journal of Complementary and Alternative Medicine, 2005, 2, 15-21.	1.0	1
2358	Principles of Bioimmunotherapy. , 2005, , 69-91.		0
2359	Biological Therapy of Non-Hodgkin's Lymphomas. , 2006, , 249-277.		0
2360	Follikuläres Keimzentrums-Lymphom (zentroblastisch-zentrozytisches Lymphom). , 2006, , 2899-2927.		0
2361	Hämoblastosen. , 2006, , 630-713.		0
2362	Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 2006, , 445-457.		0

#	ARTICLE	IF	CITATIONS
2363	A Case of Primary Follicular Lymphoma of the Duodenum. Japanese Journal of Gastroenterological Surgery, 2007, 40, 1684-1689.	0.1	0
2364	Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma – a Single-center, Retrospective Study. Acta Medica (Hradec Kralove), 2007, 50, 113-118.	0.5	0
2366	Development of a New Fully Human Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies.. Blood, 2007, 110, 2349-2349.	1.4	1
2367	Monoclonal Antibodies as Therapeutic Agents. , 2008, , 107-126.		0
2371	POEMS Syndrome and Other Atypical Plasma Cell Disorders. , 2008, , 571-623.		1
2372	Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2008, , 141-164.		0
2373	Drug Immunoconjugates. , 2009, , 451-462.		0
2374	Biological therapy of B and T cell lymphoproliferative disorders. , 2009, , 693-709.		0
2375	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
2376	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. , 2009, , 321-363.		0
2378	Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma. The Showa University Journal of Medical Sciences, 2009, 21, 215-225.	0.1	0
2379	TRANSPLANT MEDICINE. , 2009, , 1269-1294.		0
2380	Immunotherapy of Cancer. , 2009, , 209-240.		1
2381	Lymphomas and Chronic Lymphocytic Leukemia. , 2009, , 173-187.		1
2382	Biologic Therapies for Chronic Lymphocytic Leukemia. , 2009, , .		0
2383	Biologic Therapies For Non-hodgkin Lymphoma And Hodgkin Disease. , 2009, , .		0
2384	Monoclonal Antibody Therapy for Hematologic Malignancies. , 2010, , 493-536.		0
2385	Multidisciplinary Treatment of Cancer. , 2009, , 28-42.		0

#	ARTICLE	IF	CITATIONS
2386	Ocular Adnexal Lymphoproliferative Disease. Essentials in Ophthalmology, 2010, , 1-19.	0.1	0
2387	Primary Orbital Cancers in Adults. , 2010, , 3-12.		1
2388	Overview of the Lymphoid Neoplasms. , 2012, , 3-39.		0
2390	Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 432-438.	0.7	1
2394	Chronic Lymphocytic Leukemia (CLL). , 2012, , 67-96.		0
2396	Maintenance treatment of follicular lymphoma: evidence from recent clinical trials. Clinical Investigation, 2011, 1, 1707-1716.	0.0	0
2399	Non-Hodgkinâ€™s Lymphomas. , 2012, , 115-157.		0
2401	Emerging Therapies in Chronic Lymphocytic Leukemia. , 0, , .		0
2403	Lymphomas. , 2013, , 153-187.		0
2404	From Transplant to Tablets : A Paradigm Shift in Oncology = ù...ù† Ø²Ø±Ø¹ Øšù„ù†Ø®ØšØ¹ Ø¥ù„ù% Øšù„ØØ“ù“Ø“ : ù†ù„ù„Ø© ù† Journal, 2012, 12, 402-405.	1.0	0
2405	Biological Treatments (Antibodies). , 2013, , 915-948.		0
2406	Understanding the Mechanisms of Resistance to Rituximab: Paving the Road for the Development of Therapeutic Strategies to Overcome Rituximab-Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 73-92.	0.1	0
2407	Monoclonal Antibodies in Cancer. , 2013, , 337-359.		1
2408	Cell-Targeted Biologics and Targets. , 2013, , 978-1000.		0
2409	Rituximab Therapy in Cutaneous Infiltration of Chronic Lymphocytic Leukaemia. Acta Haematologica, 2013, 130, 47-51.	1.4	0
2410	Tumor Resistance to Antibody-Mediated Immunotherapy and Reversal of Resistance: Rituximab as Prototype. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 93-124.	0.1	0
2414	Therapeutic Antibodies and Immunologic Conjugates. , 2014, , 508-518.e7.		2
2415	Lymphomes : principes thÃ©rapeutiques et imagerie post-thÃ©rapeutique. , 2014, , 265-298.		0

#	ARTICLE	IF	CITATIONS
2416	Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World Journal of Hematology, 2014, 3, 29.	0.1	0
2417	Hematologic Malignancies. Oncologist, 1999, 4, 287-292.	3.7	0
2418	Anticuerpos Monoclonales como Terapia Antineoplásica. Anales De La Facultad De Medicina, 2014, 62, 31.	0.1	0
2421	Monoclonal Antibodies in Chronic Lymphocytic Leukemia. Lymphoma and Chronic Lymphocytic Leukemias, 0, 6, 1-11.	0.0	0
2422	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2016, , 1-42.		0
2423	Bleeding Associated with Thrombocytopenia. , 2016, , 103-117.		0
2424	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
2425	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2017, , 353-393.		0
2426	COMPARISON IMMUNOCHEMOTHERAPY AND CHEMOTHERAPY EFFICASY IN FOLLICULAR LYMPHOMA. , 2017, 16, 24-31.	0.3	0
2427	Rituximab-Related Late-Onset Neutropenia in Kidney Transplant Recipients Treated for Antibody-Mediated Acute Rejection. Experimental and Clinical Transplantation, 2017, 15, 414-419.	0.5	6
2428	Alkylating Agent-Induced ER Stress Overcomes Microenvironmental Resistance to Lymphoma Therapy. SSRN Electronic Journal, 0, , .	0.4	0
2429	Anticorps monoclonaux en oncologie : déclencher une réponse immunitaire en plus de la réduction tumorale spécifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
2430	Weight Parameters and Green Tea Effect; A Review. Advances in Science, Technology and Engineering Systems, 2018, 3, 104-107.	0.5	0
2431	Rituximab dosing in B cell lymphoma. Science Proceedings, 0, 4, .	0.0	0
2432	Resistance to Monoclonal Antibody Therapeutics in Lymphoma. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 27-55.	0.1	0
2433	Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review). International Journal of Oncology, 2020, 56, 7-17.	3.3	3
2434	Antibody Therapy in Follicular Lymphoma. , 2020, , 189-206.		0
2435	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2020, , 159-212.		0

#	ARTICLE	IF	CITATIONS
2436	VIII. Adult Nephrotic Syndrome: Treatment with Rituximab. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 933-938.	0.0	0
2437	Ocular Adnexal Lymphoproliferative Disease. , 2021, , 769-816.		1
2439	Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Non-coding RNA, 2021, 7, 1.	2.6	9
2440	Chapter 33: Therapeutic Applications of Radioactive Agents. , 2020, , .		0
2441	COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge. Frontiers in Immunology, 2021, 12, 763412.	4.8	43
2446	Neue Arzneimittel. , 0, , 37-107.		0
2447	Dawn of a new era in molecular cancer therapeutics. , 2005, 63, 1-17.		1
2448	Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. , 2006, 131, 221-250.		2
2449	Monoclonal Antibody Therapy of Cancer. , 2007, , 321-342.		20
2451	Monoclonal Antibodies in Lymphomas. , 2007, , 511-536.		0
2453	Targeted Therapy in Chronic Lymphocytic Leukemia. , 2008, , 61-86.		0
2455	Non-Hodgkin-Lymphome niedriger Malignität. , 0, , 342-384.		0
2458	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma. , 0, , 1207-1220.		2
2459	Posttransplant Lymphoproliferative Disorders. , 2008, 142, 273-292.		8
2460	Remission of cold hemagglutinin disease induced by rituximab therapy. Cmaj, 2001, 164, 1405.	2.0	1
2461	Biological response modifiers in cancer. MedGenMed: Medscape General Medicine, 2006, 8, 33.	0.2	5
2462	Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas. Transactions of the American Clinical and Climatological Association, 2004, 115, 255-72.	0.5	2
2463	Tumor targeting using liposomal antineoplastic drugs. International Journal of Nanomedicine, 2008, 3, 21-9.	6.7	47

#	ARTICLE	IF	CITATIONS
2464	Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. <i>Biologics: Targets and Therapy</i> , 2007, 1, 215-27.	3.2	13
2465	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2009, 3, 225-32.	3.2	4
2466	I-Tositumomab in lymphoma. <i>Current Oncology</i> , 2009, 16, 32-47.	2.2	7
2467	Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. <i>P and T</i> , 2010, 35, 148-57.	0.9	85
2468	Rituximab: a review of dermatological applications. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2009, 2, 29-37.	0.1	28
2469	Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value. <i>Core Evidence</i> , 2007, 2, 121-9.	4.7	0
2470	Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 391-407.	0.2	42
2471	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 381-9.	0.2	36
2472	C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma. <i>American Journal of Blood Research</i> , 2011, 1, 204-14.	0.6	1
2473	Predicting success or failure of immunotherapy for cancer: insights from a clinically applicable mathematical model. <i>American Journal of Cancer Research</i> , 2012, 2, 204-13.	1.4	8
2474	Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. <i>American Journal of Blood Research</i> , 2012, 2, 86-97.	0.6	7
2475	Cancer therapy with bispecific antibodies: Clinical experience. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 340-9.	2.8	45
2476	Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy. <i>International Journal of Molecular and Cellular Medicine</i> , 2015, 4, 143-51.	1.1	27
2477	Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 17515-22.	1.3	10
2478	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. <i>American Journal of Cancer Research</i> , 2016, 6, 403-24.	1.4	18
2479	Fulminant Colitis Following Rituximab Therapy. <i>Gastroenterology and Hepatology</i> , 2016, 12, 58-60.	0.1	5
2480	Physicochemical Evaluation of Lyophilized Formulation of -SCN-Bn-DOTA- and -SCN-Bn-DTPA-rituximab for NHL Radio Immunotherapy. <i>Iranian Journal of Pharmaceutical Research</i> , 2016, 15, 295-302.	0.5	0
2481	Combination of celecoxib (Celebrex) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas. <i>American Journal of Clinical and Experimental Immunology</i> , 2017, 6, 27-42.	0.2	2

#	ARTICLE	IF	CITATIONS
2482	Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 407-414.	1.0	6
2484	Follicular lymphoma with paraneoplastic pemphigus as the first symptom: a case report and review of the literature. International Journal of Clinical and Experimental Pathology, 2020, 13, 1915-1923.	0.5	3
2486	NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1218-1230.	4.9	98
2487	Theranostics of Hematologic Disorders. , 2022, , 359-432.		0
2488	Clinical development of IDH1 inhibitors for cancer therapy. Cancer Treatment Reviews, 2022, 103, 102334.	7.7	18
2490	Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases. Frontiers in Pharmacology, 2021, 12, 785770.	3.5	2
2491	Off-the-Shelf Prostate Stem Cell Antigen- Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer. Gastroenterology, 2022, 162, 1319-1333.	1.3	38
2492	The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies. International Journal of Molecular Sciences, 2022, 23, 1599.	4.1	0
2493	Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). International Journal of Oncology, 2022, 60, .	3.3	7
2494	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leukemia and Lymphoma, 2022, , 1-10.	1.3	2
2495	Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation, 2022, , .	2.4	2
2496	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer. JAMA Oncology, 2022, 8, 537.	7.1	11
2497	Journal Club Review of “Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis” ACR Open Rheumatology, 2022, , .	2.1	0
2498	Antibody response to COVID-19 vaccination in patients with lymphoma. International Journal of Hematology, 2022, 115, 728-736.	1.6	13
2499	PepSeA: Peptide Sequence Alignment and Visualization Tools to Enable Lead Optimization. Journal of Chemical Information and Modeling, 2022, 62, 1259-1267.	5.4	3
2500	Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Journal of Allergy and Clinical Immunology, 2022, 149, 1525-1560.	2.9	53
2501	Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy. Scientific Reports, 2022, 12, 2678.	3.3	5
2502	Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Communications Biology, 2022, 5, 229.	4.4	8

#	ARTICLE	IF	CITATIONS
2503	Signaling domains of cancer-associated glycolipids. Glycoconjugate Journal, 2022, 39, 145-155.	2.7	9
2504	Rituximab-treated patients with lymphoma develop strong <scp>CD8</scp> Tâ€cell responses following <scp>COVID</scp>-19 vaccination. British Journal of Haematology, 2022, 197, 697-708.	2.5	22
2505	Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clinical and Experimental Medicine, 2023, 23, 371-379.	3.6	14
2506	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies. Frontiers in Oncology, 2021, 11, 719140.	2.8	2
2507	Patient parameters and response after administration of rituximab in pediatric mature Bâ€cell nonâ€Hodgkin lymphoma. Pediatric Blood and Cancer, 2022, 69, e29514.	1.5	3
2508	Epitope Mapping of an Anti-CD20 Monoclonal Antibody (C₂₀Mab-60) Using Enzyme-Linked Immunosorbent Assay. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 250-254.	1.6	1
2509	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2022, 40, 3020-3031.	1.6	26
2510	Prompt Hematological Recovery in Response to a Combination of Pegylated Interferon Î±-2a and Rituximab in a Profoundly Immuno-Suppressed Hairy Cell Leukemia Patient with a Mycobacterial Infection at Onset: Benefits and Drawbacks of Rapid Immune Reconstitution. Hematology Reports, 2022, 14, 135-142.	0.8	2
2511	Follicular lymphomas. , 0, , 338-366.		0
2512	Treatment approaches to MALT/marginal zone lymphoma. , 0, , 404-409.		0
2513	Nodular Lymphocyte Predominant Hodgkin's Lymphoma. , 2008, 142, 367-381.		16
2516	Aetiology and Management of Non-Hodgkin's Lymphoma. , 0, , 735-760.		0
2517	Radioimmunotherapy and Hematopoietic Cell Transplantation. , 0, , 198-208.		1
2518	Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia. , 0, , 1105-1115.		1
2519	Treatment of Extrahepatic Diseases Caused by Hepatitis B and Hepatitis C Viruses. , 0, , 780-793.		0
2521	Rituximab-induced acute pulmonary fibrosis. Mayo Clinic Proceedings, 2004, 79, 949, 953.	3.0	30
2522	B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. Biologics: Targets and Therapy, 2009, 3, 225.	3.2	1
2525	Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. Leukemia Research Reports, 2022, 17, 100319.	0.4	0

#	ARTICLE	IF	CITATIONS
2526	A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy. International Journal of Infectious Diseases, 2022, 121, 85-88.	3.3	4
2527	Rheumatoid arthritis: current therapeutics compendium. Endocrine Regulations, 2022, 56, 148-162.	1.3	4
2528	FDG PET/CT and Dosimetric Studies of ¹⁷⁷ Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?. Molecular Imaging and Biology, 2022, 24, 807-817.	2.6	3
2529	Treatment of indolent lymphoma. Blood Research, 2022, 57, S120-S129.	1.3	2
2530	Template-Assisted Crystallization Behavior in Stirred Solutions of the Monoclonal Antibody Anti-CD20: Probability Distributions of Induction Times. Crystal Growth and Design, 2022, 22, 3637-3645.	3.0	3
2532	Rituximab and future biological therapies. , 2013, , 333-341.e3.		1
2534	Ocular adnexal lymphoma: A single-institution retrospective study. Saudi Journal of Ophthalmology, 2021, 35, 230.	0.3	1
2536	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. Frontiers in Oncology, 0, 12, .	2.8	3
2537	Biological impediments to monoclonal antibody—based cancer immunotherapy. Molecular Cancer Therapeutics, 2004, 3, 1493-1501.	4.1	100
2538	General Principles of Medical Cancer Treatment. Journal of Internal Medicine and Emergency Research, 0, , .	0.0	0
2539	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. Journal of Controlled Release, 2022, 349, 425-433.	9.9	2
2541	Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in <i>scid</i> mouse/human lymphoma xenografts. Molecular Cancer Therapeutics, 2004, 3, 1693-1699.	4.1	21
2542	A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Molecular Cancer Therapeutics, 2004, 3, 1559-1564.	4.1	36
2543	Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncology, 2022, 18, 2943-2966.	2.4	12
2544	Secondary rituximab—associated versus primary immunodeficiencies: The enigmatic border. European Journal of Immunology, 2022, 52, 1572-1580.	2.9	2
2545	Late-onset toxicities of monoclonal antibodies in cancer patients. Immunotherapy, 2022, 14, 1067-1083.	2.0	3
2546	Immunoglobulin Superfamily Receptor Translocation Associated 2 Protein on Lymphoma Cell Lines and Hairy Cell Leukemia Cells Detected by Novel Monoclonal Antibodies. Clinical Cancer Research, 2005, 11, 87-96.	7.0	32
2547	Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway. Frontiers in Immunology, 0, 13, .	4.8	13

#	ARTICLE	IF	CITATIONS
2548	The Evolution of Antibodies into Versatile Tumor-Targeting Agents. <i>Clinical Cancer Research</i> , 2005, 11, 129-138.	7.0	62
2549	Anti-viral efficacy of a next-generation CD4-binding site bNAb in SHIV-infected animals in the absence of anti-drug antibody responses. <i>IScience</i> , 2022, 25, 105067.	4.1	2
2550	Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. <i>Indian Journal of Medical Research</i> , 2022, 155, 335.	1.0	7
2551	Diagnostic Applications of Nuclear Medicine: Lymphomas. , 2022, , 431-474.		0
2552	Diagnostic Accuracy of Four Serological Tests for COVID-19 and Differences in Antibody Positivity Rates Based on the Need for Treatment or Ventilator Support. <i>Journal of St Marianna University</i> , 2022, 13, 29-37.	0.1	0
2553	Drug allergy: AÂ2022 practice parameter update. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1333-1393.	2.9	131
2554	Low Cost Immunosuppressive Strategies in Renal Transplantation. , 0, , .		0
2555	Off-Label Uses of Rituximab in Dermatology. <i>Current Dermatology Reports</i> , 0, , .	2.1	2
2556	MALIGNANT LYMPHOMA -DIAGNOSIS, THERAPY AND PROGNOSIS HODGKINâ€™S LYMPHOMAS -HODGKINâ€™S DISEASE, DIFFUSE LARGE CELL B LYMPHOMA - DLCL. , 2021, 4, 1-14.		0
2557	Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab. <i>Cancers</i> , 2022, 14, 4787.	3.7	4
2558	Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review. <i>British Journal of Cancer</i> , 2022, 127, 1827-1836.	6.4	18
2561	Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction. <i>Vaccines</i> , 2022, 10, 1827.	4.4	0
2562	The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. <i>Irish Journal of Medical Science</i> , 2023, 192, 1959-1973.	1.5	3
2563	Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose. <i>Clinical Immunology</i> , 2022, 245, 109144.	3.2	3
2564	Delayed-onset and long-lasting severe neutropenia due to rituximab. <i>Swiss Medical Weekly</i> , 0, , .	1.6	1
2565	Transitioning immunotherapy in neuromyelitis optica spectrum disorder “when and how to switch. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1393-1404.	3.1	0
2566	Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: A two-center prospective cohort study. <i>Clinical Immunology</i> , 2023, 246, 109211.	3.2	1
2567	The unmet need for COVID-19 treatment in immunocompromised patients. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	9

[illegible]

#	ARTICLE	IF	CITATIONS
2587	COVID-19 after rituximab therapy in cSLE patients. , 2023, 11, .	2.3	1
2588	Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood, 2023, 142, 1348-1358.	1.4	2
2589	Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases. Clinical Cancer Research, 2023, 29, 4230-4241.	7.0	1
2590	Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection. Cancers, 2023, 15, 2852.	3.7	0
2591	Cytotoxicity of the CD3 α –CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting. Blood Advances, 2023, 7, 4089-4101.	5.2	7
2592	Humoral and cellular responses to <scp>SARSâ€CoV</scp>â€2 in patients with Bâ€cell haematological malignancies improve with successive vaccination. British Journal of Haematology, 2023, 202, 1091-1103.	2.5	3
2593	Sotrovimab Treatment for COVID-19 Effective in a B-Cell-Depleted Patient After Anti-CD20 Treatment. Cureus, 2023, , .	0.5	0
2594	Nanotheranostics: Platforms, Current Applications, and Mechanisms of Targeting in Breast and Prostate Cancers. Journal of Nanotheranostics, 2023, 4, 346-383.	3.1	0
2595	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	5
2596	The frequency and associated factors of infusion-related reactions to rituximab for patients with rheumatoid arthritis. , 2023, 14, 105-110.		0
2597	Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Annals of the Rheumatic Diseases, 2024, 83, 103-111.	0.9	1
2598	Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy. , 2024, , 103-122.		0
2599	Anti-CD20 antibody treatment for B-cell malignancies. , 2024, , 31-75.		0
2601	Risk factors of rituximabâ€induced thrombocytopenia in patients with autoimmune bullous diseases. Journal of Dermatology, 0, , .	1.2	0
2602	What Is the Clinical Course of Advanced Solid-Tumor Cancers?. , 2023, , 300-307.		0
2603	A Brief History of Radiopharmaceutical Therapy. , 2023, , 13-38.		0
2604	SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencing. BMJ Case Reports, 2023, 16, e255255.	0.5	0
2605	Clinical and serological characterization of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation. Chinese Medical Journal, 2014, 127, 1235-1238.	2.3	0

#	ARTICLE	IF	CITATIONS
2606	Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action. Journal of Clinical Medicine, 2024, 13, 15.	2.4	0
2607	Antibody-Based Biotherapeutics in Cancer. , 2024, , 547-589.		0
2608	A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas. , 2024, 2, 10-24.		0
2609	Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer Treatment Reviews, 2024, 124, 102691.	7.7	0
2610	How does time speak about cancer, its diagnosis, treatments, and challenges?. , 2024, , 55-81.		0
2611	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2024, , 165-207.		0
2612	A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies. Diseases (Basel, Switzerland), 2024, 12, 33.	2.5	0
2613	Preclinical Development of Antibodyâ€“Drug Conjugates. , 2024, , 671-692.		0
2615	Emerging therapeutic targets in systemic sclerosis. Journal of Molecular Medicine, 2024, 102, 465-478.	3.9	0
2616	Gene Therapy and Gene Editing for Cancer Therapeutics. , 2023, , 711-800.		0